Methods and compositions
Beta solenoid concatemers address the limitations of natural structural proteins by providing improved mechanical stability and solubility, enabling diverse applications in textiles, drug delivery, and packaging through recombinant expression, thus overcoming environmental and economic challenges.
Patent Information
- Application Number
- PCT/EP2026/063412
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Conventional structural proteins derived from natural sources face issues such as poor mechanical stability, limited functionalization potential, inadequate control over degradation rates, poor water solubility, and high economic and environmental costs, along with challenges in recombinant expression and post-translational modifications, limiting their applications in industries like medicine, food, and agriculture.
Development of beta solenoid concatemers produced through recombinant protein expression technology, capable of forming fibres, films, hydrogels, and microcapsules, overcoming the limitations of natural structural proteins by providing improved mechanical stability and solubility without the need for harsh processing.
The beta solenoid concatemers offer enhanced mechanical stability, solubility, and flexibility, enabling diverse applications in textiles, wound dressings, drug delivery systems, and packaging without the drawbacks of natural proteins, while being more sustainable and accessible.
Smart Images

Figure EP2026063412_12112026_PF_FP_ABST
Abstract
Description
[0001] Methods and Compositions
[0002] FIELD
[0003] The invention is in the field of bio-based materials.
[0004] BACKGROUND
[0005] Structural proteins with the ability to form fibres, films, hydrogels, microcapsules and coacervates have a diversity of applications across many industries including medical, food and beverage, cosmetic, agriculture and packaging.
[0006] In medicine, structural proteins have a variety of applications including in drug delivery systems, wound healing, tissue engineering, encapsulation of cells and encapsulation of therapeutic agents (e.g. biologies or small molecules). In the food and beverage industry structural proteins may be used in the encapsulation of nutrients and flavours, for example protecting vitamins and probiotics from degradation to improve shelf life, in edible films and coatings to act as biodegradable packaging and reduce the need for synthetic plastics in food storage, and as texturizing agents, for example recent increases in the use of hydrogels to improve texture and taste profiles of meat alternatives.
[0007] Structural proteins in films are able to provide moisture and gas barriers which can be selective and therefore improve product protection whilst reducing environmental impact. The microencapsulation of fragrances can allow for long-lasting fragrance release such as in perfumes and scented textiles. Structural proteins can also enhance cosmetic formulations, such as by encapsulating bioactive agents, and hydrogels are increasingly used to improve skin hydration.
[0008] Hydrogels also have the potential to be self-adjusting, meaning that they can respond to environmental factors including pH and temperature for superior skincare, food, and drug delivery purposes. Other industries and uses for structural proteins include in agriculture and pest control where pesticides can be encapsulated for slow release thereby reducing environmental contamination and reducing the total volume of pesticides applied. Structural protein films or hydrogels may be used to encapsulate and protect plant seeds from desiccation, UV, temperature extremes and enzymatic / chemical degradation. Hydrogels can also act as flexible substrates inwearable devices, and improve properties such as water resistance, UV protection or antibacterial properties of textiles and coatings.
[0009] Conventional fibres, hydrogels, microcapsules, and films are often produced from naturally derived proteins including collagen, elastin, silk, and keratin. Such proteins are often obtained from natural sources such as animal tissues, fish, or plants. Harvesting proteins from natural sources has a variety of environmental impacts, for example overfishing associated with marine collagen or excessive livestock farming which contributes to deforestation and greenhouse gas emissions.
[0010] While these materials exhibit desirable properties such as biocompatibility, they frequently suffer from drawbacks including poor mechanical stability, limited functionalization potential, inadequate control over degradation rates, and poor water solubility resulting in the need for further processing such as hydrolyzation.
[0011] Additionally there is a demand for protein products which are not animal derived due to the limitations around batch-to-batch variation, ethical considerations of consumers, disease, allergens and sensitivities in some individuals and religious and cultural beliefs prohibiting the use and consumption of particular animal products. The extraction and purification of structural proteins from natural sources is also associated with high economic cost. These shortcomings hinder the potential of fibres, films, hydrogels and microcapsules across the aforementioned industries.
[0012] Many natural structural proteins contain highly repetitive sequences that are difficult to express in recombinant microbial systems due to genetic instability, codon bias, and high metabolic burden on the host. Recombinant expression often fails to replicate essential post-translational modifications or self-assembly processes required for native functionality, such as disulphide bond formation, proline hydroxylation, or phase separation behaviours. Even when expression is successful, the resulting proteins can exhibit poor solubility, aggregation, or incorrect folding, requiring harsh solubilisation or refolding steps that reduce yield and consistency.
[0013] Hence there is a need for synthetic protein alternatives which confer the benefits of natural structural proteins but with fewer drawbacks in terms of their properties, sustainability profiles, and accessibility to consumer markets.SUMMARY OF THE INVENTION
[0014] The present inventors identified beta solenoid concatemers that can be produced through recombinant protein expression technology, and which are able to form fibres, films, hydrogels, hydrogel shell microcapsules and various other compositions, circumventing many of the problems associated with currently used structural proteins.
[0015] DETAILED DESCRIPTION OF THE INVENTION
[0016] The invention provides a range of products, including various fibres, films, therapeutic films, cosmetic films, coacervates, hydrogels, therapeutic hydrogels, cosmetic hydrogels, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer films, transdermal delivery systems, compositions, therapeutic compositions, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogels or protein-based viscoelastic non-flowable hydrogels that comprise or consist of a polypeptide that comprises a concatemer of at least two beta solenoids.
[0017] Details of the concatemer of at least two beta solenoids are described below, and apply to all aspects, methods, products, uses, fibres, films, therapeutic films, cosmetic films, coacervates, hydrogels, therapeutic hydrogels, cosmetic hydrogels, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer films, transdermal delivery systems, compositions, therapeutic compositions, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogels or protein-based viscoelastic non-flowable hydrogels of the invention. The term "beta solenoid" may be used interchangeably with "solenoid fold".
[0018] The invention provides a concatemer of at least two beta solenoids wherein each beta solenoid comprises an N-terminal cap and a C-terminal cap, and wherein a linker links each capped beta solenoid, and wherein the linker is a peptide of SEQ ID NO: 203. Preferences for the sequence of the beta solenoids and caps are as set out elsewhere herein.
[0019] The invention also provides a concatemer of at least two beta solenoids comprising or consisting of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185. Preferably the concatemer comprises or consists of SEQ ID NO: 178 or 186, optionally 178.It should be clear that the concatemer itself comprises or consists of the above sequences, rather than the sequences being the sequences only of the beta solenoids.
[0020] In some embodiments the concatemer comprises or consists of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185. Preferably the concatemer comprises or consists of SEQ ID NO: 178 or 186, optionally 178.
[0021] The invention also provides a fibre comprising a concatemer of at least two beta solenoids comprising or consisting of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185. Preferably the concatemer comprises or consists of SEQ ID NO: 178 or 186, optionally 178.
[0022] The invention also provides a fibre comprising a concatemer of at least two beta solenoids where the concatemer comprises or consists of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185. Preferably the concatemer comprises or consists of SEQ ID NO: 178 or 186, optionally 178.
[0023] In some embodiments the fibre of the invention has been produced via a wet-spinning method.
[0024] In some embodiments the fibre of the invention comprises more than one different concatemer of at least two beta solenoids comprising or consisting of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185.
[0025] In some embodiments the fibre of the invention comprises more than one different concatemer of at least two beta solenoids where the concatemer comprises or consists of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185.
[0026] The beta solenoids that make up each concatemer may be the same as one another or may be different. For example in some embodiments each beta solenoid in a concatemer is identical to the preceding beta solenoid in the concatemer. In other embodiments the beta solenoid may be a concatemer of non-identical sequences. Insome embodiments one or more or all of the beta solenoids in a concatemer conform to the consensus sequence set out elsewhere herein.
[0027] Similarly, the separate concatemers in a fibre may be the same, or may be different to one another.
[0028] In some embodiments the fibre comprises at least two different concatemers, wherein at least one concatemer is a concatemer of at least two beta solenoids comprising or consisting of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185, and at least a second concatemer is a concatemer that comprises at least two beta solenoid domains that may have an amino acid sequence that is not any of sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185.
[0029] In some embodiments the fibre comprises at least two different concatemers, wherein at least one concatemer is a concatemer of at least two beta solenoids where the concatemer comprises or consists of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185, and at least a second concatemer is a concatemer that comprises at least two beta solenoid domains where the second concatemer may have an amino acid sequence that does not comprise or consist of any of sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185.
[0030] The invention also provides a yarn comprising a fibre of the invention.
[0031] In some embodiments the yarn comprises at least two different fibres of the invention.
[0032] The invention also provides a textile comprising the concatemer of the invention or the fibre of the invention.
[0033] The invention also provides the use of a concatemer according to the invention, a fibre according to the invention, or a textile according to the invention in the production of any one or more of:
[0034] sportswear (e.g. for protective uses such as rash guards); Protective wear for motorcyclists and / or other motorsports; Personal protective equipment (e.g. body armour, protective underwear for soldiers); Blast containment; Blade containment (e.g. for aircraft engines); Textiles for parachutes; Ropes; Textiles for clothing; Textiles for shoes; general medical textiles; Wound dressings; Resorbable and non-resorbablesurgical sutures; Resorbable and non-resorbable stents; Guide-wires for surgery (including non-metallic guide wires suitable for MRI); Biocompatible coatings for implanted medical devices; Surgical meshes; Scaffolds for 3D tissue engineering.
[0035] The invention also provides sportswear (e.g. for protective uses such as rash guards); Protective wear for motorcyclists and / or other motorsports; Personal protective equipment (e.g. body armour, protective underwear for soldiers); Blast containment; Blade containment (e.g. for aircraft engines); Textiles for parachutes; Ropes; Textiles for clothing; Textiles for shoes; general medical textiles; Wound dressings; Resorbable and non-resorbable surgical sutures; Resorbable and non-resorbable stents; Guidewires for surgery (including non-metallic guide wires suitable for MRI); Biocompatible coatings for implanted medical devices; Surgical meshes; or Scaffolds for 3D tissue engineering comprising a concatemer according to the invention, a fibre according to the invention or a textile according to the invention.
[0036] The inventors have also surprisingly found that a polypeptide comprising or consisting of concatemer of at least two beta solenoids is able to form a film. Accordingly the invention provides a film comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0037] In some embodiments the film comprises only the polypeptide that comprises or consists of a concatemer of at least two beta solenoids. For example in some embodiments the film consists only of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids. For example the film may have been made from an aqueous solution that comprises only the polypeptide that comprises or consists of a concatemer of at least two beta solenoids that was allowed to dry, leaving only the protein-based film, or has been made using some other solvent which has been evaporated.
[0038] In some embodiments the film is a water-soluble film.
[0039] In some embodiments the film comprises or consists of only the polypeptide that comprises or consists of a concatemer of at least two beta solenoids and is a water-soluble film.
[0040] In some embodiments the film consists only of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids and is water soluble.In some embodiments the film is a water insoluble film. In some embodiments the film comprises one or more agents that prevents the film from being soluble in water.
[0041] As described below, the polypeptide that comprises or consists of a concatemer of at least two beta solenoids is water soluble.
[0042] In some preferred embodiments the film is flexible. By flexible we include the meaning of not brittle. In some embodiments the film of the invention can be bent, twisted, folded and / or stretched without cracking or breaking. The film may undergo elastic, viscoelastic, or plastic deformation, either independently or in combination, depending on its composition and environmental conditions (e.g. temperature, humidity, hydration state, or applied stress). In some embodiments the film is pliable. The skilled person will appreciate what is meant by a flexible film.
[0043] Flexible protein-based films are known, but these tend to also comprise various additives which are required to make the film flexible, for example known films comprise a plasticiser, for example a triol, for example wherein the triol is glycerine or sorbitol, or the plasticiser may be sucrose.
[0044] In some embodiments then the film of the invention is flexible in the absence of the presence of any plasticiser, for example is flexible even when the film does not comprise a triol, for example wherein the triol is glycerine or sorbitol, or the plasticiser may be sucrose.
[0045] In some embodiments the film does not comprise:
[0046] a) a polyol, optionally does not comprise glycerol, sorbitol, ethylene glycol, propylene glycol, and / or polyethylene glycol (e.g. PEG 400 or PEG 600 but wider ranges of MWs possible);
[0047] b) urea;
[0048] c) one or more sugars, optionally does not comprise glucose, sucrose and / or fructose;
[0049] d) one or more lipids, optionally does not comprise oleic acid, linoleic acid and / or lecithin;
[0050] e) one or more amino acids, optionally does not comprise proline, arginine and / or lysine.In some embodiments the film forms on one or more surfaces, for example in some embodiments the one or more surfaces is an external surface of a subject, for example of a human subject.
[0051] In some embodiments the film forms on a first surface and can then be transferred to one or more external surfaces of a subject, for example a human subject.
[0052] The one or more external surfaces of a subject may be selected from the group comprising or consisting of: skin, hair, nails, and mucosa, optionally human skin, human hair, human nails and human mucosa.
[0053] In some embodiments the surface is a powder coated surface. The powder coat is considered to aid in removal of the film for deployment elsewhere. In some embodiments the surface is selected from epoxy, polyester, polyester-epoxy hybrid, polyurethane, acrylic. In some embodiments the surface is powder coated epoxy, powder coated polyester, powder coated polyester-epoxy hybrid, powder coated polyurethane, or powder coated acrylic.
[0054] In some embodiments the film is flexible, and flexes with the skin, hair, nails and / or mucosa.
[0055] In some embodiments the film is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.
[0056] The film may comprise at least a second agent. The second agent may be a therapeutic agent or a cosmetic agent or an agent used in packaging such as food packaging such as an anti-spoilant.
[0057] In some embodiments the second agent is a therapeutic agent, and may be a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0058] In some embodiments the second agent is a cosmetic agent and may be a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0059] In some embodiments the film is a therapeutic film. The therapeutic film may:
[0060] a) be a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;b) be a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0061] c) act as a wound dressing;
[0062] d) act as an antimicrobial
[0063] e) deliver one or more therapeutic agents to the skin of a subject; and / or f) be occlusive.
[0064] The therapeutic agent may be selected from the group comprising or consisting of:
[0065] i) A therapeutic agent for local delivery; and / or
[0066] ii) A therapeutic agent for systemic delivery.
[0067] The films of the invention are, in some embodiments, considered to form a barrier and can be applied directly to the skin or other surface, or over other products such as other transdermal delivery systems. Accordingly in one embodiment the film is applied over a transdermal delivery system.
[0068] In some embodiments the film is a cosmetic film and may:
[0069] a) be a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0070] b) be a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0071] c) deliver one or more cosmetic agents to the skin, nails or mucosa of a subject; and / or
[0072] d) be occlusive
[0073] The cosmetic agent may be selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, and antioxidants.
[0074] In some embodiments the cosmetic agent is for local delivery and / or for systemic delivery.
[0075] In addition to therapeutic and cosmetic uses, the films of the invention may also be used in various forms of packaging, such as for food or household products. For example water soluble films are used in various food packaging, and for detergent capsules. Accordingly in some embodiments the film is suitable for use in packaging, and in some embodiments is a water-soluble film for use in packaging.In some embodiments the film is suitable for packaging food.
[0076] The invention also provides a multilayer film comprising at least two layers, wherein at least one layer comprises or consists of a film of the invention (i.e. a film that comprises a polypeptide that comprises or consists of a concatemer of beta solenoids).
[0077] The invention also provides a transdermal delivery system comprising the film of the invention (i.e. a film that comprises a polypeptide that comprises or consists of a concatemer of beta solenoids). The transdermal delivery system may be a therapeutic transdermal delivery system or a cosmetic transdermal delivery system.
[0078] The invention provides a cosmetic composition comprising the film of the invention, or the multilayer film of the invention or the transdermal delivery system of the invention.
[0079] The invention provides a therapeutic composition comprising the film of the invention, or the multilayer film of the invention or the transdermal delivery system of the invention.
[0080] The invention also provides a wound dressing comprising the film of the invention, or the multilayer film of the invention or the transdermal delivery system of the invention.
[0081] The invention also provides a flexible package comprising the film of the invention (i.e. a film that comprises a polypeptide that comprises or consists of a concatemer of beta solenoids).
[0082] The invention also provides a package comprising the film of the invention (i.e. a film that comprises a polypeptide that comprises or consists of a concatemer of beta solenoids).
[0083] The invention also provides a container comprising a film seal, wherein the film seal is a film of the invention (i.e. a film that comprises a polypeptide that comprises or consists of a concatemer of beta solenoids).
[0084] The invention also provides methods of making the film of the invention. In some embodiments the invention provides a method of producing a protein-based film, wherein the method comprises:a) applying a protein solution that comprises at least a polypeptide to a surface; and
[0085] b) allowing the solution to dry
[0086] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0087] In some embodiments the surface is a solid surface. In other embodiments the surface is a liquid surface wherein the protein solution and the liquid are immiscible.
[0088] In some embodiments the surface is a powder coated surface. The powder coat is considered to aid in removal of the film for deployment elsewhere. In some embodiments the surface is selected from epoxy, polyester, polyester-epoxy hybrid, polyurethane, acrylic. In some embodiments the surface is powder coated epoxy, powder coated polyester, powder coated polyester-epoxy hybrid, powder coated polyurethane, or powder coated acrylic.
[0089] For example the surface may be the surface of a hydrophobic liquid upon which the aqueous protein solution forms a layer.
[0090] In some preferred embodiments the protein solution is an aqueous protein solution.
[0091] In some embodiments the protein solution comprises a buffer, for example a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSO, CAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer, for example the buffer may comprise one or more salts, optionally sodium chloride and / or potassium chloride,
[0092] The polypeptide that comprises or consists of at least two beta solenoids of may be present in the protein solution at any concentration. In some embodiments the polypeptide is present in the protein solution at a concentration of at least 5 mg / mL, at least 7 mg / mL, at least 10 mg / mL, at least 12 mg / mL, at least 15 mg / mL, at least 17 mg / mL, optionally at least 18.7 mg / ml, at least 20 mg / mL, optionally at least 25 mg / ml, at least 30 mg / ml, optionally at least 35 mg / ml, optionally at least 37.5 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml,optionally at least 70 mg / ml, optionally at least 75 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml.
[0093] In some embodiments the protein solution from which the film is made comprises only the polypeptide and water.
[0094] In some embodiments the protein solution from which the film is made may comprise at least a second agent. The second agent may be a therapeutic agent, for example a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0095] In some embodiments the formulation of protein and the second agent may be prepared by mixing the dried protein powder with second agent. The second agent may be in liquid, semi-solid, or gel form, depending on the desired application and mode of delivery.
[0096] In some embodiments the second agent is a cosmetic agent, for example a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0097] In some embodiments the solid surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon. In some embodiments the protein solution is adapted for application to and drying on the surface.
[0098] In some embodiments said applying is selected from the group comprising or consisting of pouring, spreading, spraying, dip coating, spin coating, doctor blading, tape casting, interfacial casting, electrospraying, roll-to-roll coating, inkjet printing, brush application, microcasting, wire-bar coating, draw-down coating, slot-die coating, and / or immersion precipitation.
[0099] The invention also provides a film made according to the method of making a film of the invention.The inventors have also found that the polypeptide that comprises or consists of a concatemer of at least two beta solenoids can be used to produce hydrogels.
[0100] Accordingly the invention provides a hydrogel comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0101] As for the film, in some embodiments the hydrogel is water insoluble. In some embodiments the polypeptide prior to hydrogel formation is water soluble.
[0102] The hydrogel may be flexible. Preferences for the flexible nature of the hydrogel are as described elsewhere herein.
[0103] In some embodiments the hydrogel is a flowable hydrogel.
[0104] Similarly to the film, in some embodiments the hydrogel is flexible even when the hydrogel does not comprise any plasticiser, or is formed from a composition that did not comprise any plasticiser. In some embodiments the hydrogel does not comprise a plasticiser, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose.
[0105] In some embodiments the hydrogel forms on one or more surfaces or external surfaces of a subject, optionally of a human subject.
[0106] The hydrogel may form on a first surface and then be transferred to one or more second surfaces, such as an external surface of a subject, optionally a human subject. The one or more external surfaces of a subject may be selected from the group comprising or consisting of: skin, hair, nails and / or mucosa, optionally human skin, human hair, human nails and human mucosa.
[0107] In some embodiments the hydrogel is flexible, and preferably flexes with the skin, hair, nails and / or mucosa when located on the skin, hair, nails and / or mucosa.
[0108] In some embodiments the hydrogel is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.
[0109] In some embodiments the surface is a powder coated surface. The powder coat is considered to aid in removal of the hydrogel for deployment elsewhere. In someembodiments the surface is selected from epoxy, polyester, polyester-epoxy hybrid, polyurethane, acrylic. In some embodiments the surface is powder coated epoxy, powder coated polyester, powder coated polyester-epoxy hybrid, powder coated polyurethane, or powder coated acrylic.
[0110] The hydrogel may comprise at least a second agent (i.e. where the first agent is the polypeptide)
[0111] The hydrogel and second agent may be present in a ratio of hydrogel: second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or at least 1:100.
[0112] The hydrogel and second agent may be present in a ratio of polypeptide:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or at least 1:100.
[0113] The second agent may be a therapeutic agent, for example a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0114] The second agent may be a cosmetic agent, for example a cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum.
[0115] In some embodiments the hydrogel is a therapeutic hydrogel. The therapeutic hydrogel may:
[0116] a) be a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0117] b) be a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0118] c) act as a wound dressing;
[0119] d) act as an antimicrobial
[0120] e) delivers one or more therapeutic agents to the skin, nails and / or mucosa of a subject.
[0121] The therapeutic agent may be selected from the group comprising or consisting of a therapeutic agent for local delivery; and / or a therapeutic agent for systemic delivery.In some embodiments the hydrogel may be applied over a transdermal delivery system.
[0122] In some embodiments the hydrogel is a cosmetic hydrogel. The cosmetic hydrogel may:
[0123] a) be a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0124] b) be a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0125] c) deliver one or more cosmetic agents to the skin, nails and / or mucosa of a subject.
[0126] The cosmetic agent may be selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, biologies, and antioxidants.
[0127] The invention also provides a multilayer hydrogel comprising at least two layers, wherein at least one layer comprises or consists of a hydrogel according to the invention.
[0128] The invention also provides a transdermal delivery system comprising the hydrogel of the invention for example the transdermal delivery system may be a therapeutic transdermal delivery system or a cosmetic transdermal delivery system.
[0129] The invention also provides:
[0130] a) a cosmetic composition comprising the hydrogel of the invention;
[0131] b) a therapeutic composition comprising the hydrogel of the invention; and / or c) a wound dressing comprising the hydrogel of the invention.
[0132] The invention also provides methods of making the hydrogel of the invention. The invention therefore provides a method of producing a protein-based hydrogel, wherein the method comprises:
[0133] a) providing a protein solution that comprises at least a polypeptide;
[0134] b) providing a gelling agent;c) mixing the protein solution with the gelling agent
[0135] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0136] By "gelling agent" we include any agent that transforms a liquid into a gel-like or solidlike form. In some embodiments the gelling agent is an alcohol, for example ethanol.
[0137] The method may further comprise incubating the mixture of the protein solution and gelling agent for a period of time so as to allow the hydrogel to form, optionally incubating for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more;
[0138] and optionally incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C.
[0139] In some preferred embodiments the protein solution is an aqueous protein solution. The protein solution may also comprise a buffer for example a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSO CAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer, optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride.
[0140] In some embodiments the protein is provided in the form of a powder, which can be mixed with, for example water, or mixed directly into a composition as described elsewhere herein, such as a cream or lotion or moisturiser or shampoo or conditioner or other such product.
[0141] In some preferred embodiments the protein powder is formed by drying (e.g. freeze drying, spray drying, drum drying) an aqueous protein solution. The protein solution may also comprise a buffer for example a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris,Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSO CAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer, optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride.
[0142] The polypeptide may be present in the mixture of the protein solution and gelling agent at any concentration. In some embodiments the polypeptide is present in the mixture of the protein solution and the gelling agent at a concentration of at least 5 mg / mL, at least 7 mg / mL, at least 7.5 mg / ml, at least 10 mg / mL, at least 12 mg / mL, at least 15 mg / mL, at least 17 mg / mL, optionally at least 18.7 mg / ml, at least 20 mg / mL, optionally at least 25 mg / ml, at least 30 mg / ml, optionally at least 35 mg / ml, optionally at least 37.5 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml, optionally at least 70 mg / ml, optionally at least 75 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml.
[0143] In some embodiments the gelling agent is selected from the group comprising or consisting of:
[0144] i) ethanol; and / or
[0145] ii) metal 2+ ions, optionally Cu2+ or Ca2+, optionally copper sulphate or calcium chloride.
[0146] In some embodiments the concentration of ethanol in the mixture of the protein solution and the gelling agent is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or more.
[0147] In some embodiments the gelling agent is ethanol, and:
[0148] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 20% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0149] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml.In some embodiments, the gelling agent is ethanol, and:
[0150] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0151] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0152] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[0153] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0154] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0155] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;
[0156] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0157] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0158] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[0159] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0160] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0161] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0162] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0163] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[0164] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0165] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml.
[0166] In some embodiments the gelling agent is ethanol and the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of between 20-30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of 20 mg / ml.
[0167] In some embodiments the gelling agent is not heat, for example is not heat up to 95 °C. In some embodiments the gelling agent is not a low pH, for example is not pH down to 2.
[0168] In some embodiments the hydrogel has not been made by heating the protein solution to 95 °C. In some embodiments the hydrogel has not been made by lowering the pH of the protein solution to pH 2.
[0169] In some embodiments the hydrogel is a non-flowable hydrogel, and the gelling agent is ethanol and is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30%, optionally at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or at least 75%.
[0170] In alternative embodiments the hydrogel is a flowable hydrogel, and the gelling agent is ethanol and is present in the mixture of the protein solution and the gelling agent at a concentration of at 30% or less, optionally less than 25%, 20%, 15%, or less than 10%.In some embodiments:
[0171] i) the gelling agent is copper sulphate, and is present in the mixture of the protein solution and the gelling agent at a concentration of at least 15 mM, or at least 20 mM, 25mM, 30 mM, 35 mM, 40 mM, 45 mM, 50mM, 55 mM, 60mM, 65 mM or 70 mM or more; or
[0172] ii) the gelling agent is calcium chloride, and is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mM, or at least 20 mM, 25mM, 30 mM, 35 mM, 40 mM, 45 mM, 50mM, 55 mM, 60mM, 65 mM or 70 mM or more.
[0173] In one embodiment the gelling agent is not, or does not comprise or consist of any one or more of:
[0174] i) sodium tetraborate; and / or
[0175] ii) sodium tetraborate and hydrogen peroxide.
[0176] In some embodiments one or both of the following are not used to gel the hydrogel:
[0177] i) heat of 95C; and / or
[0178] ii) pH of 2 or lower.
[0179] In some embodiments the method further comprises mixing the hydrogel with a second agent. In one embodiment the second agent is a liquid, a cream, or a powder.
[0180] In some embodiments the hydrogel and second agent may be present in a ratio of hydrogel:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or at least 1:100.
[0181] The hydrogel and second agent may be present in a ratio of polypeptide:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or at least 1:100.
[0182] In some embodiments the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0183] In some embodiments the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.In some embodiments the method further comprises applying the hydrogel to a surface, optionally wherein said applying is selected from the group comprising or consisting of pouring, spreading and spraying. In one embodiment the surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon. In some embodiments the hydrogel is adapted for application to a surface wherein the surface is selected from skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa.
[0184] The invention also provides a protein-based flowable hydrogel produced according to the following method:
[0185] a) providing a protein solution that comprises or consists of at least a polypeptide that comprises or consists of a concatemer of at least two beta solenoids, as described herein;
[0186] b) mixing the protein solution with the ethanol to produce a mixture of protein solution and ethanol; and
[0187] c) incubating the mixture of protein solution and ethanol for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more,
[0188] optionally incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C.
[0189] Preferences for the protein-based flowable hydrogel are as set out elsewhere herein.
[0190] The invention also provides a protein-based viscoelastic non-flowable hydrogel produced according to the following method:
[0191] a) providing a protein solution wherein the protein comprises or consists of at least a polypeptide that comprises or consists of a concatemer of at least two beta solenoids, as described herein;
[0192] b) mixing the protein solution with the ethanol to produce a mixture of protein solution and ethanol
[0193] andwherein the concentration of ethanol in the mixture of protein solution and ethanol is at least 30%, optionally at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or at least 75%.
[0194] Preferences for the protein-based viscoelastic non-flowable hydrogel are as set out elsewhere herein.
[0195] In addition, the invention provides a hydrogel shell microcapsule comprising or consisting of:
[0196] a) a core made of a material that is not miscible or is not fully miscible with water;
[0197] b) a hydrogel shell surrounding and containing the core;
[0198] wherein the hydrogel shell comprises or consists of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0199] In one embodiment, the core of the hydrogel shell microcapsule is of a material selected from the group comprising or consisting of: a non-polar liquid, optionally oil; or an organic solvent such as an alcohol (such as ethanol, propylene glycol), glycerine, or, deep eutectic solvents; or a non-water miscible gas that is a gas at a temperature of at least between 4C and 40C.
[0200] In one embodiment the core of the hydrogel shell microcapsule further comprises one or more therapeutic or cosmetic agents. In a further embodiment, the one or more therapeutic or cosmetic agent is selected from the group comprising or consisting of: a small molecule, a protein such as an antibody, hormone such as insulin, enzyme, food ingredient, flavour or fragrance.
[0201] In one embodiment the hydrogel shell microcapsule is at least 1 µm, at least 5 µm, at least 10 µm, at least 20 µm, at least 50 µm, at least 100 µm, at least 200 µm, preferably 10 - 100 µm in length.
[0202] In one embodiment the hydrogel shell microcapsule is at least 150 µL, at least 180 µL, at least 200 µL, at least 300 µL, at least 400 µL or at least 500 µL in volume.In one embodiment, the stability of the hydrogel shell microcapsule is greater than the stability of microcapsules formed without the polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0203] The invention also provides a method of producing the hydrogel shell microcapsule as described herein, wherein the method comprises producing droplets of a material that is not miscible or is not fully miscible with water in an aqueous protein solution, wherein the protein solution comprises a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0204] Preferences for the method of producing the hydrogel shell microcapsule as described herein are set out elsewhere herein.
[0205] It is understood in the art that miscible includes the capability of being mixed.
[0206] In one embodiment, production of said droplets is achieved by:
[0207] i) sonicating a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution.
[0208] ii) stirring a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0209] iii) pipetting a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution; and / or
[0210] iv) a microfluidic droplet generation method, optionally cross-flowing droplet generation, flow-focusing droplet formation, or co-flowing droplet formation.
[0211] In one embodiment, said material that is not miscible or is not fully miscible with water is selected from the group comprising or consisting of: a non-polar liquid, optionally oil; or an organic solvent such as an alcohol (such as ethanol, propylene glycol), glycerine, or, deep eutectic solvents; or a non-water miscible gas that is a gas at a temperature of at least between 4C and 40C, optionally in one embodiment the material that is not miscible or is not fully miscible with water is oil, optionally Captex 300.
[0212] In one embodiment the droplets are at least 1 µm, at least 5 µm, at least 10 µm, at least 20 µm, at least 50 µm, at least 100 µm, at least 200 µm, preferably 10 - 100 µm in length.In one embodiment the droplets are at least 150 µL, at least 180 µL, at least 200 µL, at least 300 µL, at least 400 µL or at least 500 µL in volume.
[0213] In one embodiment the ratio of the material that is not miscible or is not fully miscible with water and the aqueous protein solution is less than 1:1. In an alternative embodiment the ratio of the material that is not miscible or is not fully miscible with water and the aqueous protein solution is more than 1:1.
[0214] In one embodiment, the method of producing the hydrogel shell microcapsule further comprises isolating the hydrogel shell microcapsules from the aqueous protein solution and optionally producing more hydrogel shell microcapsules from the aqueous protein solution.
[0215] The invention also provides a hydrogel comprising a plurality of hydrogel shell microcapsules wherein:
[0216] i) the hydrogel shell microcapsules comprise or consist of:
[0217] a) a core made of a material that is not miscible or is not fully miscible with water;
[0218] b) a hydrogel shell surrounding and containing the core;
[0219] wherein the hydrogel shell comprises or consists of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids;
[0220] and
[0221] ii) the hydrogel that comprises the plurality of hydrogel shell microcapsules comprises or consists of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0222] Preferences for a hydrogel comprising a plurality of hydrogel shell microcapsules are set out elsewhere herein.
[0223] In one embodiment, the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel shell is the same polypeptide as the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel that comprises the plurality of hydrogel shell microcapsules.
[0224] In one embodiment, the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel shell is a different polypeptide to thepolypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel that comprises the plurality of hydrogel shell microcapsules.
[0225] In one embodiment the hydrogel is water insoluble.
[0226] In one embodiment the hydrogel is flexible, and optionally flexes with the skin, hair, nails and / or mucosa.
[0227] In one embodiment the hydrogel is a flowable hydrogel.
[0228] By "flowable hydrogel" we include a hydrogel which is capable of moving and spreading such as a liquid, and may exhibit shear-thinning behaviour meaning that the hydrogel may flow easily under stress (such as during injection) but returns to a more gel-like state when the stress is removed.
[0229] In one embodiment the hydrogel is flexible even when the hydrogel does not comprise any plasticiser, or is formed from a composition that did not comprise any plasticiser.
[0230] As such, in one embodiment the hydrogel does not comprise a plasticiser, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose.
[0231] It is understood in the art that the term 'plasticiser' includes any substance or agent added to a material to make it softer and / or more flexible, to promote plasticity, to decrease brittleness or material viscosity, and / or to decrease fracturing during handling of the material.
[0232] In one embodiment the hydrogel forms on one or more surfaces or external surfaces of a subject, optionally of a human subject. In one embodiment the hydrogel is adapted to form on one or more surfaces or external surfaces of a subject, optionally of a human subject. In one embodiment the hydrogel forms on a first surface and can then be transferred to one or more external surfaces of a subject, optionally a human subject. In a further embodiment, the one or more external surfaces of a subject is selected from the group comprising or consisting of: skin, hair, nails and / or mucosa, optionally human skin, human hair, human nails and human mucosa.
[0233] In one embodiment the hydrogel is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.In one embodiment, the hydrogel comprising a plurality of hydrogel shell microcapsules further comprises at least a second agent. In one embodiment the hydrogel and second agent are present in a ratio of hydrogel:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or at least 1:10. In some embodiments the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream. In some embodiments the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0234] In one embodiment, the hydrogel comprising a plurality of hydrogel shell microcapsules is a therapeutic hydrogel. In one embodiment the therapeutic hydrogel:
[0235] a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0236] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0237] c) acts as a wound dressing;
[0238] d) acts as an antimicrobial
[0239] e) delivers one or more therapeutic agents to the skin, nails and / or mucosa of a subject.
[0240] In one embodiment the hydrogel comprising a plurality of hydrogel shell microcapsules hydrogel is a cosmetic hydrogel. In one embodiment the cosmetic hydrogel:
[0241] a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0242] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0243] c) delivers one or more cosmetic agents to the skin, nails and / or mucosa of a subject.
[0244] In one embodiment, the cosmetic agent is selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, and antioxidants.The invention also provides a multilayer hydrogel comprising a plurality of hydrogel shell microcapsules comprising at least two layers, wherein at least one layer comprises or consists of a hydrogel as described herein.
[0245] Preferences for the multilayer hydrogel are set out elsewhere herein.
[0246] The invention also provides a method of making a hydrogel comprising a plurality of hydrogel shell microcapsules wherein said method comprises:
[0247] a) producing a plurality of droplets of a material that is not miscible or is not fully miscible with water in an aqueous protein solution, wherein the protein solution comprises a polypeptide that comprises or consists of a concatemer of at least two beta solenoids;
[0248] b) mixing the plurality of droplets with ethanol, optionally ethanol at a final concentration of 30%; and
[0249] optionally
[0250] c) incubating the mixture obtained in (b), optionally
[0251] i) incubating for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more;
[0252] ii) incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C; and / or
[0253] iii) incubating with agitation, optionally in a shaking incubator.
[0254] Preferences for the method of making a hydrogel comprising a plurality of hydrogel shell microcapsules are as set out elsewhere herein.
[0255] In one embodiment, production of said droplets is achieved by:
[0256] i) sonicating a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0257] ii) stirring a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0258] iii) pipetting a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution; or
[0259] iv) a microfluidic droplet generation method, optionally cross-flowing droplet generation, flow-focusing droplet formation, or co-flowing droplet formation.The invention also provides a composition comprising a plurality of hydrogel shell microcapsules according to the plurality of hydrogel shell microcapsules as described herein.
[0260] The invention also provides a therapeutic composition comprising a plurality of hydrogel shell microcapsules according to the plurality of hydrogel shell microcapsules as described herein.
[0261] The invention also provides a cosmetic composition comprising a plurality of hydrogel shell microcapsules according to the plurality of hydrogel shell microcapsules as described herein.
[0262] The invention also provides a therapeutic film comprising a film as described herein.
[0263] The invention also provides a cosmetic film comprising a film as described herein.
[0264] The invention also provides a composition comprising a hydrogel according to the hydrogel as described herein.
[0265] The invention also provides a therapeutic composition comprising a hydrogel according to the hydrogel as described herein.
[0266] The invention also provides a cosmetic composition comprising a hydrogel according to the hydrogel as described herein.
[0267] The invention provides a therapeutic composition comprising a polypeptide that comprises or consists of a concatemer of at least two beta solenoids. The invention provides a therapeutic composition comprising a polypeptide that comprises or consists of a concatemer of at least two beta solenoids for use in medicine. Preferences for a concatemer of at least two beta solenoids are set out elsewhere herein.
[0268] The invention provides a cosmetic composition comprising a polypeptide that comprises or consists of a concatemer of at least two beta solenoids. Preferences for a concatemer of at least two beta solenoids are set out elsewhere herein.
[0269] The invention provides an aqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids. The invention provides anaqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids for use in medicine. Preferences for a concatemer of at least two beta solenoids are set out elsewhere herein.
[0270] The invention provides an aqueous cosmetic composition comprising a cosmetic agent and a concatemer of at least two beta solenoids, optionally wherein the cosmetic composition is an aqueous cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum. Preferences for a concatemer of at least two beta solenoids are set out elsewhere herein.
[0271] The invention also provides a method of making an aqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids, said method comprising mixing an aqueous therapeutic agent with a concatemer of at least two beta solenoids wherein the concatemer of at least two beta solenoids is in a powdered or lyophilised form.
[0272] The invention also provides a method of making an aqueous cosmetic composition comprising a cosmetic agent and a concatemer of at least two beta solenoids, said method comprising mixing an aqueous cosmetic agent with a concatemer of at least two beta solenoids wherein the concatemer of at least two beta solenoids is in a powdered or lyophilised form, optionally wherein the cosmetic agent is an aqueous cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum.
[0273] The invention provides the use of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids in a method of making a film, a hydrogel, a hydrogel shell microcapsule or a hydrogel comprising a plurality of hydrogel shell microcapsules of any of the hydrogel shell microcapsules as described herein.
[0274] The invention provides a method of treating a subject in need thereof, said method comprising administering any one more of the film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as set out elsewhere herein.The invention provides a film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel, as set out elsewhere herein, for use in a method of treating a subject in need thereof.
[0275] The invention provides the use of any one more of the film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel, as set out elsewhere herein, for the manufacture of a medicament for the treatment of a subject in need thereof.
[0276] The invention also provides a method of cosmetic treatment said method comprising administering one or more of any one more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as set out elsewhere herein.
[0277] The invention provides the use of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as described elsewhere herein adapted for application to skin, hair, nails, and mucosa, optionally human skin, human hair, human nails and human mucosa.
[0278] The invention also provides the use of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as set out elsewhere herein in the manufacture of a cosmetic or therapeutic agent.
[0279] The invention also provides the use of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition,multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as set out elsewhere herein in medicine.
[0280] The invention provides a method of providing a semi-permeable boundary layer between the skin and the environment, said method comprising applying any one or more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, proteinbased flowable hydrogel or protein-based viscoelastic non-flowable hydrogel, as described elsewhere herein, the skin. In one embodiment, the method is a non-surgical method.
[0281] The invention provides a cosmetic method of maintaining hydration of the skin, said method comprising applying any one or more of the as set out elsewhere herein film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel to the skin.
[0282] The invention provides a cosmetic composition comprising a moisturising lotion and any one or more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, proteinbased flowable hydrogel or protein-based viscoelastic non-flowable hydrogel as set out elsewhere herein.
[0283] Polypeptide comprising or consisting of a concatemer of at least two beta solenoids
[0284] As set out elsewhere herein, the various products of the invention, such as the various films, therapeutic films, cosmetic films, hydrogels, therapeutic hydrogels, cosmetic hydrogels, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer films, transdermal delivery systems, compositions, therapeutic compositions, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogels or protein-based viscoelastic non-flowable hydrogels of the invention all comprise or consist of a polypeptide that comprises at least twobeta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0285] Suitable concatemers of at least two beta solenoids are set out in WO2019175591, which is hereby incorporated by reference in its entirety. A solenoid is a discrete, rigid rod-shaped structural unit.
[0286] Solenoid proteins are coil-like structures formed by repeating of amino acid motifs, which can act like a spring.
[0287] The solenoids of the concatemer in some embodiments each comprises an amino acid sequence that comprises at least 4 units of a consensus motif. Examples of suitable consensus motifs are set out elsewhere herein.
[0288] In some embodiments one or both of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are rodshaped. In some embodiments by rod-shaped we mean that one or both of the at least two beta solenoids has a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1;
[0289] optionally wherein both of the at least two beta solenoid have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9: 1, optionally 10:1;
[0290] optionally wherein all of the beta solenoid have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1.
[0291] In some embodiments one or both of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids has an aspect ratio of 10:1 or less, optionally wherein all of the beta solenoid have an aspect ratio of 10:1 or less.In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises between 4 and 3000 units of the consensus motif, optionally between 5 and 2800, optionally between 6 and 2600, optionally between 7 and 2400, optionally between 8 and 2200, optionally between 9 and 2000, optionally between 10 and 1800, optionally between 11 and 1600, optionally between 12 and 1400, optionally between 13 and 1200, optionally between 14 and 1000, optionally between 15 and 800, optionally between 16 and 600, optionally between 17 and 500, optionally between 18 and 400, optionally between 19 and 300, optionally between 21 and 200, optionally between 22 and 150, optionally between 23 and 100, optionally between 24 and 90, optionally between 25 and 85, optionally between 26 and 80, optionally between 27 and 75, optionally between 28 and 70, optionally between 29 and 65, optionally between 30 and 60, optionally between 35 and 55, optionally between 40 and 50, optionally 45 units of the consensus motif.
[0292] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises at least 5 units of the consensus motif, optionally at least 6 units, optionally at least 7 units, optionally at least 8 units, optionally at least 9 units, optionally at least 10 units, optionally at least 11 units, optionally at least 12 units, optionally at least 13 units, optionally at least 14 units, optionally at least 15 units, optionally at least 16 units, optionally at least 17 units, optionally at least 18 units, optionally at least 19 units, optionally at least 20 units, optionally at least 21 units, optionally at least 24 units, optionally at least 25 units, optionally at least 26 units, optionally at least 27 units, optionally at least 28 units, optionally at least 29 units, optionally at least 30 units, optionally at least 40 units, optionally at least 50 units, optionally at least 60 units, optionally at least 70 units, optionally at least 80 units, optionally at least 90 units, optionally at least 100 units, optionally at least 200 units of the consensus motif.
[0293] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises the same number of units of the consensus motif.
[0294] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids have a cross-section selected from the group consisting of a tesselatable cross-section, optionally a square, a rectangle, a parallelogram, a hexagon, or a triangle crosssection; or a circle or an oval cross-section.In some embodiments the concatemer of at least two beta solenoid domains, or one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are capable of forming a lyotropic liquid crystal mesophase when expressed as monomers.
[0295] In some embodiments the concatemer of at least two beta solenoid domains, or one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids is capable of forming a lyotropic liquid crystal mesophase.
[0296] Preferably, each unit within each beta solenoid domains in the concatemer of the invention conforms to the same consensus sequence. However, concatemers of different beta solenoid domains are contemplated and included in the invention. In a non-limiting example, a concatemer may comprise a beta solenoid that conforms to SEQ ID NO: 195 below and a beta solenoid domain that conforms to SEQ ID NO: 1 below.
[0297] The concatemers of the invention comprise a polypeptide chain that comprises at least two beta solenoid proteins covalently linked, and preferably expressed as a single transcript and subsequently translated into a single protein.
[0298] As mentioned above, the beta solenoids comprise or consist of repeats of a motif. The motif may be of a sequence that conforms to a consensus sequence, i.e. the repeats of the motif may not be identical, but share features of a consensus sequence. In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises units of a consensus motif selected from the group consisting of:
[0299] i) A X1L / F X2X3[SEQ ID NO: 147]
[0300] wherein X1is any residue
[0301] X2is any residue
[0302] X3is any residue;
[0303] optionally
[0304] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or VX2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[0305] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 148]
[0306] ii) A X1L X2X3[SEQ ID NO: 149]
[0307] wherein X1is any residue
[0308] X2is any residue
[0309] X3 is any residue;
[0310] optionally
[0311] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[0312] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[0313] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 150]
[0314] iii) A (N / D) L * X [SEQ ID NO: 151]
[0315] where * is a polar residue (C, R, H, K, D, E, S, T, N, Q) and X is any residue;
[0316] iv) (S / G / T / A)X(A / V / G)X(G / A)XX [SEQ ID NO: 152]
[0317] where X is any residue;
[0318] v) (S / G / T / A)X(A / V / G)X(G / A)XX(S / G / T / A)*(A / V / G)*(G / A)XX [SEQ ID NO: 153] where * is a hydrophobic residue and where X is any residue;
[0319] vi) SXAXGXXS*A*GXX [SEQ ID NO: 154]
[0320] where * is a hydrophobic residue and where X is any residue;
[0321] vii) NXAXGXXST(I / V)(G / A)GGXX [SEQ ID NO: 155]
[0322] where X is any residue;
[0323] viii) NXAXGXXSTIGGGXX [SEQ ID NO: 156]
[0324] where X is any residue;
[0325] ix) GXQX(V / I / L)XXGGXAXXTX(V / I / L)XXG [SEQ ID NO: 157]
[0326] where X is any residue;optionally wherein (i), (ii) and (iii) generate a beta solenoid with a square crosssection; (iv), (v), (vi), (vii) and (viii) generate an oval shaped cross-section; and (ix) forms a triangular cross-section.
[0327] Preferably the consensus motif is:
[0328] i) A X1L / F X2X3[SEQ ID NO: 147]
[0329] wherein X1is any residue
[0330] X2is any residue
[0331] X3is any residue;
[0332] optionally
[0333] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[0334] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[0335] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 148]
[0336] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that are present in the concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202. In some embodiments at least two of the beta solenoids comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202. In some embodiments all of the beta solenoids comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202.
[0337] In some embodiments the at least one, the at least two or all of the beta solenoid have a) at least 75% homology to any one of the sequences of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202, optionally at least 80% homology, optionally at least 85% homology, optionally at least 90% homology, optionally at least 95% homology, optionally at least 96% homology, optionally at least 97% homology, optionally at least 98% homology, optionally at least 99% homology, optionally 100% homology, or b) at least 75% sequence identity to any one of the sequences of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202, optionally at least 80% sequence identity, optionally at least 85% sequence identity, optionally at least 90% sequence identity, optionally at least 95% sequence identity, optionally at least 96% sequence identity, optionally at least 97% sequence identity, optionally at least 98% sequence identity, optionally at least 99% sequence identity, optionally 100% sequence identity.In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 195.
[0338] The solenoids that are part of the concatemer may comprise a capping sequence at the N-terminal end, the C-terminal end, or preferably both the N and C-terminal end, so that each solenoid is flanked by a cap.
[0339] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises a capping sequence at a first end or a second end, or both the first end and the second end of the beta solenoid. Accordingly in one embodiment at least one, both or preferably all of the beta solenoids comprises a capping sequence at a first end or a second end, or preferably both the first end and the second end of each beta solenoid.
[0340] The capping sequences are considered to prevent the beta solenoid domains from joining end-to-end and aggregating. Accordingly, in one embodiment the beta solenoid domain or domains as described herein comprise one or two capping sequences that prevent the beta solenoid domains from joining end-to-end and aggregating. The skilled person is able to design such capping sequences and there are a number of different ways in which this can be achieved. For example, a terminal repeat similar to the consensus sequence of the units of the beta solenoid domain may be used but in which the solvent exposed residues that would normally be buried are instead mutated to polar or charged residues, which is considered to help in shielding the hydrophobic core. Another approach that will be apparent to the skilled person would be to disrupt the normal hydrogen bonding backbone pattern of the terminal repeat by introducing a structural irregularity such as adding a proline residue or forming a betabulge. Yet a further approach is to design the sequence of the beta solenoid doing so that part of the polypeptide chain folds over and covers the end. For example, the capping sequences disclosed herein form alpha helices which cover the ends of the beta-helices. Such capping sequences can be found in nature or designed de novo by, for example redesigning existing structures using computational protein design methods / tools, or by using generative Al methods such as hallucination, diffusion, or flow matching to generate novel backbone structures.Accordingly in some embodiments the capping sequence prevents the beta solenoid from joining end-to-end and aggregating. In some embodiments the capping sequence is an alpha helix.
[0341] In some embodiments one or both or all of the capping sequences comprises:
[0342] a) a sequence that conforms to the consensus sequence of SEQ ID NO: 82 and / or SEQ ID NO: 83, optionally wherein the first cap conforms to SEQ ID NO: 82 and the second cap conforms to SEQ ID NO: 83; and / or
[0343] b) any one or more of SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190
[0344] optionally wherein at least one of or both of or all of the capping sequence comprises a sequence with a) at least 80% homology, optionally at least 85% homology, optionally at least 90% homology, optionally at least 95% homology, optionally at least 96% homology, optionally at least 97% homology, optionally at least 98% homology, optionally at least 99% homology, optionally 100% homology to SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190; or b) at least 80% sequence identity, optionally at least 85% sequence identity, optionally at least 90% sequence identity, optionally at least 95% sequence identity, optionally at least 96% sequence identity, optionally at least 97% sequence identity, optionally at least 98% sequence identity, optionally at least 99% sequence identity, optionally 100% sequence identity to SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190.
[0345] In a preferred embodiment each solenoid in the concatemer comprises an N-terminal cap and a C-terminal cap. Preferably the N-terminal cap is selected from any one of SEQ ID NO: 2, 84-104, 187, 188 or a sequence with at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2, 84-104, 187, 188; and the C-terminal cap is selected from any one SEQ ID NO: 3, 105-125, 189 or 190 or a sequence with at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 3, 105-125, 189 or 190.
[0346] In some embodiments one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids does not consist of any of the sequences of SEQ ID NO: 1, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62; and / or SEQ ID NO: 66-80.In some embodiments the beta solenoids in the concatemer are linked by a linker. The at least two beta solenoid domains of the invention are linked together by a linker, preferably a flexible linker. Linkers are commonly used by those in the field for example to link protein domains, for example when tagging a protein with GFP. GFP is not considered to be a flexible linker itself. The presence of the linker allows each of the linked components to act somewhat independently of one another whilst being spatially restricted and retaining connectivity.
[0347] In one embodiment the flexible linker is also formed from amino acids. In this advantageous embodiment it is possible to transcribe both the at least two beta solenoid domains as a single RNA transcript and translate into a single polypeptide. However, other means of linking protein domains such as the beta solenoid domains of the invention are known and are included in the invention.
[0348] The skilled person will understand and appreciate the features of suitable linkers. Examples of suitable linkers are considered to be poly glycine linkers, poly alanine linkers, glycine rich linkers, alanine rich linkers, glycine and alanine rich linkers, and glycine / alanine / serine rich linker. Examples of suitable linkers are described in SEQ ID NO: 34 - GGGS, and SEQ ID NO: 168 - GGGSAAAAAAGGGS, or SEQ ID NO: 203 (GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQ).
[0349] In some preferred embodiments the linker is GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQSEQ ID NO: 203.
[0350] In some embodiments the linker, when present, is located between the C-terminal cap of a first upstream solenoid and the N-terminal cap of a second, downstream solenoid, i.e C-cap, solenoid, N-cap, linker, C-cap, solenoid, N-Cap.
[0351] In some embodiments the concatemer that comprises or consists of at least two beta solenoids has a molecular weight of at least 30 kDa, optionally at least 40 kDa, optionally at least 50 kDa, optionally at least 60 kDa, optionally at least 70 kDa, optionally at least 80 kDa, optionally at least 90 kDa, optionally at least 100 kDa, optionally at least 120 kDa, optionally at least 150 kDa, optionally at least 200 kDa, optionally at least 250 kDa, optionally at least 300 kDa, optionally at least 350 kDa, optionally at least 400 kDa, optionally at least 450 kDa, optionally at least 500 kDa, optionally at least 600 kDa, optionally at least 650 kDa, optionally at least 700 kDa, optionally at least 800 kDa, optionally at least 900 kDa, optionally at least 1000 kDa.; optionally between 30 kDa and 1000 kDa.In some embodiments the concatemer that comprises or consists of at least two beta solenoids is soluble at high concentrations, optionally soluble at a concentration of at least 20 mg / ml, optionally at least 30 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml, optionally at least 70 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml,
[0352] optionally soluble in a solvent selected from the group consisting of:
[0353] a) a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSOCAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer,
[0354] optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride,
[0355] optionally wherein the buffer is at a pH range of 3 to 10, optionally pH 7;
[0356] b) an organic solvent, optionally HFIP.
[0357] In some embodiments the concatemer that comprises or consists of at least two beta solenoids has:
[0358] a) a high net charge, optionally has a net charge of at least +3 charge units, optionally at least +5 charge units, optionally at least +7 charge units, optionally at least +10 charge units, optionally at least +15 charge units, optionally at least +20 charge units, optionally at least +25 charge units, optionally at least +30 charge units, optionally at least +35 charge units, optionally at least +40 charge units, optionally at least +45 charge units, optionally at least +50 charge units, optionally at least +55 charge units, optionally at least +60 charge units, optionally at least +65 charge units, optionally at least +70 charge units, optionally at least +75 charge units, optionally at least +80 charge units, optionally at least +85 charge units, optionally at least +90 charge units,optionally at least +95 charge units, optionally at least +100 charge units, optionally at a pH range of 3 to 10, optionally pH 7;
[0359] b) a high negative net charge, optionally has a net charge of less than -3 charge units, optionally at less than -5 charge units, optionally less than -7 charge units, optionally less than -10 charge units, optionally less than -15 charge units, optionally less than -20 charge units, optionally less than -25 charge units, optionally less than -30 charge units, optionally less than -35 charge units, optionally less than -40 charge units, optionally less than -45 charge units, optionally less than -50 charge units, optionally less than -55 charge units, optionally less than -60 charge units, optionally less than -65 charge units, optionally less than -70 charge units, optionally less than -75 charge units, optionally less than -80 charge units, optionally less than -85 charge units, optionally less than -90 charge units, optionally less than -95 charge units, optionally less than -100 charge units, optionally at a pH range of 3 to 10, optionally pH 7
[0360] c) a net charge of at least +3 charge units, optionally at least +5 charge units, optionally at least +7 charge units, optionally at least +10 charge units, optionally at least +15 charge units, optionally at least +20 charge units, optionally at least +25 charge units, optionally at least +30 charge units, optionally at least +35 charge units, optionally at least +40 charge units, optionally at least +45 charge units, optionally at least +50 charge units, optionally at least +55 charge units, optionally at least +60 charge units, optionally at least +65 charge units, optionally at least +70 charge units, optionally at least +75 charge units, optionally at least +80 charge units, optionally at least +85 charge units, optionally at least +90 charge units, optionally at least +95 charge units, optionally at least +100 charge units, optionally at least +200 charge units, optionally at least +300 charge units, optionally at least +400 charge units, optionally at least +500 charge units, optionally at least +600 charge units, optionally at least +700 charge units, optionally at least +800 charge units, optionally at least +900 charge units, optionally at least +1000 charge units, optionally at least +2000 charge units, optionally at least +3000 charge units, optionally at least +4000 charge units, optionally at least +5000 charge units, optionally at least +6000 charge units, optionally at least +7000 charge units, optionally at least +8000 charge units, optionally at least +9000 charge units, optionally at least +10000 charge units;
[0361] and / or
[0362] d) a high negative net charge, optionally has a net charge of less than -3 charge units, optionally at less than -5 charge units, optionally less than -7 charge units, optionallyless than -10 charge units, optionally less than -15 charge units, optionally less than -20 charge units, optionally less than -25 charge units, optionally less than -30 charge units, optionally less than -35 charge units, optionally less than -40 charge units, optionally less than -45 charge units, optionally less than -50 charge units, optionally less than -55 charge units, optionally less than -60 charge units, optionally less than -65 charge units, optionally less than -70 charge units, optionally less than -75 charge units, optionally less than -80 charge units, optionally less than -85 charge units, optionally less than -90 charge units, optionally less than -95 charge units, optionally less than -100 charge units, optionally less than -200 charge units, optionally less than -300 charge units, optionally less than -400 charge units, optionally less than -500 charge units, optionally less than -600 charge units, optionally less than -700 charge units, optionally less than -800 charge units, optionally less than -900 charge units, optionally less than -1000 charge units, optionally less than -2000 charge units, optionally less than -3000 charge units, optionally less than -4000 charge units, optionally less than -5000 charge units, optionally less than -6000 charge units, optionally less than -7000 charge units, optionally less than -8000 charge units, optionally less than -9000 charge units, optionally less than -10000 charge units.
[0363] In some embodiments the concatemer that comprises or consists of at least two beta solenoids comprises at least three beta solenoids, optionally at least four beta solenoids, optionally at least 5 beta solenoids, optionally at least 6 beta solenoids, optionally at least 7 beta solenoids, optionally at least 8 beta solenoids, optionally at least 9 beta solenoids, optionally at least 10 beta solenoids, optionally at least 11 beta solenoids, optionally at least 12 beta solenoids, optionally at least 13 beta solenoids, optionally at least 14 beta solenoids, optionally at least 15 beta solenoids, optionally at least 16 beta solenoids, optionally at least 17 beta solenoids, optionally at least 18 beta solenoids, optionally at least 19 beta solenoids, optionally at least 20 beta solenoids, optionally at least 21 beta solenoids, optionally at least 22 beta solenoids, optionally at least 23 beta solenoids, optionally at least 24 beta solenoids, optionally at least 25 beta solenoids, optionally at least 26 beta solenoids, optionally at least 27 beta solenoids, optionally at least 28 beta solenoids, optionally at least 29 beta solenoids, optionally at least 30 beta solenoids, optionally at least 35 beta solenoids, optionally at least 40 beta solenoids, optionally at least 45 beta solenoids, optionally at least 50 beta solenoids, optionally at least 55 beta solenoids, optionally at least 60 beta solenoids, optionally at least 65 beta solenoids, optionally at least 70 beta solenoids, optionally at least 75 beta solenoids, optionally at least 80 beta solenoids, optionally at least 85 beta solenoids, optionally at least 90 beta solenoids, optionally at least 95 beta solenoids, optionally at least 100 beta solenoids.In some embodiments the concatemer of at least two beta solenoids comprises or consists of one or more of the sequences according to SEQ ID NO: 29-32, 158-162, and 174-186
[0364] Preferably the concatemer of at least two beta solenoids comprises or consists of one or more of the sequences according to SEQ ID NO: 178 or 186, preferably 178.
[0365] In some embodiments the concatemer of at least two beta solenoids is capable of being expressed by a cell or a cell-free transcription and translation system, optionally a) wherein the cell is a prokaryotic cell, optionally a bacterial cell, optionally an E. coli cell, a Bacillus subtilis cell, a Bacillus megaterium cell, a Vibrio natriegens cell, or a Pseudomonas fluorescens cell; or
[0366] b) wherein the cell is a eukaryotic cell, optionally a yeast cell, optionally Pichia pastoris or Saccharomyces cerevisiae; an insect cell, optionally a baculovirus infected insect cell; or a mammalian cell, optionally a baculovirus infected mammalian cell, a HEK293 cell, a HeLa cell, or CHO cells.
[0367] SEQUENCES
[0368] The polypeptide that comprises or consists of a concatemer that comprises or consists of at least two beta solenoids may comprise features with sequences from the following table:
[0369]
[0370]
[0371] Full concatemer sequences, with N and C terminal caps at the end of each solenoid, with flexible linker between each C-terminal cap and the next N-terminal cap:
[0372] 29, 30, 31, 32, 158, 159, 160, 161, 162, 170, 172, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, and 186.
[0373] It will be appreciated that concatemer may comprise repeats of the same beta solenoid sequence, or a concatemer may comprise more than one different beta solenoid sequence.
[0374] Key to sequence features
[0375] Shading = N-terminal cap
[0376] Italics = C-terminal cap
[0377] Underline – solenoid domain sequence
[0378] Bold = tail sequence
[0379] Lowercase = His-tag and thrombin protease sequence
[0380] SynRFR24.new_caps solenoid domain UNITSn [SEQ ID NO: 1] ASLTGADLSYANLHHANLSRANLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQADLSG
[0381] Cap sequence 1 SynRFR24.new_caps [SEQ ID NO: 2] RMRRDEILEEYRRGRRNFQHINLQEIELTN
[0382] Cap sequence 2 SynRFR24.new_caps [SEQ ID NO: 3] ARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG
[0383] SynRFR24.1 solenoid domain [SEQ ID NO: 1] ASLTGADLSYANLHHANLSRANLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQADLSG
[0384] Cap sequence 1 original SynRFR24.1 [SEQ ID NO: 4] HMNVGEILRHYAAGKRNFQHINLQEIELTN
[0385] Cap sequence 2 original SynRFR24.1 [SEQ ID NO: 5]ARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLCLAGG
[0386] > SynRFR24.new_caps solenoid domain plus both caps plus his tag [SEQ ID NO: 6]
[0387] mgsshhhhhhssglvprgsRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANLRS AD LRN AN LS HAN LSG AN LE EAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LS DAN LEQAD LAG ADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVLWRTASLR GAKMEEEQRREYERARGKSDDG
[0388] > SynRFR24.1 solenoid domain plus both caps plus his tag [SEQ ID NO: 7]
[0389] mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA
[0390] N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEA N LTQAN LKDAN LSDAN LEQAD LAG ADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEOA DLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLCLAGGSGC
[0391] Further solenoid domain sequences:
[0392] [SEQ ID NO: 8] >rfr_ref_minprep_ren_neg_num_20_0004 UNITSn
[0393] AKLAKAN LSNAN LKKARLQN AN LANAKLQNAN LENAN LAGAN LKKAN LRGAN LHGAD LAGAN LKGADLRE ADLRNADLRKAN LTGAKLKNAKLEGAN LADATLKDAN LHGAKLKNAN LARAN LERADLRNADLTG
[0394] [SEQ ID NO: 9] >rfr_ref_minprep_ren_neg_num_21_0003 UNITSn AKLAGADLSNAKLHNAN LENADLKGAN LAGAN LQKAN LHGADLTNADLRKAN LANAN LANAN LEGARLAD ADLRNADLRGAKLKRADLENADLTGAN LKGAN LEGARLERANLKKARLQNAKLAGADLRNARLAG
[0395] [SEQ ID NO: 10] >rfr_ref_minprep_ren_neg_num_22_0001 UNITSn
[0396] ATLAGAN LTGAKLHNARLENADLKDAKLARAN LQKAN LRGAN LRNADLREADLANAN LARADLTGAKLAD ADLRNADLREAN LKNAN LARAN LKGAN LHGAN LHGARLEKAN LENAN LQNAN LQNAN LANADLRG
[0397] [SEQ ID NO: 11] >rfr_ref_minprep_ren_neg_num_23_0004 UNITSn AKLAGADLSNADLRNAN LQNAN LANAN LENADLENADLKGARLENAN LRRAN LRGAN LAEARLEKADLRN AN LANADLRRAN LRNAELQNADLQGAN LEGADLTGAN LKGAKLKNAN LQNARLAKADLRNADLTG
[0398] [SEQ ID NO: 12] >rfr_ref_minprep_ren_neg_num_24_0002 UNITSn
[0399] AELAGAN LAGAN LKNAN LRNAN LKDADLRKAN LQKADLKGAN LQNARLQGAN LENAN LAGARLQGAN LAK ADLRGADLRNANLTNARLEKADLTDADLHGARLQGADLHGANLERARLQNANLAEADLRNANLTG
[0400] [SEQ ID NO: 13] >rfr_ref_minprep_ren_neg_num_25_0003 UNITSn
[0401] ATLAGADLSNAN LKQADLARAN LKDAN LQNAN LKNAKLEGAN LA KAN LEKAN LHGAN LARADLTGAN LAN AKLENADLRKADLTNADLTNADLRGADLEGAN LHGAN LKGAN LRKAKLKRAELQNADLRNADLTG
[0402] [SEQ ID NO: 14] >rfr_ref_minprep_ren_neg_num_26_0004 UNITSnATLAGAKLRNAN LHN ARLQNAN LANADLQQADLEEAN LHGAN LANAN LEEAN LRRADLANADLTGAN LAN ADLRQADLRGAN LRNARLQKAN LADADLHGADLHGAN LEGAN LRRARLENAKLANADLRNADLKG
[0403] [SEQ ID NO: 15] >rfr_ref_minprep_ren_neg_num_27_0004 UNITSn ATLAGADLSKANLHRADLKNANLKGANLEKADLREADLHGADLTNANLHGARLARADLANANLKGADLAN ADLREANLHGADLTNARLQNARLQDADLHGANLTGARLHGADLTNARLQRADLSKADLRNANLEG
[0404] [SEQ ID NO: 16] >rfr_ref_minprep_ren_neg_num_28_0002 UNITSn
[0405] ATLAGADLRNAN LKNAN LQKAN LANAN LRNAN LQGADLAKARLENADLHGARLAKAN LAGAN LHGADLAN ADLRNAN LRNADLRNARLERADLAGADLEGAN LHGAN LREARLENAN LKRAN LQNAN LANADLTG
[0406] [SEQ ID NO: 17] >rfr_ref_minprep_ren_neg_num_29_0005 UNITSn ATLAGAKLEGADLTRAKLKDAN LAKAN LRNAN LQEAN LKGAN LRNAD LAGAN LERAN LAKADLHGAN LAN ADLREADLRNANLDNADLRNADLTGADLEGASLHGANLKKARLENARLRRARLENAN LAKAN LTG
[0407] [SEQ ID NO: 18] >rfr_ref_minprep_ren_neg_num_30_0005 UNITSn ATLAGADLSGADLHNADLQNAKLKGAN LEKARLRRAN LRGADLTNAN LRGADLEEADLAGARLHGAN LAR ARLANADLRNADLRNAN LREADLTGAN LHGAN LHGADLERAN LTNADLENARLERAN LAEAN LQD
[0408] [SEQ ID NO: 19] >rfr_ref_minprep_ren_neg_num_31_0005 UNITSn
[0409] ATLKGANLQDAN LQEAN LQNAN LQGARLSNADLRRADLEGANLENADLSGARLQEANLAGARLEGADLAD ADLRGADLRNADLTNARLERANLADADLHGADLHGAKLHGANLERARLENARLENADLRNAKLAG
[0410] [SEQ ID NO: 20] >rfr_ref_minprep_ren_neg_num_32_0001 UNITSn
[0411] ATLAGADLSNAN LEN ADLQN ADLANAKLQNAN LARAN LHGADLRNADLEGAD LAEAN LANAN LEGADLAN ADLRNADLRGANLTNARLQNANLTGANLRGANLHGADLHGAKLRKADLEKARLENADLRKADLKG
[0412] [SEQ ID NO: 21] >rfr_ref_minprep_ren_neg_num_33_0004 UNITSn AKLAGADLRDADLQRAN LENADLANAKLKNAN LEQAN LEGAN LENAN LAKADLRN AN LARADLTGADLSN ADLRGADLRKANLTNADLTNADLEGADLTDARLQGAN LHGAN LTNAN LARAN LAGADLRNAKLSG
[0413] [SEQ ID NO: 22] >rfr_ref_minprep_ren_neg_num_34_0001 UNITSn
[0414] ATLSGAKLEGAN LKRADLRN AN LSKADLRNAN LQQAN LQGADLENADLQGAN LEEAN LAKAN LTGAN LSN ADLRKADLRNANLKDADLENADLEGANLHGADLHGAKLHGADLTRADLENARLENADLRNARLNG
[0415] [SEQ ID NO: 23] >rfr_ref_minprep_ren_neg_num_35_0005 UNITSn
[0416] AELAGAD LANAN LHRAN LENAN LANAKLEEAN LEEAN LAGADLRNANLQRANLARADLAGADLTGANLAEA DLREARLQKAN LENADLTNADLTGADLEGARLHGAN LEGAN LTNAN LRKAN LEN ADLRNADLTG
[0417] [SEQ ID NO: 24] >rfr_ref_minprep_ren_neg_num_36_0005 UNITSnAELAGADLSGADLTRADLRDANLANADLQEANLAEAKLQGAN LENAN LARADLSRANLAGADLHGAN LAE ADLRNADLRNANLQNADLRKARLQGADLEGANLEGANLHGADLENADLARADLQKADLRNANLTG
[0418] [SEQ ID NO: 25] >rfr_ref_minprep_ren_neg_num_37_0002 UNITSn ATLADADLSDARLHRADLQDADLENANLENADLS EAN LRGADLRNANLRKAD LA RAD LAGAN LHGAD LAN AKLAEADLRDADLRNAN LEN ADLTGAN LQGARLEGAKLHGAN LTNAN LKDADLSGADLRDAN LTG
[0419] [SEQ ID NO: 26] >rfr_ref_minprep_ren_neg_num_38_0005 UNITSn
[0420] ATLKGAN LQGARLHN ADLEEAELKDAN LAEADLQNAN LRRADLTN AD LANAN LHGAN LAEAN LHGAN LAG ADLRNADLEN ADLRNAN LEDADLKGAN LHGAN LQGAN LEGARLQNAN LKNARLAEADLRNADLKG
[0421] [SEQ ID NO: 27] >rfr_ref_minprep_ren_neg_num_39_0003 UNITSn AELAGADLSNADLRNAKLENANLADANLENADLENANLRGADLENADLRRADLHGADLAKANLEGANLAE ADLRNADLRNANLTNADLKNADLEGADLHGARLEGANLEGANLENADLANADLSDADLRKADLTG
[0422] [SEQ ID NO: 28] >rfr_ref_minprep_ren_neg_num_40_0004 UNITSn
[0423] AELAGADLSDAN LEQAN LQNAN LANAN LENAN LQDADLHGARLQNADLRGAN LEDADLANARLEGAN LAE ADLRRADLRGADLTNADLEDADLEGAN LHGARLEGAN LRGAN LTDARLENADLSGADLRNAN LEG
[0424] [SEQ ID NO: 169]
[0425] AELAGAD LANAN LHRAN LENAN LANAKLEEAN LEEAN LAGADLRNANLQRANLARADLAGADLTGANLAEA DLREARLQSANLENADLTNADLTGADLEGARLHGANLEGAN LTNAN LRKAN LEN ADLRNADLTG
[0426] > SynRFR24.new_caps.x4.1 concatemer of four beta solenoid domains, not including N-terminal His tag [SEQ ID NO: 29]
[0427] RM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANLSHANLSGA N LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGA N LN NAN LSEAM LTRAN QA SGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG GGGSRM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANLSHAN LSGAN LEEAN LEAAN LRG AD LH EAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN QA SGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEORREYE
[0428] / MflGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANL S HAN LSGAN LE EAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LSDAN LEQADLAG AD LOG AVL DGAN LHGAN LN NAN LSEAM LTRAN QA SGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEO RREYERARGGGGSR RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADL RN AN LSH AN LSGAN LEEAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LS DAN LEQAD LAG AD L OGAVLDG AN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVL WRTASLR GAKMEEEQRREYERARGKSDDG
[0429] > SynRFR24.new_caps.x4.1 concatemer of four beta solenoid domains, including N-terminal His tag [SEQ ID NO: 30]mgsshhhhhhssglvprgsRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRAN LRS AD LRN AN LS HAN LSG AN LE EAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LS DAN LEQAD LAG ADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVLWRTASLR GAKMEEEQRREYERARGGGGSRM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSR AN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRG ADLH EAN LSGADLQEAN LTQAN LKDAN LSDAN LEO ADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVL WR
[0430] 7ASZ-RGA / CMGGGC GYE7MRGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHH AN LSRANLRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEANLSGADLQEANLTQAN LKDAN LSD AN LEQADLAGADLQG AVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDP
[0431] . IV / ? 7AS / - / ? GA / <7WEEEO / ? / ? EYE / M / ? GGGGSRM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDA N LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRANLEQADLSGARTTGARLDDADLRG ATVDPVLWRTASLR GAKMEEEQRREYERARGKSDDG
[0432] > SynRFR24.new_caps.x8.1 concatemer of eight beta solenoid domains, not including N-terminal His tag [SEQ ID NO: 31]
[0433] RM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGA N LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGA N LN NAN LSEAM LTRAN EEQAEfESGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG GGGSRM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRG AD LH EAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN EEQAEfESGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEORREYE / ? A / ? GGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANL S HAN LSGAN LE EAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LSDAN LEQADLAG AD LOG AVL DGAN LHGAN LN NAN LSEAM LTRAN EEQAEfESGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEO RREYERARGGGGS \ RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSRAN LRSADL RN AN LSHAN LSGAN LEEAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LS DAN LEQAD LAG AD L OGAVLDG AN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVL WRTASLRGAK
[0434] M£7z7rO / ? / ?£Y£7? A / ? GGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANL RSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDANLEQADL AG AD LOG AVLDGAN LHGAN LN NAN LSEAM LTRAN LEQAD ESGARTTGARLDDADLRGATVDPVL WRTAS
[0435] L / ? GA / <7WEEEO / ? / ? EYE / ? A / ? GGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANL S RAN LRSADLRNAN LS HAN LSGAN LEEAN LEAAN LRG AD LH EAN LSG AD LOEAN LTQAN LKDAN LS DAN L EOADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVL IV / ? 7AS / - / ? GA / <7WEEEO / ? / ? EYE / ? A / ? GGGGSRMRRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LE0ADLSGA / ?7TGA / ? / -DDAD / - / ? GAT VD / LlV / ? TASZ_ / ? GA / < WE z7rQ / ? / ? / rYE7? A / ? GGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGAD LSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEANLTQANLKDAN LSDAN LEQADLAG ADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDAD LRGATVDPVLWRTASLRGAKMEEEQRREYERARGKSDDG
[0436] > SynRFR24.new_caps.x8.1 concatemer of eight beta solenoid domains, including N-terminal His tag [SEQ ID NO: 32]
[0437] mgsshhhhhhssglvprgsRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLS RAN LRS AD LRN AN LS HAN LSG AN LE EAN LEAAN LRG AD LH EAN LSG AD LO EAN LTQAN LKDAN LS DAN LEQAD LAG ADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVLWRTASLR GAKMEEEQRREYERARGGGGSRM RRDEILEEYRRGRRN FQHINLQEIELTNASLTGADLSYAN LHHAN LSR AN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRG ADLH EAN LSGADLQEAN LTQAN LKDAN LSDAN LEO ADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVL WR TAS / -PGA / C / WEEEOPPEYEPAPGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHH AN LSRANLRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEANLSGADLQEANLTQAN LKDAN LSD AN LEQADLAGADLQG AVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDP
[0438] V'Z-IVPTASZ-PGA MEEEOPPEYEPAPGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDA N LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQAD LSGAP7TGAP / -DDAD / -PG A7VDPV' / . IVPTAS / . PGA / C / WEEEQPPEYEPAPGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGA DLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLH EAN LSGADLQEANLTOA N LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQAD LSGAP7TGAP / -DD ADLPGATVDPV'Z. IVPTAS / . PGA / C / WEEEQPPEYEPAPGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTN ASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEA NLTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQAD LSGAP7TGA RLDDADLRGAT DPVLWRTASLRGAKMEEEQRREYERARGGGGSRMRRDEILEE RRGRRNEQmNLQEI ELTNASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGAD LOEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQAD LSGAP TTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGGSRM DE LEE G. NEQmN LQ El E LTN AS LTG AD LSYAN LH HAN LS RAN LRSADLRNAN LS HAN LSGAN LEEAN LEAAN LRGADLH EAN L SGADLQEANLTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQAD SGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG SPPG
[0439] His tag + protease site [SEQ ID NO: 33]
[0440] mgsshhhhhhssglvprgs
[0441] Linker sequences
[0442] GGGS [SEQ ID NO: 34]
[0443] GGGSAAAAAAGGGS [SEQ ID NO: 168]
[0444] nucleic acid encoding SynRFT24.1 both capping sequences plus His tag [SEQ ID NO: 35] ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCACATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCATGAAGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAACCTGAAAGATGCTAATCTGTCTGATGCCAACCTGGAACAGGCA GATCTGGCAGGGGCTGATCTGCAGGGTGCAGTTCTGGACGGTGCTAATCTGCATGGCGCA AATCTGAATAATGCGAACCTGAGCGAAGCAATGCTGACCCGTGCGAATCTGGAGCAGGCC GACCTGAGCGGTGCACGTACCACCGGTGCACGTCTGGATGATGCCGACCTGCGTGGTGCA ACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGAT CAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0445] [SEQ ID NO: 36]- synRFR24.2 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRGADLH EAN LSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQA DLSGARTTGARLDDASLHGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLCLAGGSGC
[0446] [SEQ ID NO: 37]Nucleic acid encoding for synR. FR.24.2 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCATGAAGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAACCTGAAAGATGCTAATCTGTCTGATGCCAACCTGGAACAGGCA GATCTGGCAGGGGCTGATCTGCAGGGTGCAGTTCTGGACGGTGCTAATCTGCATGGCGCA AATCTGAATAATGCGAACCTGAGCGAAGCAATGCTGACCCGTGCGAATCTGGAGCAGGCC GACCTGAGCGGTGCACGTACCACCGGTGCACGTCTGGATGATGCTAGCCTCCATGGTGCA ACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGAT CAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0447] [SEQ ID NO: 38]- synRFR20.1 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRGADLH EAN LSGADLQEA N LTQAN LKDAN LSDAN LEQAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGA TVDPVLWRTASLVGARVDVDQAVAFAAAHGLCLAGGSGC
[0448] [SEQ ID NO: 39]- nucleic acid encoding synRFR20.1 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCCAATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCATGAAGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAACCTGAAAGATGCTAATCTGTCTGATGCCAACCTGGAACAGGCA AATCTGAATAATGCGAACCTGAGCGAAGCAATGCTGACCCGTGCGAATCTGGAGCAGGCC GACCTGAGCGGTGCACGTACCACCGGTGCACGTCTGGATGATGCCGACCTGCGTGGTGCA ACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGAT CAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0449] [SEQ ID NO: 40]- synRFR28.1 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRGADLH EAN LSGADLQEA NLTQANLKDANLSDANLEQADLAGADLQGAVLDGANLHGADLNGADLKQADLSGADLGGA N LN NAN LSEAM LTRAN E ADLSGARTTGARLDDADLRGATVDPVL WRTASLVGARVDVD QA VAFAAAHGLCLAGGSGC
[0450] [SEQ ID NO: 41]
[0451] - nucleic acid encoding synR. FR.28.1 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCATGAAGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAACCTGAAAGATGCTAATCTGTCTGATGCCAACCTGGAACAGGCA GATCTGGCAGGGGCTGATCTGCAGGGTGCAGTTCTGGACGGTGCTAATCTGCATGGCGCG GACCTCAACGGTGCCGATTTAAAACAGGCTGATTTATCTGGAGCAGATTTAGGTGGCGCA AATCTGAATAATGCGAACCTGAGCGAAGCAATGCTGACCCGTGCGAATCTGGAGCAGGCC GACCTGAGCGGTGCACGTACCACCGGTGCACGTCTGGATGATGCCGACCTGCGTGGTGCA ACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGAT CAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0452] [SEQ ID NO: 42]- synRFR24.t754 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LKGAN LEEAN LEAAN LRGAN LAGAN LSGADLQEA NLTQAQLGGWSDNGETGADLSDANLEQADLAGADLYGAVLDGANLHGANLNNANLDNAML
[0453]
[0454] [SEQ ID NO: 43]- nucleic acid encoding synRFR24.t754 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCCAATCTGTCACATGCGAATCTGAAAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGAACCTGGCGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGCAGCTGGGCGGCTGGAGCGATAACGGCGAAACCGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTGATCTGTATGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAACGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0455] [SEQ ID NO: 44]- synRFR24.t801 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LRGAN LEEAN LEAAN LRGADLIGAN LSGADLQEA NLTQAQLGLGVEDGGLGADLSDANLEQADLAGANLAGAVLDGANLHGANLNNANLDYAML PA E ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0456] [SEQ ID NO: 45]- Nucleic acid encoding synR. FR.24.t801 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGCGCGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGATTGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGCAGCTGGGCCTGGGCGTGGAAGATGGCGGCCTGGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTAACCTGGCGGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATTATGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0457] [SEQ ID NO: 46]- synRFR24. till? mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LRGAN LEEAN LEAAN LRGADLVGAN LSGADLQEA N LTQAQLGGVYRLG EPGADLSDAN LEQADLAGAN LMG AVLDGAN LHGAN LN NAN LDYAM L GPMA ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0458] [SEQ ID NO: 47]- nucleic acid encoding synRFR24. tlll7 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCAAATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGCGCGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGGTGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGCAGCTGGGCGGCGTGTATCGCCTGGGCGAACCGGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTAACCTGATGGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATTATGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0459] [SEQ ID NO: 48]- synRFR24.tll66 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLRGAN LSGADLQEA N LTQAKLGTWSSSG LTGADLSDAN LEQADLAGADLKGAVLDGAN LHGAN LN NAN LDYAM L PA E ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0460] [SEQ ID NO: 49]- nucleic acid encoding synR. FR.24.tH66 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCGCGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAAACTGGGCACCTGGAGCAGCAGCGGCCTGACCGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTGATCTGAAAGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATTATGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0461] [SEQ ID NO: 50]- synRFR24.tl428 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGAN LVGAN LSGADLQEA N LTQAM LGQTYPWGTVG ADLSDAN LEQADLAGAQLVGAVLDGAN LHGAN LN NAN LDN AM L GPMA ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0462] [SEQ ID NO: 51]- nucleic acid encoding synRFR24.tl428 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATTAACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGAACCTGGTGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGATGCTGGGCCAGACCTATCCGTGGGGCACCGTGGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAGCTGGTGGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAACGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0463] [SEQ ID NO: 52]- synRFR24.tl555 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLAGAN LSGADLQEA N LTQAM LGKDEDGWYGADLSDANLEQADLAGAQLVGAVLDGAN LHGAN LN NAN LDNAML PA E ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0464] [SEQ ID NO: 53]- nucleic acid encoding synRFR24.tl555 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGGCGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGATGCTGGGCAAAGATGAAGATGGCGTGGTGTATGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAGCTGGTGGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAACGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0465] [SEQ ID NO: 54]- synRFR24.tl916 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGALLTGAN LSGADLQEA NLTQAWLGRDPRLGLSGADLSDANLEQADLAGAQLKGAVLDGAN LHGAN LN NAN LDNAML GPMA ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0466] [SEQ ID NO: 55]- nucleic acid encoding synRFR24.tl916
[0467] ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCACATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGCTGCTGACCGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGTGGCTGGGCCGCGATCCGCGCCTGGGCCTGAGCGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAGCTGAAAGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAACGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0468] [SEQ ID NO: 56]- synRFR24.t2570 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LKGAN LEEAN LEAAN LRGAN LAGAN LSGADLQEA N LTQADLGG PPDEG KTGADLSDAN LEQADLAGAQLYGAVLDGAN LHGAN LN NAN LDYAM L PA E ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0469] [SEQ ID NO: 57]- nucleic acid encoding synRFR24.t2570 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGAAAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGAACCTGGCGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGGATCTGGGCGGCCCGCCGGATGAAGGCAAAACCGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAGCTGTATGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATTATGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0470] [SEQ ID NO: 58]- synRFR24.t3280 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLRGAN LSGADLQEA N LTQAKLGGYDDEGLGGADLSDANLEQADLAGAELFGAVLDGAN LHGAN LN NAN LDKAM L GPMA ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0471] [SEQ ID NO: 59]-nucleic acid encoding synRFR24.t3280ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGAGCGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGGATCTGCGCGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAAACTGGGCGGCTATGATGATGAAGGCCTGGGCGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTGAACTGTTTGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAAAGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0472] [SEQ ID NO: 60]- synRFR24.t3284 mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LEG AN LEEAN LEAAN LRGARLAGAN LSGADLQEA NLTQANLGGPPDDGDPGADLSDANLEQADLAGANLAGAVLDGANLHGANLNNANLDNAML PA E ADLSGARTTGARLDDADLRGATVDPVLWRTASLVGARVDVDQAVAFAAAHGLC LAGGSGC
[0473] [SEQ ID NO: 61] nucleic acid encoding synRFR24.t3284 ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGGAAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGCGCCTGGCGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGAACCTGGGCGGCCCGCCGGATGATGGCGATCCGGGCGCTGATCTG TCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTAACCTGGCGGGTGCAGTTCTG GACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAACCTGGATAACGCAATGCTG ACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGTACCACCGGTGCACGTCTG GATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTGTGGCGTACCGCAAGCCTG GTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCAGCAGCACATGGTCTGTGT CTGGCAGGTGGATCCGGCTGCTAA
[0474] [SEQ ID NO: 62]- synRFR24.tl428 sfGFP mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRGAN LVGAN LSGADLQEA NLTQAMLGQTYPGGGGSMRKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLT LKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDD GTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA NFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGMDELSGGGGWGTVGADLSDANLEQADLAGAQLVGAVLDGANLHGANLNNAN LD N AM LTRAN EEQADLSGAR TTGARLDDADLRGATVDPVL WRTASL VGARVDVDQA VAFA AAHGLCLAGGSGC
[0475] [SEQ ID NO: 63]-nucleic acid encoding synRFR24.tl428 sfGFP ATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGAACCTGGTGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGATGCTGGGCCAGACCTATCCGGGAGGTGGAGGCTCAATGCGTAAA GGCGAAGAGCTGTTCACTGGTGTCGTCCCTATTCTGGTGGAACTGGATGGTGATGTCAAC GGTCATAAGTTTTCCGTGCGTGGCGAGGGTGAAGGTGACGCAACTAATGGTAAACTGACG CTGAAGTTCATCTGTACTACTGGTAAACTGCCGGTACCTTGGCCGACTCTGGTAACGACG CTGACTTATGGTGTTCAGTGCTTTGCTCGTTATCCGGACCATATGAAGCAGCATGACTTC TTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCCTTTAAGGATGAC GGCACGTACAAAACGCGTGCGGAAGTGAAATTTGAAGGCGATACCCTGGTAAACCGCATT GAGCTGAAAGGCATTGACTTTAAAGAAGACGGCAATATCCTGGGCCATAAGCTGGAATAC AATTTTAACAGCCACAATGTTTACATCACCGCCGATAAACAAAAAAATGGCATTAAAGCG AATTTTAAAATTCGCCACAACGTGGAGGATGGCAGCGTGCAGCTGGCTGATCACTACCAG CAAAACACTCCAATCGGTGATGGTCCTGTTCTGCTGCCAGACAATCACTATCTGAGCACG CAAAGCGTTCTGTCTAAAGATCCGAACGAGAAACGCGATCATATGGTTCTGCTGGAGTTC GTAACCGCAGCGGGCATCACGCATGGTATGGATGAACTGTCTGGAGGCGGTGGATGGGGC ACCGTGGGCGCTGATCTGTCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAG CTGGTGGGTGCAGTTCTGGACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAAC CTGGATAACGCAATGCTGACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGT ACCACCGGTGCACGTCTGGATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTG TGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCA GCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0476] [SEQ ID NO: 64]- synRFR24.tl428 sfGFPmut mgsshhhhhhssglvprgsHMNVGEILRHYAAGKRNFQHINLQEIELTNASLTGADLSYA N LH HAN LSRAN LRSADLRN AN LSHAN LSG AN LEEAN LEAAN LRGAN LVGAN LSGADLQEA NLTQAMLGQTYPGGGGSMRKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLT LKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDD GTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA NFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEF VTAAGITHGMDELSGGGGAGTVGADLSDANLEQADLAGAQLVGAVLDGANLHGANLNNAN LD N AM LTRAN LEQADLSGAR TTGARLDDADLRGATVDPVL WRTASL VGARVDVDQA VAFA AAHGLCLAGGSGC
[0477] [SEQ ID NO: 65]- nucleic acid encoding synRFR24.t!428 sfGFPmutATGGGTAGCAGCCATCATCATCATCACCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCAC ATGAATGTTGGTGAAATTCTGCGTCATTATGCAGCAGGTAAACGCAATTTTCAGCATATT AACCTGCAAGAAATTGAACTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCA AATCTGCATCATGCAAATCTGAGCCGTGCCAATCTGCGTTCTGCAGACCTGCGTAATGCC AATCTGTCACATGCGAATCTGTCAGGTGCAAATCTGGAAGAAGCCAATCTGGAAGCCGCT AATCTGCGTGGTGCGAACCTGGTGGGCGCGAATCTGAGTGGCGCTGATCTGCAAGAGGCA AATCTGACCCAGGCGATGCTGGGCCAGACCTATCCGGGAGGTGGAGGCTCAATGCGTAAA GGCGAAGAGCTGTTCACTGGTGTCGTCCCTATTCTGGTGGAACTGGATGGTGATGTCAAC GGTCATAAGTTTTCCGTGCGTGGCGAGGGTGAAGGTGACGCAACTAATGGTAAACTGACG CTGAAGTTCATCTGTACTACTGGTAAACTGCCGGTACCTTGGCCGACTCTGGTAACGACG CTGACTTATGGTGTTCAGTGCTTTGCTCGTTATCCGGACCATATGAAGCAGCATGACTTC TTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCCTTTAAGGATGAC GGCACGTACAAAACGCGTGCGGAAGTGAAATTTGAAGGCGATACCCTGGTAAACCGCATT GAGCTGAAAGGCATTGACTTTAAAGAAGACGGCAATATCCTGGGCCATAAGCTGGAATAC AATTTTAACAGCCACAATGTTTACATCACCGCCGATAAACAAAAAAATGGCATTAAAGCG AATTTTAAAATTCGCCACAACGTGGAGGATGGCAGCGTGCAGCTGGCTGATCACTACCAG CAAAACACTCCAATCGGTGATGGTCCTGTTCTGCTGCCAGACAATCACTATCTGAGCACG CAAAGCGTTCTGTCTAAAGATCCGAACGAGAAACGCGATCATATGGTTCTGCTGGAGTTC GTAACCGCAGCGGGCATCACGCATGGTATGGATGAACTGTCTGGAGGCGGTGGAGCTGGC ACCGTGGGCGCTGATCTGTCTGATGCCAACCTGGAACAGGCAGATCTGGCAGGGGCTCAG CTGGTGGGTGCAGTTCTGGACGGTGCTAATCTGCATGGCGCAAATCTGAATAATGCGAAC CTGGATAACGCAATGCTGACCCGTGCGAATCTGGAGCAGGCCGACCTGAGCGGTGCACGT ACCACCGGTGCACGTCTGGATGATGCCGACCTGCGTGGTGCAACCGTTGATCCGGTTCTG TGGCGTACCGCAAGCCTGGTTGGTGCACGTGTTGATGTTGATCAGGCAGTTGCATTTGCA GCAGCACATGGTCTGTGTCTGGCAGGTGGATCCGGCTGCTAA
[0478] Solenoid domain sequence of synR. FR.24.2 [SEQ ID NO: 66]
[0479] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQ
[0480] Solenoid domain sequence of synRFR20.1[SEQ ID NO: 67]
[0481] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEA N LTQAN LKDAN LSDAN LEQAN LN NAN LSEAM LTRAN LEQ
[0482] Solenoid domain sequence of synRFR28.1[SEQ ID NO: 68]
[0483] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGADLNGADLKQADLSGADLGGA N LN NAN LSEAM LTRAN LEQ
[0484] Solenoid domain sequence of synRFR24.t764[SEQ ID NO: 69]
[0485] AN LHHAN LSRAN LRSADLRNAN LSHAN LKGAN LEEAN LEAAN LRGAN LAGAN LSGADLQEA NLTQAQLGGWSDNGETGADLSDANLEQADLAGADLYGAVLDGAN LHGAN LN NAN LDNAML TRAN LEQSolenoid domain sequence of synRFR24.t801[SEQ ID NO: 70] AN LHHAN LSRAN LRSADLRNAN LSHAN LRGAN LEEAN LEAAN LRGADLIGAN LSGADLQEA NLTQAQLGLGVEDGGLGADLSDANLEQADLAGANLAGAVLDGAN LHGAN LN NAN LDYAML TRANLEQ
[0486] Solenoid domain sequence of synRFR24.tlll7[SEQ ID NO: 71]
[0487] AN LHHAN LSRAN LRSADLRNAN LSHAN LRGAN LEEAN LEAAN LRGADLVGAN LSGADLQEA N LTQAQLGGVYRLG EPGADLSDAN LEQAD LAGAN LMG AVLDGAN LHGAN LN NAN LDYAM L TRANLEQ
[0488] Solenoid domain sequence of synRFR24.tll66[SEQ ID NO: 72]
[0489] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLRGAN LSGADLQEA N LTQAKLGTWSSSG LTGADLSDAN LEQAD LAG AD LKG AVLDGAN LHGAN LN NAN LDYAM L TRANLEQ
[0490] Solenoid domain sequence of synRFR24.tl428[SEQ ID NO: 73]
[0491] AN LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGAN LVGAN LSGADLQEA N LTQAM LGQTYPWGTVG ADLSDAN LEQAD LAG AQLVG AVLDGAN LHGAN LN NAN LDN AM L TRANLEQ
[0492] Solenoid domain sequence of synRFR24.tl555[SEQ ID NO: 74]
[0493] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGAD LAGAN LSGADLQEA N LTQAM LGKDEDGWYGADLSDANLEQADLAGAQLVGAVLDGAN LHGAN LN NAN LDNAML TRANLEQ
[0494] Solenoid domain sequence of synRFR24.tl916[SEQ ID NO: 75]
[0495] AN LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGALLTGAN LSGADLQEA NLTQAWLGRDPRLGLSGADLSDAN LEQAD LAGAQLKGAVLDGAN LHGAN LN NAN LDNAML TRANLEQ
[0496] Solenoid domain sequence of synRFR24.t2570[SEQ ID NO: 76]
[0497] AN LHHAN LSRAN LRSADLRNAN LSHAN LKGAN LEEAN LEAAN LRGAN LAGAN LSGADLQEA N LTQADLGG PPDEG KTGADLSDAN LEQAD LAGAQLYGAVLDGAN LHGAN LN NAN LDYAM L TRANLEQ
[0498] Solenoid domain sequence of synRFR24.t3280[SEQ ID NO: 77]
[0499] AN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLRGAN LSGADLQEA N LTQAKLGGYDDEGLGGADLSDANLEQADLAGAELFGAVLDGAN LHGAN LN NAN LDKAM L TRANLEQSolenoid domain sequence of synRFR24.t3284[SEQ ID NO: 78] AN LHHAN LSRAN LRSADLRNAN LSHAN LEGAN LEEAN LEAAN LRGARLAGAN LSGADLQEA NLTQANLGGPPDDGDPGADLSDANLEQADLAGANLAGAVLDGANLHGANLNNANLDNAML TRANLEQ
[0500] Solenoid domain sequence of synRFR24.tl428.sfGFP[SEQ ID NO: 79]
[0501] AN LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGAN LVGAN LSGADLQEA NLTQAMLGQTYPGGGGSMRKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLT LKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDD GTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA NFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEF VTAAGITHGMDELSGGGGWGTVGADLSDANLEQADLAGAQLVGAVLDGANLHGANLNNAN LDNAMLTRANLEQ
[0502] Solenoid domain sequence of synRFR24.tl428.sfGFP[SEQ ID NO: 80]
[0503] AN LH HAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGAN LVGAN LSGADLQEA NLTQAMLGQTYPGGGGSMRKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLT LKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDD GTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA NFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEF VTAAGITHGMDELSGGGGAGTVGADLSDANLEQADLAGAQLVGAVLDGANLHGANLNNAN LDNAMLTRANLEQ
[0504] Tail sequence [SEQ ID NO: 81] SDDG
[0505] N-terminal capping consensus sequence [SEQ ID NO: 82] xMxxxxILxxYxxGxxxFxxIxLxx(I / A)xLxx
[0506] where x is any residue
[0507] C-terminal capping consensus sequence [SEQ I NO: 83]
[0508] Ax(T / L / F)xxAx( L / F)xxAx( L / F)xxAxVxPVLWxxAxLxGAx( M / V)xxxxxxx(Y / F)xxAxx Where x is any residue
[0509] NCAP sequences:
[0510] >rfr_ref_minprep_ren_neg_num_20_0004.pdb NCAP [SEQ ID NO: 84] SMGKNEILNQYKNGRHDFSGINLAKADLEN
[0511] >rfr_ref_minprep_ren_neg_num_21_0003.pdb NCAP [SEQ ID NO: 85] TMQTKQILKEYKKG RTN FSGIN LANAN LKN
[0512] >rfr_ref_minprep_ren_neg_num_22_0001.pdb NCAP [SEQ ID NO: 86]
[0513] TMRTKDILKQYNNGRHNFSGIDLANADLEK>rfr_ref_minprep_ren_neg_num_23_0004.pdb NCAP [SEQ ID NO: 87] TMQTNQILKEYKNGRHNFSKINLANANLQN
[0514] >rfr_ref_minprep_ren_neg_num_24_0002.pdb NCAP [SEQ ID NO: 88] SMGTKEILNEYKKGRKKFANINLANADLSN
[0515] >rfr_ref_minprep_ren_neg_num_25_0003.pdb NCAP [SEQ ID NO: 89] TMRRDDILREYNNGRHNFSGINLAKADLRD
[0516] >rfr_ref_minprep_ren_neg_num_26_0004.pdb NCAP [SEQ ID NO: 90] NMKTNKILKNYKKGRHDFTGIDLANADLEN
[0517] >rfr_ref_minprep_ren_neg_num_27_0004.pdb NCAP [SEQ ID NO: 91] SMQADQILQQYDNGRRNFSGIDLENADLRN
[0518] >rfr_ref_minprep_ren_neg_num_28_0002.pdb NCAP [SEQ ID NO: 92] TMRTNEILQEYKNGRHNFEGIDLANANLQN
[0519]
[0520] >rfr_ref_minprep_ren_neg_num_30_0005.pdb NCAP [SEQ ID NO: 94] TMRTKDILKEYNKGRHDFSGINLRNANLRN
[0521] >rfr_ref_minprep_ren_neg_num_31_0005.pdb NCAP [SEQ ID NO: 95] HMQTNQILEEYNRGRHNFAGIDLQGADLRN
[0522] >rfr_ref_minprep_ren_neg_num_32_0001.pdb NCAP [SEQ ID NO: 96] TMSTNEILNEYKKGRHDFSGINLKDADLSN
[0523] >rfr_ref_minprep_ren_neg_num_33_0004.pdb NCAP [SEQ ID NO: 97] SMTTDKILEEYNKGRTDFRDIDLQNANLQN
[0524] >rfr_ref_minprep_ren_neg_num_34_0001.pdb NCAP [SEQ ID NO: 98] SMHASKILQEYNNGRHDFANIDLAKANLEN
[0525] >rfr_ref_minprep_ren_neg_num_35_0005.pdb NCAP [SEQ ID NO: 99] SMQTEQILQEYNRGRTDFAKIDLENANLKN
[0526] >rfr_ref_minprep_ren_neg_num_36_0005.pdb NCAP [SEQ ID NO: 100] TMATDKILQQYKDGQHDFSGIDLANADLSK>rfr_ref_minprep_ren_neg_num_37_0002.pdb NCAP [SEQ ID NO: 101] SMQTNQILKEYNKGRHNFSGIDLQNADLSG
[0527] >rfr_ref_minprep_ren_neg_num_38_0005.pdb NCAP [SEQ ID NO: 102] TMGTNEILQQYKNGQHDFADIDLKNANLQK
[0528] >rfr_ref_minprep_ren_neg_num_39_0003.pdb NCAP [SEQ ID NO: 103] SMSANAILEAYDRGQRDFSKINLANANLSK
[0529] >rfr_ref_minprep_ren_neg_num_40_0004.pdb NCAP [SEQ ID NO: 104] SMHEDEILDEYNNGRKNFSGIDLQGADLED
[0530] CCAP sequences:
[0531] >rfr_ref_minprep_ren_neg_num_20_0004.pdb CCAP [SEQ ID NO: 105] AKTKGANLRKANLEGAKLDPVLWRTANLKGARMSKKQAQEYQRANG
[0532] >rfr_ref_minprep_ren_neg_num_21_0003.pdb CCAP [SEQ ID NO: 106] ADTRGANLDDAKLEGAELRPVLWRTASLSGARMSKKQKQQYQRANG
[0533] >rfr_ref_minprep_ren_neg_num_22_0001.pdb CCAP [SEQ ID NO: 107] AKTTGANLKRANLKGATLDPVLWRTANLEGAKMKKEQKKEYKRARG
[0534] >rfr_ref_minprep_ren_neg_num_23_0004.pdb CCAP [SEQ ID NO: 108] AKTTGAELRNADLRGAKLDPVLWRTAKLTGAQMTKKQKKEYQRARG
[0535] >rfr_ref_minprep_ren_neg_num_24_0002.pdb CCAP [SEQ ID NO: 109] AKTKGADLARADLRGAKLRPVLWNTARLEGAQMTKEQKKEYQRANG
[0536] >rfr_ref_minprep_ren_neg_num_25_0003.pdb CCAP [SEQ ID NO: 110] AETTGAKLARADLRGAKLRPVLWNTATLTGAQMTTKQKQQYKRANG
[0537] >rfr_ref_minprep_ren_neg_num_26_0004.pdb CCAP [SEQ ID NO: 111] AKTKGAKLSGADLRGAKLDPVLWNTAKLQGAKMTDNQRNEYKRANG
[0538] >rfr_ref_minprep_ren_neg_num_27_0004.pdb CCAP [SEQ ID NO: 112] ANTQGAKLDNADLRGAKLRPVLWNTASLQGAKMQKKQKEQYKRAKG
[0539] >rfr_ref_minprep_ren_neg_num_28_0002.pdb CCAP [SEQ ID NO: 113] AETEGADLRRADLRGATLDPVLWNKADLKGAQMKDNQRKEYKRANG
[0540] >rfr_ref_minprep_ren_neg_num_29_0005.pdb CCAP [SEQ ID NO: 114] ANTQDANLQNADLRGATLDPVLWNTANLNGAQMTDKQKQEYQRANG>rfr_ref_minprep_ren_neg_num_30_0005.pdb CCAP [SEQ ID NO: 115] AETTGAKLDNADLRGAKLDPVLWNTASLSGAQMTTAQAEQYERANG
[0541] >rfr_ref_minprep_ren_neg_num_31_0005.pdb CCAP [SEQ ID NO: 116] AKTTGADLANADLRGATLDPVLWRTARLTGAQMKTEQKNQYKRANG
[0542] >rfr_ref_minprep_ren_neg_num_32_0001.pdb CCAP [SEQ ID NO: 117] ADTRGADLRNANLRGATLDPVLWNTADLTGAQMEAEQKKEYNRARG
[0543] >rfr_ref_minprep_ren_neg_num_33_0004.pdb CCAP [SEQ ID NO: 118] ANTSGADLRNADLRGATLDPVLWNTANLKGAKMEDNQKAEYERANG
[0544] >rfr_ref_minprep_ren_neg_num_34_0001.pdb CCAP [SEQ ID NO: 119] ANTSGADLENADLRGAELQPVLWRTARLQGAQMETAQKEEYKRANG
[0545] >rfr_ref_minprep_ren_neg_num_35_0005.pdb CCAP [SEQ ID NO: 120] ANTKGANLDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARG
[0546] >rfr_ref_minprep_ren_neg_num_36_0005.pdb CCAP [SEQ ID NO: 121] AETTGANLNNADLRGATLDPVLWNTASLEGAQMKKEQKKEYKRANG
[0547] >rfr_ref_minprep_ren_neg_num_37_0002.pdb CCAP [SEQ ID NO: 122] ANTQGANLDNADLRGATLDPVLWNTASLEGAQMTTEEAKEYQRANG
[0548] >rfr_ref_minprep_ren_neg_num_38_0005.pdb CCAP [SEQ ID NO: 123] AETEGAELNDADLRGAELAPVLWNTASLEGAKMEEKQEQQYDRARG
[0549] >rfr_ref_minprep_ren_neg_num_39_0003.pdb CCAP [SEQ ID NO: 124] AETTGADLNNADLRGATLDPVLWNTAKLQGAQMTTNQKAEYQRANG
[0550] >rfr_ref_minprep_ren_neg_num_40_0004.pdb CCAP [SEQ ID NO: 125] ANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANG
[0551] Tail sequences:
[0552] >rfr_ref_minprep_ren_neg_num_20_0004.pdb TAIL [SEQ ID NO: 126] KQTEG
[0553] >rfr_ref_minprep_ren_neg_num_21_0003.pdb TAIL [SEQ ID NO: 127] KQTKG
[0554] >rfr_ref_minprep_ren_neg_num_22_0001.pdb TAIL [SEQ ID NO: 128] QQTNG
[0555] >rfr_ref_minprep_ren_neg_num_23_0004.pdb TAIL [SEQ ID NO: 129] KTTEG>rfr_ref_minprep_ren_neg_num_24_0002.pdb TAIL [SEQ ID NO: 130] QQDNG
[0556] >rfr_ref_minprep_ren_neg_num_25_0003.pdb TAIL [SEQ ID NO: 131] QQDEG
[0557] >rfr_ref_minprep_ren_neg_num_26_0004.pdb TAIL [SEQ ID NO: 132] QKDNG
[0558] >rfr_ref_minprep_ren_neg_num_27_0004.pdb TAIL [SEQ ID NO: 133] KQDNG
[0559] >rfr_ref_minprep_ren_neg_num_28_0002.pdb TAIL [SEQ ID NO: 134] QEDKG
[0560] >rfr_ref_minprep_ren_neg_num_29_0005.pdb TAIL [SEQ ID NO: 135] RKTNG
[0561] >rfr_ref_minprep_ren_neg_num_30_0005.pdb TAIL [SEQ ID NO: 136] KSTDG
[0562] >rfr_ref_minprep_ren_neg_num_31_0005.pdb TAIL [SEQ ID NO: 137] QKDNG
[0563] >rfr_ref_minprep_ren_neg_num_32_0001.pdb TAIL [SEQ ID NO: 138] QETRG
[0564] >rfr_ref_minprep_ren_neg_num_33_0004.pdb TAIL [SEQ ID NO: 139] QQDKG
[0565] >rfr_ref_minprep_ren_neg_num_34_0001.pdb TAIL [SEQ ID NO: 140] QSDDG
[0566] >rfr_ref_minprep_ren_neg_num_35_0005.pdb TAIL [SEQ ID NO: 141] QEDKG
[0567] >rfr_ref_minprep_ren_neg_num_36_0005.pdb TAIL [SEQ ID NO: 142] QSDDG
[0568] >rfr_ref_minprep_ren_neg_num_37_0002.pdb TAIL [SEQ ID NO: 143] KEDRG
[0569] >rfr_ref_minprep_ren_neg_num_38_0005.pdb TAIL [SEQ ID NO: 144] QSDDG
[0570] >rfr_ref_minprep_ren_neg_num_39_0003.pdb TAIL [SEQ ID NO: 145] QSDDG
[0571] >rfr_ref_minprep_ren_neg_num_40_0004.pdb TAIL [SEQ ID NO: 146] QQTNG
[0572] Beta solenoid domain consensus sequences:
[0573] A X1L / F X2X3[SEQ ID NO: 147]
[0574] wherein X1is any residue
[0575] X2is any residue
[0576] X3is any residue;
[0577] A Xi L / F X2X3[SEQ ID NO: 148]
[0578] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or VX2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[0579] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y;
[0580] A Xi L X2X3[SEQ ID NO: 149]
[0581] wherein X1is any residue
[0582] X2is any residue
[0583] X3is any residue;
[0584] A Xi L X2X3[SEQ ID NO: 150]
[0585] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[0586] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[0587] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y;
[0588] A (N / D) L * X [SEQ ID NO: 151]
[0589] where * is a polar residue (C, R, H, K, D, E, S, T, N, Q) and X is any residue
[0590] (S / G / T / A)X(A / V / G)X(G / A)XX [SEQ ID NO: 152]
[0591] where X is any residue
[0592] (S / G / T / A)X(A / V / G)X(G / A)XX(S / G / T / A)*(A / V / G)*(G / A)XX [SEQ ID NO: 153]
[0593] where * is a hydrophobic residue and where X is any residue
[0594] SXAXGXXS*A*GXX [SEQ ID NO: 154]
[0595] where * is a hydrophobic residue and where X is any residue
[0596] NXAXGXXST(I / V)(G / A)GGXX [SEQ ID NO: 155]
[0597] where X is any residue
[0598] NXAXGXXSTIGGGXX [SEQ ID NO: 156]
[0599] where X is any residue
[0600] GXQX(V / I / L)XXGGXAXXTX(V / I / L)XXG [SEQ ID NO: 157]
[0601] where X is any residue.
[0602] > SynRFR24.nnum35.x4 [Amino Acid Sequence] [SEQ ID NO: 158]
[0603] MGSSHHHHHHSSGLVPRGSSMOTEOILOEYNRGRTDFAKIDLENANLKNaelagadlananlhranlenan lanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanlenadltnadltgadlegarlhganleganlt nan\rkan\enad\mad\tgANTKGANLDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARGgggsSMQ TEQILQEYNRGRTDFAKIDLENANLKNaelagadlananlhranlenanlanakleeanleeanlagadlrnanlqran laradlagadltganlaeadlrearlqkanlenadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgA / V77CGA / V LDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARGQQQSSMQTEQILQEYNRGRTDFAKIDLENANLKNaelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanle nadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgANTKGANLDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARGggggsSMQTEQILQEYNRGRTDFAKIDLENANLKNaelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanlenadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgANTKGANLDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARGqedkg
[0604] Where:
[0605] MGSSHHHHHHSSGLVPRGS – His tag and protease site [SEQ ID NO: 33] SMQTEQILQEYNRGRTDFAKIDLENANLKN - NCAP sequence [SEQ ID NO: 99] aelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanlenadltna dltgadlegarlhganleganltnanlrkanlenadlrnadltg - Solenoid domain sequence [SEQ ID NO: 23] > rfr_ref_mi n prep_ren_neg_n u m_35_0005 U N ITSn
[0606] ANTKGANLDNADLRGATLDPVLWRTASLQGAKMTTRQAEEYDRARG - CCAP sequence [SEQ ID NO: 120]
[0607] gggs – Linker sequence [SEQ ID NO: 34]
[0608] qedkg - Tail sequence [SEQ ID NO: 134]
[0609] > SynRFR24.nnum36.x4 [Amino Acid Sequence] [SEQ ID NO: 159]
[0610] MGSSHHHHHHSSGLVPRGSTMATDKILQQYKDGQHDFSGIDLANADLSKaelagadlsgadltradlrdanl anadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadl enad\arad\gkad\man\tgAETTGANLNNADLRGATLDPVLWNTASLEGAQMKKEQKKEYKRANGgggsTMA TDKILQQYKDGQHDFSGIDLANADLSKaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlarad IsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgAFTTGA NLNNADLRGATLDPVLWNTASLEGAQMKKEQKKEYKRANGgggsTMATDKILQQYKDGQHDFSGIDL ANADLSKaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrna nlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgAETTGA / VL / V / VADLRGATLDPVZ-lV / VTASLE GAQ / WKSQKKSYTCRA / VGgggsTMATDKILQQYKDGQHDFSGIDLANADLSKaelagadlsgadltradlrda nlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhga d\enad\arad\qkad\man\tgAETTGANLNNADLRGATLDPVLWNTASLEGAQMKKEQKKEYKRANGqsddg
[0611] Where:
[0612] MGSSHHHHHHSSGLVPRGS – His tag and protease site [SEQ ID NO: 33]
[0613] TMATDKILQQYKDGQHDFSGIDLANADLSK - NCAP sequence [SEQ ID NO: 100]
[0614] aelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrka rlqgadleganleganlhgadlenadlaradlqkadlrnanltg - Solenoid domain sequence [SEQ ID NO: 24] > rfr_ref_mi n prep_ren_neg_n u m_36_0005 U N ITSnAETTGANLNNADLRGATLDPVLWNTASLEGAQMKKEQKKEYKRANG - CCAP sequence [SEQ ID NO: 121]
[0615] gggs – Linker sequence [SEQ ID NO: 34]
[0616] qsddg - Tail sequence [SEQ ID NO: 140]
[0617] > SynRFR24.nnum40.x4 [Amino Acid Sequence] [SEQ ID NO: 160]
[0618] MGSSHHHHHHSSGLVPRGSSMHEDEILDEYNNGRKNFSGIDLQGADLEDaelagadlsdanleqanlqnanlananlenanlqdadlhgarlqnadlrganledadlanarleganlaeadlrradlrgadltnadledadleganlhgarleganlrganltdarlenadlsgadlrnanlegANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANGgggsSMHEDEILDEYNNGRKNFSGIDLQGADLEDaelagadlsdanleqanlqnanlananlenanlqdadlhgarlqnadlrganledadlanarleganlaeadlrradlrgadltnadledadleganlhgarleganlrganltdarlenadlsgadlrnanlegANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANGgggsSMHEDEILDEYNNGRKNFSGIDLQGADLEDaelagadlsdanleqanlqnanlananlenanlqdadlhgarlqnadlrganledadlanarleganlaeadlrradlrgadltnadledadleganlhgarleganlrganltdarlenadlsgadlrnanlegANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANGgggsSMHEDEILDEYNNGRKNFSGIDLQGADLEDaelagadlsdanleqanlqnanlananlenanlqdadlhgarlqnadlrganledadlanarleganlaeadlrradlrgadltnadledadleganlhgarleganlrganltdarlenadlsgadlrnanlegANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANGqqtng
[0619] Where:
[0620] MGSSHHHHHHSSGLVPRGS – His tag and protease site [SEQ ID NO: 33]
[0621] SMHEDEILDEYNNGRKNFSGIDLQGADLED - NCAP sequence [SEQ ID NO: 104]
[0622] aelagadlsdanleqanlqnanlananlenanlqdadlhgarlqnadlrganledadlanarleganlaeadlrradlrgadltnadled adleganlhgarleganlrganltdarlenadlsgadlrnanleg - Solenoid domain sequence [SEQ ID NO: 28] >rfr_ref_minprep_ren_neg_num_40_0004 UNITSn
[0623] ANTRGARLQDADLRGAKLRPVLWNTANLEGAQMQTNQKAEYQRANG - CCAP sequence [SEQ ID NO: 125]
[0624] gggs – Linker sequence [SEQ ID NO: 34]
[0625] qqtng - Tail sequence [SEQ ID NO: 128]
[0626] > SynRFR24.nnum35.nc.lLx4. K129S [Amino Acid Sequence] [SEQ ID NO: 161]MGSSHHHHHHSSGLVPRGSRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlananlhranlenanl anakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqsanlenadltnadltgadlegarlhganleganltn an\rkan\enad\mad\tgARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGgggsaaaaaa gggsRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlananlhranlenanlanakleeanleeanlagadlr nanlqranlaradlagadltganlaeadlrearlqkanlenadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgA RTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGgggsaaaaaagggsRMRRDEILEEY RRGRRNFQHINLQEIELTNaelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadlt ganlaeadlrearlqkanlenadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgA / ?7TGA / ? LDD.4DL / ? GA 7VDP WRTASZ_RGA / M£££QRR£ 'E7MRGgggsaaaaaagggsRMRRDEILEEYRRGRRNFQHINLQE lELTNaelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanle nadltnadltgadlegarlhganleganltnanlrkanlenadlrnadltgAR7TGARZ. DDADZ. RGA7VDPV7.lVR7ASZ. RGA KMEEEQRREYERARGqed kg
[0627] Where:
[0628] MGSSHHHHHHSSGLVPRGS – His tag and protease site [SEQ ID NO: 33]
[0629] RMRRDEILEEYRRGRRNFQHINLQEIELTN - NCAP sequence [SEQ ID NO: 2]
[0630] aelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqsanlenadltna dltgadlegarlhganleganltnanlrkanlenadlrnadltg - Solenoid domain sequence 1 of 4 [SEQ ID NO: 169]
[0631] aelagadlananlhranlenanlanakleeanleeanlagadlrnanlqranlaradlagadltganlaeadlrearlqkanlenadltna dltgadlegarlhganleganltnanlrkanlenadlrnadltg - Solenoid domain sequence 2, 3 and 4 of 4 [SEQ ID NO: 23] >rfr_ref_minprep_ren_neg_num_35_0005 UNITSn
[0632] ARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG - CCAP sequence [SEQ ID NO: 3]
[0633] gggsaaaaaagggs – Linker sequence [SEQ ID NO: 168]
[0634] qedkg - Tail sequence [SEQ ID NO: 134]
[0635] > SynRFR24.nnum36.nc.x4 [Amino Acid Sequence] [SEQ ID NO: 162]
[0636] MGSSHHHHHHSSGLVPRGSRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGgggsRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGgggsRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGgggsRMRRDEILEEYRRGRRNFQHINLQEIELTNaelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrkarlqgadleganleganlhgadlenadlaradlqkadlrnanltgARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGqsddg
[0637] Where:
[0638] MGSSHHHHHHSSGLVPRGS – His tag and protease site [SEQ ID NO: 33]
[0639] RMRRDEILEEYRRGRRNFQHINLQEIELTN - NCAP sequence [SEQ ID NO: 2]
[0640] aelagadlsgadltradlrdanlanadlqeanlaeaklqganlenanlaradlsranlagadlhganlaeadlrnadlrnanlqnadlrka rlqgadleganleganlhgadlenadlaradlqkadlrnanltg - Solenoid domain sequence [SEQ ID NO: 24] > rfr_ref_mi n prep_ren_neg_n u m_36_0005 U N ITSn
[0641] ARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARG - CCAP sequence [SEQ ID NO: 3]
[0642] gggs – Linker sequence [SEQ ID NO: 34]
[0643] qsddg - Tail sequence [SEQ ID NO: 134]
[0644] > SynRFR24.nnum36.nc.x4 [DNA Sequence] [SEQ ID NO: 163]
[0645] ATGGGTAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCGTATGCGTCGT GATGAAATTCTGGAAGAATATCGTCGTGGTCGTCGTAACTTTCAGCATATTAATCTGCAAGAAATCGAAC TGACCAATGCAGAACTGGCAGGCGCAGATCTGAGCGGTGCCGATCTGACCCGTGCGGATCTGCGTGAT GCAAATCTGGCAAACGCAGACCTGCAAGAAGCCAATCTGGCCGAAGCAAAACTGCAGGGTGCGAATCT GGAAAATGCCAACCTGGCTCGTGCTGATCTGTCACGTGCTAATTTAGCCGGTGCCGACCTGCATGGTGC AAACCTGGCGGAAGCCGATCTGCGCAATGCGGATTTACGTAATGCCAATCTGCAGAATGCGGACCTGC GTAAAGCACGTCTGCAAGGGGCAGATCTGGAAGGTGCTAACCTGGAAGGCGCAAATTTACATGGTGCA GATTTAGAAAACGCCGATCTGGCTCGCGCAGATTTACAGAAAGCTGATCTGCGTAACGCGAATCTGACC GGTGCACGTACCACCGGTGCGCGTCTGGATGATGCCGATTTACGCGGTGCAACCGTTGATCCGGTTCT GTGGCGTACCGCAAGCCTGCGTGGTGCCAAAATGGAAGAAGAACAGCGTCGCGAATATGAACGTGCCC GTGGTGGTGGCGGTTCTCGCATGCGTAGAGATGAAATCTTAGAAGAGTACCGTCGCGGACGTCGCAAT TTTCAACATATCAACTTACAAGAGATCGAGCTGACAAACGCCGAATTAGCGGGTGCTGATTTAAGCGGA GCGGATTTAACACGTGCAGACTTACGTGATGCGAACCTGGCCAATGCCGATCTTCAAGAAGCAAATTTA GCAGAGGCCAAATTACAGGGTGCCAACCTTGAAAACGCTAATCTTGCGCGTGCAGACCTGAGTCGTGC TAACCTTGCCGGTGCAGATCTTCACGGTGCCAATCTTGCGGAGGCTGACCTGCGGAATGCAGACCTTC GCAACGCGAACCTGCAAAACGCGGATCTTCGCAAAGCTCGCCTGCAAGGTGCCGACTTAGAAGGTGCG AATTTAGAGGGTGCTAATCTTCATGGTGCGGACCTTGAGAACGCGGATTTAGCTAGAGCTGATCTTCAGAAAGCCGACTTACGCAATGCAAATTTAACAGGCGCTCGCACCACAGGTGCACGCTTAGATGACGCTGAT TTGCGTGGCGCTACAGTTGACCCTGTGCTGTGGCGCACAGCCAGCTTACGTGGCGCTAAGATGGAAGA GGAACAACGCCGTGAGTACGAACGTGCACGCGGTGGCGGTGGCAGTCGGATGCGTCGGGACGAGATT TTAGAGGAATACCGTAGAGGTCGCAGAAATTTTCAGCACATAAACCTTCAAGAAATTGAGCTTACGAAT GCGGAACTTGCTGGGGCTGATCTGAGTGGGGCAGACTTAACTAGAGCCGACCTTCGTGATGCCAATTT AGCGAACGCCGATTTGCAAGAGGCGAATTTGGCGGAGGCGAAACTTCAAGGTGCAAACTTAGAGAATG CGAACTTAGCAAGAGCGGATCTGAGTCGCGCAAATCTTGCTGGCGCAGACTTGCATGGTGCCAATTTG GCAGAGGCAGATCTTCGTAACGCTGATTTACGGAACGCAAATCTTCAGAACGCAGATTTGCGGAAAGCA CGCCTTCAGGGTGCTGATCTTGAGGGTGCAAATTTGGAAGGGGCAAACTTGCACGGTGCTGACTTGGA GAACGCTGACCTGGCACGAGCGGACTTGCAGAAAGCAGACCTGAGAAATGCAAATCTGACTGGCGCAC GCACAACTGGCGCTCGTTTAGATGATGCGGACTTAAGAGGTGCCACAGTAGATCCGGTTTTATGGCGCA CGGCATCATTACGGGGAGCAAAAATGGAAGAGGAGCAAAGACGTGAATATGAGCGTGCTCGCGGAGG TGGTGGCTCCCGCATGCGACGCGACGAGATCCTTGAAGAGTATCGCAGAGGCCGTCGGAATTTCCAAC ACATTAACCTGCAAGAGATAGAGTTAACTAATGCCGAGCTTGCTGGTGCCGATTTATCTGGTGCGGATT TGACTCGAGCGGACCTTCGGGACGCAAACCTTGCGAATGCTGATTTACAAGAAGCTAACCTGGCTGAG GCCAAGCTGCAAGGCGCTAATTTGGAAAATGCGAATCTTGCACGGGCAGATTTATCAAGAGCCAACCTT GCTGGGGCAGATTTACATGGGGCTAATCTGGCTGAAGCTGACCTTCGTAATGCTGATCTTAGAAATGCA AACCTGCAGAACGCTGACTTACGTAAAGCCCGTTTGCAGGGTGCAGACCTTGAAGGCGCTAACTTAGA GGGTGCCAACTTACATGGCGCAGATCTTGAGAATGCAGATCTGGCAAGAGCCGATCTGCAAAAGGCCG ATCTGAGAAACGCCAACCTGACAGGTGCTAGAACCACGGGTGCTCGCCTGGACGATGCAGACCTGCGT GGCGCAACCGTAGATCCAGTACTTTGGAGAACCGCATCTCTTCGCGGAGCCAAGATGGAGGAGGAGCA GCGAAGAGAATATGAAAGAGCACGCGGTCAGTCAGATGATGGTTAA
[0646] > SynRFR24.nnum35.nc.ll.x4. K129S [DNA Sequence] [SEQ ID NO: 164]
[0647] ATGGGTAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCGTATGCGTCGT GATGAAATTCTGGAAGAATATCGTCGTGGTCGTCGTAACTTTCAGCATATTAATCTGCAAGAAATCGAAC TGACCAATGCAGAACTGGCAGGCGCAGATCTGGCAAATGCAAATCTGCATCGTGCCAATCTGGAAAATG CCAACCTGGCCAATGCGAAACTGGAAGAAGCAAATCTGGAAGAGGCCAATCTTGCCGGTGCCGATCTG CGTAACGCCAACCTGCAGCGTGCAAACCTGGCACGTGCGGATTTAGCGGGTGCAGATCTGACCGGTGC GAATCTGGCCGAAGCGGATCTGCGTGAAGCACGTCTGCAGAGTGCGAACCTGGAAAACGCCGATCTGA CTAATGCGGACCTGACAGGTGCCGACCTGGAAGGTGCCCGTCTGCATGGTGCAAATTTAGAAGGCGCA AATCTGACCAACGCCAATCTGCGCAAAGCCAATTTGGAGAATGCAGACCTGCGTAATGCTGATTTAACC GGTGCACGTACCACCGGTGCGCGTCTGGATGATGCCGATTTACGTGGTGCAACCGTTGATCCGGTTCT GTGGCGTACCGCAAGCCTGCGTGGTGCCAAAATGGAAGAAGAACAGCGTCGCGAATATGAACGTGCCC GTGGTGGTGGCGGTAGCGCAGCTGCAGCAGCAGCCGGTGGTGGTTCTCGCATGCGTAGAGATGAAAT CTTAGAAGAGTACCGTCGCGGACGTCGCAATTTTCAACATATCAACTTACAAGAGATCGAGCTGACAAA CGCCGAATTAGCTGGCGCAGATTTAGCGAATGCCAACTTACATCGTGCGAACTTAGAAAATGCTAATCT GGCGAACGCCAAATTAGAAGAAGCTAACTTAGAAGAGGCGAACCTTGCGGGTGCTGATTTACGTAATG CGAATCTGCAACGCGCAAATCTTGCTCGTGCGGATCTTGCAGGGGCTGATCTTACAGGTGCTAACCTGG CGGAAGCAGACTTACGCGAGGCTCGTTTACAGAAAGCTAATCTTGAGAATGCTGATCTGACAAATGCCG ATCTTACCGGTGCAGACTTAGAAGGTGCACGCTTACATGGCGCAAACCTTGAAGGTGCGAACCTGACG AACGCAAATTTAAGAAAAGCGAATTTAGAAAATGCGGACCTGCGCAACGCAGACCTGACGGGTGCGCGTACCACAGGCGCACGCTTAGATGATGCAGATCTTCGCGGTGCCACAGTGGACCCTGTGCTGTGGCGCA CAGCCTCACTGAGAGGCGCTAAGATGGAAGAGGAACAACGCCGTGAGTACGAACGTGCACGCGGTGG CGGTGGTTCAGCAGCAGCTGCCGCAGCAGGTGGAGGTTCACGTATGCGACGCGACGAAATTTTAGAGG AATATAGACGCGGTCGCCGTAATTTCCAGCACATCAACCTTCAAGAAATTGAGTTAACAAATGCGGAGT TAGCCGGTGCGGACCTGGCCAACGCTAATCTTCACCGTGCTAATTTAGAGAACGCGAATTTAGCTAACG CCAAACTTGAGGAAGCCAATCTTGAAGAAGCAAACTTGGCTGGTGCGGACTTACGCAACGCAAACTTAC AACGAGCCAATTTAGCACGTGCCGACCTTGCTGGTGCAGACCTTACAGGGGCAAATTTGGCGGAGGCT GATCTGCGCGAGGCAAGACTGCAAAAAGCAAACTTAGAGAATGCCGACTTAACCAATGCGGATTTAACA GGGGCAGACCTTGAAGGCGCACGCCTGCACGGTGCCAACTTAGAGGGTGCCAACCTTACAAACGCGAA TCTTCGTAAAGCGAACCTTGAGAACGCGGATTTACGCAATGCCGATCTGACAGGCGCACGTACAACAG GTGCACGCCTGGACGACGCCGACCTGCGTGGCGCTACAGTTGATCCTGTGTTATGGCGTACAGCGAGC TTACGCGGAGCAAAAATGGAAGAGGAGCAAAGACGTGAATATGAGCGTGCTCGCGGAGGTGGTGGCT CTGCAGCCGCAGCAGCGGCAGGCGGTGGAAGTAGAATGCGTCGGGACGAAATCCTTGAGGAATACCG ACGTGGCAGACGGAACTTTCAACACATAAACCTGCAAGAGATAGAACTTACGAACGCGGAGCTTGCAG GCGCAGACCTTGCGAACGCTAACCTTCATAGAGCAAACTTGGAAAACGCGAACTTAGCCAATGCAAAAT TAGAAGAGGCAAATTTAGAAGAAGCCAACCTGGCCGGCGCAGATCTTCGTAATGCTAATTTACAGCGTG CCAATCTTGCACGCGCTGACTTAGCCGGTGCAGATTTAACTGGGGCAAATCTTGCCGAAGCAGATTTAA GAGAAGCTCGCCTTCAGAAAGCCAACTTAGAAAACGCAGATTTAACCAACGCAGATCTTACTGGCGCTG ATTTGGAGGGTGCTAGATTACACGGTGCAAACCTGGAAGGCGCAAACCTTACTAATGCTAACCTGCGTA AGGCTAATCTGGAAAACGCTGACCTGCGTAACGCGGATCTTACGGGTGCTCGCACCACGGGTGCCAGA CTGGATGACGCTGATCTTCGGGGAGCGACAGTAGATCCAGTTCTTTGGCGCACGGCCAGTTTACGGGG TGCAAAGAT GGAGGAAGAGCAGCGAAGAGAATATGAAAGAGCACGCGGTCAAGAAGATAAAGGCTAA
[0648] > SynRFR.24.nnum35.x4 [DNA Sequence] [SEQ ID NO: 165]
[0649] ATGGGCAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCAGCATGCAGAC CGAGCAGATTCTGCAAGAATATAATCGTGGTCGTACCGATTTCGCCAAAATTGATCTGGAAAATGCCAA TCTGAAAAACGCAGAACTGGCAGGCGCAGATCTGGCCAATGCAAATCTGCATCGTGCAAACCTGGAAA ACGCGAACCTGGCGAATGCCAAACTGGAAGAAGCGAATCTGGAAGAGGCCAACCTTGCCGGTGCCGAT CTGCGTAATGCCAACCTGCAGCGTGCTAATCTGGCACGTGCGGATTTAGCGGGTGCAGATCTGACCGG TGCTAACCTGGCCGAAGCGGATCTGCGTGAAGCACGTCTGCAGAAAGCAAATTTAGAAAATGCGGATCT GACCAACGCCGATTTAACCGGTGCGGACCTGGAAGGTGCCCGTCTGCATGGTGCCAATTTAGAAGGCG CAAATCTGACAAATGCGAACCTGCGTAAGGCAAATCTTGAAAACGCTGATTTACGTAACGCCGATCTGA CTGGCGCAAATACCAAAGGTGCCAATCTTGATAATGCAGACCTGCGTGGTGCAACCTTAGATCCGGTTC TGTGGCGTACCGCAAGCCTGCAGGGTGCAAAAATGACCACACGTCAGGCCGAAGAATATGACCGTGCA CGCGGTGGTGGTGGTTCAAGTATGCAGACAGAACAAATCCTTCAAGAGTACAATCGCGGTCGCACAGA CTTTGCAAAAATTGATTTAGAGAACGCCAACCTGAAGAATGCAGAATTAGCTGGTGCCGACCTGGCTAA CGCGAATTTACATAGAGCCAACTTAGAGAATGCGAATCTTGCAAATGCCAAATTAGAGGAAGCAAACTT AGAAGAGGCAAATCTTGCTGGTGCAGATTTACGTAATGCAAATTTACAGCGTGCAAATTTAGCCCGTGC TGATCTTGCGGGTGCTGACTTAACAGGGGCAAATCTGGCGGAAGCCGATTTACGCGAGGCTCGTTTAC AGAAAGCGAACCTTGAGAACGCGGACCTGACAAACGCGGATCTTACAGGTGCAGACTTAGAAGGTGCACGCTTACATGGCGCTAATCTTGAAGGTGCGAACCTTACCAACGCCAATCTGCGCAAGGCGAACTTGGAG AATGCTGATCTGCGCAATGCTGACCTGACAGGTGCCAACACAAAGGGTGCGAACTTAGATAACGCAGAT CTTCGCGGTGCCACACTGGACCCTGTGCTGTGGCGCACAGCCTCATTACAGGGTGCCAAGATGACAAC TCGCCAAGCAGAAGAATACGATCGCGCACGTGGCGGTGG CGGTAGCTCAATGCAAACCGAACAAATTTTACAAGAGTATAACAGAGGCCGTACCGACTTTGCGAAGAT CGACCTTGAAAATGCTAACCTTAAAAATGCCGAGTTAGCTGGCGCTGACTTAGCAAACGCTAACTTACAT CGAGCTAATTTGGAGAACGCTAATTTAGCCAACGCGAAACTTGAGGAAGCTAACCTTGAAGAGGCGAAC CTGGCTGGCGCAGACCTGCGCAATGCCAATCTTCAACGTGCGAATTTAGCTCGCGCAGATTTAGCAGG GGCTGACCTTACGGGTGCGAATCTGGCTGAGGCCGATCTTCGTGAGGCAAGACTGCAAAAAGCTAATC TGGAAAACGCCGACCTGACCAATGCGGACTTGACTGGGGCAGACCTTGAAGGCGCTCGCCTGCATGGC GCAAACTTGGAGGGTGCTAATTTGACTAACGCAAACTTACGCAAAGCCAACTTGGAAAACGCAGACTTG CGTAATGCGGATTTGACAGGTGCGAATACGAAAGGCGCTAACCTGGATAATGCCGACTTACGCGGTGC TACCCTTGATCCGGTGTTATGGCGCACCGCGTCACTTCAAGGGGCTAAAATGACAACCAGACAGGCGG AAGAGTACGATAGAGCCCGTGGTGGCGGAGGTTCATCTATGCAAACTGAGCAGATCTTACAAGAATACA ACCGAGGACGCACGGATTTTGCTAAAATCGATCTTGAGAACGCAAATCTTAAGAATGCCGAACTTGCCG GTGCTGATTTAGCTAATGCTAATCTTCATAGAGCCAACCTTGAAAACGCCAATCTGGCCAACGCAAAATT AGAAGAAGCCAACCTGGAAGAGGCTAATCTTGCAGGGGCTGATCTGCGGAACGCGAATCTGCAACGCG CAAACTTAGCGCGTGCCGACTTAGCTGGTGCGGATTTAACTGGTGCCAACCTTGCGGAAGCCGACCTG CGCGAGGCACGCCTTCAAAAAGCGAACCTGGAAAATGCGGATTTAACCAATGCAGATCTGACAGGGGC TGATTTGGAAGGCGCAAGACTGCATGGTGCGAATCTTGAGGGTGCAAACTTGACCAATGCAAACCTGC GCAAAGCTAACCTTGAGAATGCAGATCTTCGTAATGCCGATTTAACGGGTGCAAACACAAAAGGTGCAA ATCTGGACAACGCGGATCTTCGTGGTGCGACATTAGATCCTGTTTTATGGCGGACAGCATCTCTGCAAG GTGCGAAGATGACGACCCGTCAAGCGGAAGAGTACGACCGTGCACGTGGTCAAGAAGATAAAGGTTAA
[0650] > SynRFR.24.nnum36.x4 [DNA Sequence] [SEQ ID NO: 166]
[0651] ATGGGCAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCACCATGGCAAC CGATAAAATTCTGCAGCAGTATAAAGATGGCCAGCATGATTTTAGCGGTATTGATCTGGCAAATGCAGA TCTGAGCAAAGCCGAACTGGCAGGCGCAGATCTGTCAGGTGCCGATCTGACCCGTGCGGATCTGCGTG ATGCAAATCTGGCCAACGCCGATCTGCAAGAAGCCAATCTGGCCGAAGCAAAACTGCAGGGTGCGAAT CTGGAAAATGCTAATCTGGCACGTGCTGATCTGTCTCGTGCAAATTTAGCCGGTGCAGACCTGCATGGT GCAAACCTGGCGGAAGCTGATCTGCGTAACGCCGACCTGCGCAATGCCAATCTGCAGAATGCGGACCT GCGTAAAGCACGTCTGCAAGGGGCAGATCTGGAAGGTGCTAACCTGGAAGGCGCAAATTTACATGGTG CCGATTTAGAAAACGCAGATTTAGCGCGTGCAGATTTACAGAAAGCCGATTTACGTAACGCAAATCTGA CCGGTGCCGAAACCACCGGTGCCAACCTGAATAATGCGGATTTACGTGGTGCAACCTTAGATCCGGTTC TGTGGAATACCGCAAGCTTAGAAGGTGCACAGATGAAAAAAGAGCAGAAAAAAGAATACAAGCGTGCC AATGGTGGTGGTGGCAGTACCATGGCCACAGATAAGATCCTTCAACAATATAAAGACGGTCAGCACGAC TTTTCAGGCATCGATCTGGCGAACGCGGATTTAAGTAAAGCAGAACTTGCGGGTGCCGACCTGAGCGG AGCAGATTTAACACGTGCCGACTTACGTGATGCGAACTTAGCAAACGCTGACCTGCAAGAGGCGAATTT AGCAGAGGCCAAATTACAGGGTGCTAACTTAGAAAATGCCAATTTAGCAAGAGCGGATCTGAGTCGTGC CAACCTTGCTGGTGCAGATCTTCACGGTGCTAATCTTGCCGAGGCCGATCTTCGCAATGCGGATCTTCG GAACGCAAACCTGCAAAATGCAGACTTAAGAAAAGCTCGCCTGCAAGGTGCGGACTTAGAGGGTGCAAATCTTGAAGGGGCAAACCTTCATGGCGCAGACCTGGAAAACGCGGACCTGGCACGGGCAGACCTTCAG AAAGCAGACTTACGCAATGCGAATTTAACAGGTGCAGAAACAACTGGCGCTAATCTGAACAATGCCGAC CTTCGCGGTGCAACACTGGACCCTGTGCTGTGGAACACAGCCTCACTTGAGGGTGCCCAAATGAAGAA AGAACAAAAGAAAGAATATAAACGCGCAAATGGCGGTGGCGGTTCAACAATGGCGACGGACAAAATCC TGCAACAGTACAAGGACGGACAACATGATTTCTCTGGTATCGACCTGGCTAACGCTGATCTTTCAAAAG CAGAATTAGCTGGGGCTGATCTGAGTGGTGCGGATTTAACTAGAGCCGATCTGCGCGACGCCAACCTG GCTAATGCCGACTTGCAAGAGGCTAACCTGGCAGAGGCGAAACTGCAAGGCGCTAACCTTGAGAATGC GAATCTTGCTAGAGCAGACCTGTCACGCGCAAACCTTGCCGGTGCTGATTTACATGGCGCTAACTTGGC CGAGGCAGACCTGAGAAACGCAGATCTTCGTAATGCAAATCTTCAGAATGCAGATCTTCGCAAAGCGCG TCTGCAGGGTGCCGACCTTGAAGGTGCAAATTTAGAAGGTGCGAACTTACATGGTGCTGATCTTGAGAA TGCCGATTTAGCCCGTGCCGATCTTCAAAAAGCTGACCTGCGGAATGCGAACCTGACAGGTGCGGAAA CGACAGGTGCAAACTTAAACAACGCGGACTTACGCGGTGCCACGCTTGACCCGGTGTTATGGAATACA GCCAGCCTTGAAGGCGCTCAAATGAAAAAAGAGCAAAAAAAAGAATATAAACGAGCCAACGGTGGCGG TGGCTCTACGATGGCTACTGATAAAATCTTGCAGCAATACAAGGATGGGCAGCACGATTTCAGTGGCAT TGATTTAGCTAACGCAGACTTGTCTAAAGCCGAGTTAGCTGGTGCGGACCTTTCTGGCGCTGACTTAAC TCGAGCTGACCTTCGTGACGCCAATCTTGCAAACGCTGATTTACAAGAAGCAAATCTTGCGGAAGCCAA ATTACAAGGCGCAAATCTGGAAAACGCAAACTTAGCTCGCGCAGACTTATCAAGAGCTAATTTAGCTGG CGCAGATTTACACGGTGCGAACCTGGCCGAAGCAGATTTACGTAATGCAGACCTGCGCAACGCAAACC TTCAGAACGCTGATTTGCGTAAAGCCCGTTTACAGGGTGCTGATTTGGAAGGTGCCAATCTTGAGGGTG CTAATCTGCATGGGGCAGACTTAGAGAATGCGGATTTGGCACGTGCGGACTTGCAGAAAGCGGATTTG AGAAATGCTAACTTAACCGGTGCGGAGACAACCGGTGCGAATCTTAATAATGCCGATCTTAGAGGTGCG ACCCTTGATCCAGTTTTATGGAACACCGCATCATTAGAGGGTGCCCAGATGAAAAAAGAGCAAAAGAAA GAATACAAACGTGCGAACGGTCAGTCAGATGATGGTTAA
[0652] > SynRFR24.nnum40.x4 [DNA Sequence] [SEQ ID NO: 167]
[0653] ATGGGCAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCAGCATGCATGA AGATGAAATTCTGGATGAGTATAACAACGGTCGCAAAAACTTTAGCGGTATTGATCTGCAGGGTGCAGA TCTGGAAGATGCAGAACTGGCAGGCGCAGATCTGAGTGATGCAAATCTGGAACAGGCAAATCTGCAGA ATGCCAATCTGGCCAATGCCAACCTGGAAAATGCGAATCTGCAGGACGCCGACCTGCATGGTGCTCGT CTGCAGAACGCGGATCTGCGTGGCGCAAATTTAGAAGATGCCGATCTGGCGAACGCACGTCTGGAAGG CGCTAATCTGGCCGAAGCCGATCTGCGTCGTGCAGACTTACGTGGTGCGGATCTGACCAATGCGGATT TAGAGGATGCGGACCTGGAAGGTGCAAATTTACATGGTGCACGTTTAGAAGGTGCGAACCTGCGTGGT GCCAATCTTACCGATGCGCGTCTGGAAAACGCCGATCTGAGCGGTGCCGATTTACGTAACGCGAATCTT GAAGGCGCAAATACCCGTGGTGCACGCCTGCAAGATGCTGATTTACGCGGTGCAAAACTGCGTCCGGT TCTGTGGAATACCGCCAACTTAGAAGGCGCACAGATGCAGACCAATCAGAAAGCAGAATATCAGCGTG CAAATGGTGGTGGTGGCAGCTCAATGCACGAGGATGAAATCCTTGACGAATACAATAATGGCCGTAAG AATTTTTCCGGCATCGATTTACAGGGTGCCGACCTTGAGGATGCCGAATTAGCCGGTGCTGATCTGTCA GACGCGAATTTAGAACAGGCCAATTTACAGAACGCAAACCTGGCAAACGCAAACTTAGAAAACGCCAAC CTTCAGGATGCTGATCTTCATGGCGCACGCTTACAGAATGCAGATCTTCGCGGAGCGAACCTTGAAGAT GCTGACCTGGCAAATGCTCGCCTTGAGGGTGCGAATCTGGCAGAGGCAGATTTACGCAGAGCGGACCT TCGTGGTGCAGATTTAACAAACGCTGATCTTGAGGACGCTGACTTAGAGGGTGCAAACCTTCACGGTGCTAGACTTGAAGGGGCTAACTTACGCGGAGCCAATCTGACAGACGCTCGTTTAGAAAATGCAGACCTGAG CGGAGCTGATCTGCGCAACGCCAATCTGGAAGGTGCCAATACACGCGGTGCCCGTTTACAGGACGCGG ATTTACGGGGAGCGAAATTACGTCCGGTGTTATGGAATACAGCAAACCTTGAAGGTGCCCAAATGCAGA CAAACCAAAAAGCCGAGTATCAACGTGCCAACGGTGGCG GAGGTTCAAGTATGCATGAGGACGAGATTTTGGACGAGTACAACAATGGAAGAAAAAACTTCTCAGGCA TCGATCTGCAAGGCGCAGACTTGGAGGACGCAGAACTTGCCGGTGCCGACTTATCAGATGCTAACCTT GAACAAGCCAATCTTCAAAATGCTAATCTTGCAAACGCTAATTTGGAGAATGCGAACTTACAAGATGCG GATCTGCACGGTGCTCGCTTGCAAAATGCCGACTTGCGAGGGGCAAACTTGGAAGATGCGGACTTAGC CAATGCACGGTTGGAGGGTGCTAATTTAGCGGAAGCAGACCTTCGTCGCGCTGACCTTCGGGGAGCCG ACCTGACCAACGCTGACCTGGAAGATGCCGATTTAGAAGGTGCAAATCTGCATGGCGCTCGCCTGGAA GGCGCAAACTTGCGTGGTGCTAACCTGACAGATGCACGGCTTGAAAACGCGGACCTGTCAGGGGCAGA CCTGCGTAATGCCAATTTGGAGGGTGCGAACACCCGTGGGGCACGTTTACAAGACGCCGATCTTAGAG GCGCTAAACTTCGTCCTGTTTTATGGAACACCGCTAATTTAGAGGGTGCCCAGATGCAAACGAATCAAA AGGCGGAATACCAACGTGCGAATGGCGGAGGCGGTAGTAGTATGCACGAAGATGAGATTTTGGATGAA TACAATAACGGACGCAAGAACTTCTCTGGAATTGACCTGCAAGGTGCGGACTTAGAAGATGCTGAGTTA GCGGGTGCCGATCTGAGTGACGCCAACCTTGAGCAGGCCAACCTGCAGAACGCAAATTTAGCAAATGC GAATTTGGAAAACGCTAACCTGCAAGACGCGGACTTACATGGCGCAAGACTGCAAAATGCGGATCTTCG GGGTGCTAACTTAGAGGACGCCGATTTAGCGAATGCTCGGTTAGAAGGGGCAAACCTGGCGGAAGCG GATTTACGTCGTGCTGATCTGCGTGGGGCAGATCTGACAAATGCCGATCTTGAAGATGCAGATCTTGAG GGTGCCAACTTGCATGGTGCACGACTTGAAGGTGCCAATTTACGTGGCGCAAATCTGACCGACGCACG CCTGGAAAATGCAGATCTTTCTGGTGCCGATCTGCGTAATGCAAACCTGGAAGGGGCTAATACGCGTG GCGCTCGGCTGCAGGATGCCGACTTAAGAGGCGCAAAATTACGCCCTGTGCTGTGGAACACGGCGAAC TTGGAAGGTGCGCAAATGCAAACTAATCAGAAAGCTGAGTACCAACGCGCTAATGGTCAGCAGACAAAT GGTTAA
[0654] > SynRFR24_nc.x6_l [SEQ ID NO: 170] MGSSHHHHHHSSGLVPRGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYAN LHHAN LSRA NLRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEANLTQANLKDAN LSDAN LEQA DLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVLWRT ASLRGAKMEEEQRREYERARGGGGSRMRRDEILEEYRRG RRN FQHIN LQEIELTNASLTGADLSYAN LHHA NLS RAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEANLTQANLKDANLSDA N LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPV
[0655] Z. LVRTASZ. RGA / CMHFGQRRGYGRARGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYA N LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEAN LTQAN LKDA N LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGA / ?7TGA / ? LDDADL / ? G A7VDPVLI / I / R7ASZ. RGA / M£££QRR£YHMRGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGA DLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLH EAN LSGADLQEANLTQA N LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGAK7TGAKLDD ADLRGA7VDPVLI / I / RTASZ. RGA / M£££QRR£YE7MRGGGGSRMRRDEILEEYRRGRRNFQHINLQEIELTN ASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAAN LRGADLHEAN LSGADLQEANLTQANLKDANLSDANLEQADLAGADLQGAVLDGANLHGANLNNANLSEAMLTRANLEQADLSGA / ?7TGA RLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGGSRMRRDE EEEYRRGRRNEQ.mNEQE ELTNASLTGADLSYANLHHANLSRANLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGAD LQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDG AN LHGAN LN NAN LS EAM LTRAN LEQADLSGA / ? TTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGKSVVG
[0656] > SynRFR24_nc.x6_l [DNA Sequence] [SEQ ID NO: 171] ATGGGCAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCGTATGCGTCG TGATGAAATTCTGGAAGAATATCGTCGTGGTCGTCGTAACTTTCAGCATATTAATCTGCAAGAAATCGAA CTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCAAATCTGCATCATGCCAATCTGAGCCGT GCCAACCTGCGTTCAGCCGATCTGCGTAATGCGAACCTGAGTCATGCGAATCTGTCAGGCGCAAACCTG GAAGAAGCAAATCTGGAAGCAGCGAACCTGCGTGGTGCGGATCTGCATGAAGCAAACCTGTCAGGTGC CGATTTACAAGAAGCCAACCTGACACAGGCAAATCTGAAAGACGCGAATCTGAGTGACGCCAATCTGGA ACAGGCAGACCTGGCAGGCGCTGATCTGCAGGGTGCAGTTCTGGATGGTGCTAATCTGCATGGTGCGA ATTTGAATAACGCTAATCTGAGCGAAGCAATGCTGACTCGTGCTAATTTAGAACAGGCGGATCTGAGCG GTGCACGTACCACCGGTGCGCGTCTGGATGATGCGGATTTACGTGGTGCAACCGTTGATCCGGTTCTG TGGCGTACCGCAAGCCTGCGTGGCGCTAAAATGGAAGAAGAACAGCGTCGCGAATATGAACGTGCCCG TGGTGGTGGCGGTTCTCGCATGCGTAGAGATGAAATCTTAGAAGAGTACCGTCGCGGACGTCGCAATT TTCAACATATCAACTTACAAGAGATCGAGCTGACAAACGCATCACTGACAGGTGCAGACCTGTCTTATG CCAATTTACATCATGCAAATTTGTCGAGAGCGAATCTGCGCTCAGCAGATTTACGCAACGCAAATCTGTC CCATGCAAACCTGAGCGGAGCAAATTTAGAGGAAGCCAATTTAGAAGCCGCAAATCTTCGCGGTGCCG ACCTGCACGAGGCTAACCTGAGTGGCGCAGATCTTCAAGAAGCGAATTTAACCCAGGCCAATCTTAAAG ATGCCAACTTATCAGATGCTAACCTTGAGCAGGCAGATTTAGCGGGTGCAGACTTACAGGGTGCCGTGT TAGATGGTGCAAATTTACACGGTGCAAATCTTAATAACGCGAACTTATCTGAGGCCATGCTGACACGCG CAAACTTAGAGCAAGCGGATTTATCAGGTGCCCGTACAACAGGCGCACGTTTAGATGATGCCGATCTTC GGGGTGCGACAGTGGACCCTGTGCTGTGGCGCACAGCCAGCTTACGCGGTGCCAAGATGGAAGAGGA ACAACGCCGTGAGTACGAACGTGCACGCGGTGGCGGTGGCAGTCGGATGCGTCGGGACGAGATTCTT GAGGAATACAGACGCGGTCGCAGAAATTTTCAGCACATAAACCTTCAAGAAATTGAGTTAACCAATGCC TCTTTAACCGGTGCGGACTTAAGCTATGCCAACCTTCATCACGCGAATTTATCACGTGCGAACCTTCGCA GCGCAGACCTGCGCAACGCTAATTTAAGCCATGCGAACTTAAGCGGTGCAAACCTTGAGGAAGCGAAC CTTGAAGCTGCGAATTTACGCGGAGCTGATTTACATGAGGCCAATTTATCTGGGGCTGACTTGCAAGAG GCAAACTTAACGCAGGCTAACTTAAAAGACGCAAACCTTTCAGACGCCAACCTTGAACAAGCCGATCTT GCTGGTGCGGACCTTCAAGGTGCCGTGCTGGACGGTGCGAACTTGCATGGGGCTAATCTTAACAATGC TAATCTTTCCGAAGCCATGTTAACCCGTGCTAACTTGGAACAAGCTGACTTAAGTGGCGCTCGCACCAC AGGTGCACGCCTGGACGACGCAGACCTTCGTGGTGCCACAGTAGATCCAGTGTTATGGCGCACCGCCT CATTACGGGGTGCAAAAATGGAAGAGGAACAAAGACGTGAATATGAGCGTGCTCGCGGAGGTGGTGG CTCTCGCATGCGACGCGACGAAATTTTAGAGGAATATCGCAGAGGTCGCCGTAATTTCCAACACATCAA TTTGCAAGAAATAGAGCTTACGAATGCGTCATTGACTGGGGCAGATCTGAGTTACGCTAACCTGCACCA CGCGAACCTTAGTCGGGCAAACCTGCGCTCTGCGGATCTTCGGAACGCCAACTTGAGCCACGCAAATTT AAGTGGTGCGAATCTGGAAGAGGCCAACTTAGAGGCTGCCAATCTTAGAGGGGCAGACCTGCATGAGG CGAATCTTTCAGGTGCTGATCTGCAAGAGGCCAATCTGACCCAAGCCAACTTGAAGGATGCAAACCTTA GTGATGCAAATCTTGAGCAAGCTGATCTGGCAGGCGCAGATTTACAAGGTGCGGTGCTTGATGGCGCTAACCTTCATGGGGCAAACTTGAATAATGCCAACCTGTCGGAAGCTATGCTTACCAGAGCGAACTTGGAG CAGGCCGACCTTTCTGGTGCACGCACAACGGGTGCTAGACTGGATGACGCCGACTTAAGAGGTGCGAC GGTTGATCCTGTTTTATGGCGGACAGCAAGTTTAAGAGGCGCAAAGATGGAAGAGGAACAGCGAAGAG AATATGAAAGAGCACGCGGTGGTGGCGGTTCTCGCATGCGTAGAGATGAAATCTTAGAAGAGTACCGT CGCGGACGTCGCAATTTTCAACATATCAACTTACAAGAGATCGAGCTGACAAACGCATCACTGACAGGT GCAGACCTGTCTTATGCCAATTTACATCATGCAAATTTGTCGAGAGCGAATCTGCGCTCAGCAGATTTAC GCAACGCAAATCTGTCCCATGCAAACCTGAGCGGAGCAAATTTAGAGGAAGCCAATTTAGAAGCCGCAA ATCTTCGCGGTGCCGACCTGCACGAGGCTAACCTGAGTGGCGCAGATCTTCAAGAAGCGAATTTAACCC AGGCCAATCTTAAAGATGCCAACTTATCAGATGCTAACCTTGAGCAGGCAGATTTAGCGGGTGCAGACT TACAGGGTGCCGTGTTAGATGGTGCAAATTTACACGGTGCAAATCTTAATAACGCGAACTTATCTGAGG CCATGCTGACACGCGCAAACTTAGAGCAAGCGGATTTATCAGGTGCCCGTACAACAGGCGCACGTTTA GATGATGCCGATCTTCGGGGTGCGACAGTGGACCCTGTGCTGTGGCGCACAGCCAGCTTACGCGGTGC CAAGATGGAAGAGGAACAACGCCGTGAGTACGAACGTGCACGCGGTGGCGGTGGCAGTCGGATGCGT CGGGACGAGATTCTTGAGGAATACAGACGCGGTCGCAGAAATTTTCAGCACATAAACCTTCAAGAAATT GAGTTAACCAATGCCTCTTTAACCGGTGCGGACTTAAGCTATGCCAACCTTCATCACGCGAATTTATCAC GTGCGAACCTTCGCAGCGCAGACCTGCGCAACGCTAATTTAAGCCATGCGAACTTAAGCGGTGCAAAC CTTGAGGAAGCGAACCTTGAAGCTGCGAATTTACGCGGAGCTGATTTACATGAGGCCAATTTATCTGGG GCTGACTTGCAAGAGGCAAACTTAACGCAGGCTAACTTAAAAGACGCAAACCTTTCAGACGCCAACCTT GAACAAGCCGATCTTGCTGGTGCGGACCTTCAAGGTGCCGTGCTGGACGGTGCGAACTTGCATGGGGC TAATCTTAACAATGCTAATCTTTCCGAAGCCATGTTAACCCGTGCTAACTTGGAACAAGCTGACTTAAGT GGCGCTCGCACCACAGGTGCACGCCTGGACGACGCAGACCTTCGTGGTGCCACAGTAGATCCAGTGTT ATGGCGCACCGCCTCATTACGGGGTGCAAAAATGGAAGAGGAACAAAGACGTGAATATGAGCGTGCTC GCGGAAAATCAGATGATGGTTAA
[0657] > SynRFR24_nc.x2_l[SEQ ID NO: 172] MGSSHHHHHHSSGLVPRGSRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRA NLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDANLEQA DLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSGARTTGARLDDADLRGATVDPVLWRT ASLRGAKMEEEQRREYERARGGGGSRMRRDEILEE RRG RRN FQHIN LQEIELTNASLTGADLSYAN LHHA NLSRANLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDA N LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LE ADLSGARTTGARLDDADLRGATVDPV L WRTASLRGAKMEEEQRREYERARGKSDDG
[0658] > SynRFR24_nc.x2_l [DNA Sequence] [SEQ ID NO: 173] ATGGGCAGCAGCCATCACCATCATCATCATAGCAGCGGTCTGGTTCCGCGTGGTAGCCGTATGCGTCG TGATGAAATTCTGGAAGAATATCGTCGTGGTCGTCGTAACTTTCAGCATATTAATCTGCAAGAAATCGAA CTGACCAATGCAAGCCTGACCGGTGCCGATCTGAGCTATGCAAATCTGCATCATGCCAATCTGAGCCGT GCCAACCTGCGTTCAGCCGATCTGCGTAATGCGAACCTGAGTCATGCGAATCTGTCAGGCGCAAACCTG GAAGAAGCAAATCTGGAAGCAGCGAACCTGCGTGGTGCGGATCTGCATGAAGCAAACCTGTCAGGTGC CGATTTACAAGAAGCCAACCTGACACAGGCAAATCTGAAAGACGCGAATCTGAGTGACGCCAATCTGGA ACAGGCAGACCTGGCAGGCGCTGATCTGCAGGGTGCAGTTCTGGATGGTGCTAATCTGCATGGTGCGA ATTTGAATAACGCTAATCTGAGCGAAGCAATGCTGACTCGTGCTAATTTAGAACAGGCGGATCTGAGCGGTGCACGTACCACCGGTGCGCGTCTGGATGATGCGGATTTACGTGGTGCAACCGTTGATCCGGTTCTG TGGCGTACCGCAAGCCTGCGTGGCGCTAAAATGGAAGAAGAACAGCGTCGCGAATATGAACGTGCCCG TGGTGGTGGCGGTTCTCGCATGCGTAGAGATGAAATCTTAGAAGAGTACCGTCGCGGACGTCGCAATT TTCAACATATCAACTTACAAGAGATCGAGCTGACAAACGCATCACTGACAGGTGCAGACCTGTCTTATG CCAATTTACATCATGCAAATTTGTCGAGAGCGAATCTGCGCTCAGCAGATTTACGCAACGCAAATCTGTC CCATGCAAACCTGAGCGGAGCAAATTTAGAGGAAGCCAATTTAGAAGCCGCAAATCTTCGCGGTGCCG ACCTGCACGAGGCTAACCTGAGTGGCGCAGATCTTCAAGAAGCGAATTTAACCCAGGCCAATCTTAAAG ATGCCAACTTATCAGATGCTAACCTTGAGCAGGCAGATTTAGCGGGTGCAGACTTACAGGGTGCCGTGT TAGATGGTGCAAATTTACACGGTGCAAATCTTAATAACGCGAACTTATCTGAGGCCATGCTGACACGCG CAAACTTAGAGCAAGCGGATTTATCAGGTGCCCGTACAACAGGCGCACGTTTAGATGATGCCGATCTTC GGGGTGCGACAGTGGACCCTGTGCTGTGGCGCACAGCCAGCTTACGCGGTGCCAAGATGGAAGAGGA ACAACGCCGTGAGTACGAACGTGCACGCGGTAAATCAGATGATGGTTAA
[0659] SynRFR24.new_caps.p3ElT.l.x4 full capped sequence with linker - B9 [SEQ ID NO: 174] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNADLEAANLKYANLHEADLSRANLTGANLTNANLHQANLTGANLSHANLSHAV LTN AN LSGADLSEAN LEGAN LAGADLRGAN LQDAN LQEAN LDQASLRGAN LRQAN LHSAM LSEADLN RAD LEGADLSDANLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLEAANLKYANLHEAD LS RAN LTG AN LTN AN LH QAN LTG AN LS HAN LS H AVLTN AN LSG AD LSEAN LEGAN LAG AD LRG AN LQDAN LQEAN LDQASLRGAN LRQAN LHSAMLSEADLNRADLEGADLSDANLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNADLEAANLKYANLHEADLSRANLTGANLTNANLHQANLTGANLSHANLSHAV LTN AN LSGADLSEAN LEGAN LAGADLRGAN LQDAN LQEAN LDQASLRGAN LRQAN LHSAM LSEADLN RAD LEGADLSDANLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLEAANLKYANLHEAD LS RAN LTG AN LTN AN LH QAN LTG AN LS HAN LS H AVLTN AN LSG AD LSEAN LEGAN LAG AD LRG AN LQDAN LQEAN LDQASLRGAN LRQAN LHSAMLSEADLNRADLEGADLSDANLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0660] SynRFR24.fdl.4.x4 full capped sequence with linker B38 [SEQ ID NO: 175] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQSLTAAEVLALKA AG ERD FSG AD LSG ID LSG AD LS HAD LS RAD LKG AN LSG AD LD H AVLREAN LAQAN LSG AN LESAN LH EAD LN QAM LSG AN LTG AS LRRAD LSEAN LQG AN LRG AN LEAAN LS N AN LQN AD LSYAN LE EAN LTDAN LE DAN LHQAN LHGAN LTGAKTTGADLSGAN LEGATVDLSFYTEAKLTGATFSADQKKALARAKGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQSLTAAEVLALKAAGERDFSGADLSGIDLSGADLSHADLSRADLKGAN LSGADLDHAVLREAN LAQAN LSGAN LESAN LHEADLNQAMLSGANLTGASLRRADLSEANLQGANLRGAN LEAAN LSNANLQNADLSYANLEEAN LTDAN LEDAN LHQAN LHGAN LTGAKTTGADLSGAN LEGATVDLSFY TEAKLTGATFSADQKKALARAKGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQSLTAAEVLALKAA GERDFSGADLSGIDLSGADLSHADLSRADLKGAN LSGADLDHAVLREAN LAQAN LSGAN LESAN LHEADL N QAM LSGAN LTG AS LRRAD LSEAN LQG AN LRG AN LEAAN LS N AN LQN AD LSYAN LE EAN LTDAN LE DAN L HQAN LHGAN LTGAKTTGADLSGAN LEGATVDLSFYTEAKLTGATFSADQKKALARAKGGGQGGQGGSGG SAAAAAAAAGGSGGSGGQGGQSLTAAEVLALKAAGERDFSGADLSGIDLSGADLSHADLSRADLKGANLSG AD LD H AVLREAN LAQAN LSG AN LESAN LH EAD LN QAM LSG AN LTG ASLRRAD LSEAN LQG AN LRG AN L EAAN LSN AN LQN ADLSYAN LEEAN LTDAN LEDAN LHQAN LHGAN LTG AKTTG AD LSGAN LEGATVDLSFYT EAKLTGATFSADQKKALARAKGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0661] SynRFR24.new_caps.p3RlE.l.x4 full capped sequence with linker - B7 [SEQ ID NO: 176] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AN LTQAN LRSAN LSG AN LTRAN LH N ADLEGAN LQGAN LEDADLSHAN LTDAD LKNAN LEGAVLSGAN LEEAN LSQAN LQYADLSHAN LSRAM LHQASLAGAN LSGADLHEAN LREADLNAAN LEEAN LSGADLDGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLTQAN LRSAN LSGANL TRAN LHNADLEGAN LQGAN LEDADLSHAN LTDADLKNAN LEGAVLSGAN LEEAN LSQAN LQYADLSHAN L SRAM LHQASLAGAN LSGADLHEAN LREADLNAAN LEEAN LSGADLDGARTTGARLDDADLRGATVDPVLW RTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRR G RRN FQHI N LQEI E LTN AN LTQAN LRSAN LSG AN LTRAN LH NAD LEG AN LQGAN LE DAD LSH AN LTDAD LK NAN LEGAVLSGAN LEEAN LSQANLQYADLSHANLSRAMLHQASLAGAN LSGADLHEAN LREADLNAAN LE EANLSGADLDGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGG SAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLTQAN LRSAN LSGANLT RAN LHNADLEGAN LQGAN LEDADLSHAN LTDADLKNAN LEGAVLSGAN LEEAN LSQAN LQYADLSHAN LS RAMLHQAS LAGAN LSGADLHEAN LREADLNAAN LEEAN LSGADLDGARTTGARLDDADLRGATVDPVLWR TASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0662] SynRFR24.new_caps.p4ElH.l.x4 full capped sequence with linker - Bll [SEQ ID NO: 177] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNADLSQANLTQADLSGANLQYAVLRRADLTNADLENAN LEDAN LHGADLSSAN LDHAMLSGASLN DAN LRQAN LSEAN LSGAN LKGAN LSGADLHGAN LEHAN LQRAN LEAADLSEAN LTGAN LHEAN LAHAN LRGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLSQANLTQAD LSGANL QYAVLRRADLTNADLENAN LEDAN LHGADLSSAN LDHAM LSGASLN DAN LRQAN LSEAN LSGAN LKGAN L SGADLHGAN LEHAN LQRAN LEAADLSEAN LTGAN LHEAN LAHAN LRGARTTGARLDDADLRGATVDPVLW RTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRR G RRN FQHIN LQEIELTNADLSQANLTQADLSGANLQYAVLRRADLTNADLENAN LEDAN LHGADLSSAN LD HAM LSGASLN DAN LRQAN LSEAN LSGAN LKGAN LSGAD LHGAN LEHAN LQRAN LEAADLSEAN LTGAN LH EAN LAHAN LRGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGG SAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLSQANLTQADLSGANLQ YAVLRRADLTNADLENAN LEDAN LHGADLSSAN LDHAMLSGASLNDAN LRQAN LSEAN LSGAN LKGAN LS GADLHGAN LEHAN LQRAN LEAADLSEAN LTGAN LHEAN LAHAN LRGARTTGARLDDADLRGATVDPVLWR TASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0663] SynRFR24.new_caps.p3ElS.l.x4 full capped sequence with linker - B2 [SEQ ID NO: 178] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AVLQSAN LEQAN LSGAN LSGAN LRQAN LSGAN LTGASLH EAN LEGADLSN ADLTAANLKNADLS RAN LSYAN LN DADLSEAD LSGAN LRGAN LRDAN LDGADLHGAN LA RAM LEHADLTQAN LHHANLQEANLSEARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNAVLQSAN LEQAN LSGANL SGAN LRQAN LSGANLTGASLHEANLEGADLSNADLTAANLKNADLS RAN LSYAN LNDADLSEADLSGANL RGAN LRDAN LDGADLHGAN LARAM LEHADLTQAN LH HAN LQEAN LSEARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AVLQSAN LEQAN LSGAN LSG AN LRQAN LSGAN LTGASLH EAN LEGADLSN AD LTAANLKNADLSRANLSYAN LN DADLSEADLSGANLRGAN LRDAN LDGADLHGAN LARAM LEHADLTQAN LHHANLQEANLSEARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNAVLQSAN LEQAN LSGANL SGAN LRQAN LSGANLTGASLHEANLEGADLSNADLTAANLKNADLS RAN LSYANLNDADLSEADLSGANL RGAN LRDAN LDGADLHGAN LARAM LEHADLTQAN LH HAN LQEAN LSEARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0664] SynRFR24.new_caps.p3TlS.l.x4 full capped sequence with linker - B5 [SEQ ID NO: 179] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNANLQNAN LEEAN LSGADLSYAN LKEADLSSAN LRQASLHGAN LHGAN LAEAN LRRADLRQANLSHANLEGADLSEAVLEGANLNNANLSDANLEGANLSQADLTGADLQGANLHRANLTDAN LSGADLSHAMLDAARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLQNAN LEEAN LSGA DLSYAN LKEADLSSAN LRQASLHGAN LHGAN LAEAN LRRADLRQAN LSHAN LEGADLSEAVLEGAN LN NA N LSDAN LEG AN LSQADLTGADLQGAN LHRAN LTDAN LSGADLSHAMLDAARTTGARLDDADLRGATVDP VLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILE EYRRGRRNFQHINLQEIELTNANLQNANLEEANLSGADLSYAN LKEADLSSAN LRQASLHGAN LHGAN LAE AN LRRADLRQAN LSHAN LEGADLSEAVLEGAN LN NAN LSDAN LEGAN LSQADLTGADLQGAN LH RAN LTD ANLSGADLSHAMLDAARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQG GSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLQNAN LEEAN LS GADLSYAN LKEADLSSAN LRQASLHGAN LHGAN LAEAN LRRADLRQAN LSHAN LEGADLSEAVLEGAN LN NAN LSDAN LEGAN LSQADLTGADLQGAN LH RAN LTDAN LSGADLSHAM LDAARTTGARLDDADLRGATV DPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0665] SynRFR24.new_caps.p3TlE.l.x4 full capped sequence with linker - B14 [SEQ ID NO: 180] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AN LQDAN LSEAN LKGADLSG AN LH RAN LSH AVLTQAN LEGAN LHGAN LRHA DLHDADLAGADLRRANLQEANLSQANLEYAMLSQANLEEAN LSGAN LENADLSEADLDAANLESASLTGA NLRGADLNGANLSNARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGG SGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLQDANLSEANLKG ADLSGAN LH RAN LSHAVLTQAN LEGAN LHGAN LRHADLHDADLAGADLRRAN LQEAN LSQAN LEYAM LSQ AN LEEAN LSGAN LENADLSEADLDAANLESASLTGANLRGADLNGANLSNARTTGARLDDADLRGATVDP VLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILE EYRRGRRN FQHIN LQEIELTNAN LQDAN LS EAN LKGADLSGAN LHRAN LSHAVLTQAN LEGAN LHGAN LRH ADLHDADLAGADLRRAN LQEAN LSQAN LEYAM LSQAN LEEAN LSGAN LENADLSEADLDAANLESASLTG ANLRGADLNGANLSNARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLQDANLSEANLK GADLSGAN LH RAN LSHAVLTQAN LEGAN LHGAN LRHADLHDADLAGADLRRAN LQEAN LSQAN LEYAM LS QAN LEEAN LSGAN LENADLSEADLDAANLESASLTGANLRGADLNGANLSNARTTGARLDDADLRGATVD PVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0666] SynRFR24.new_caps.p3HlT.l.x4 full capped sequence with linker - B17 [SEQ ID NO: 181] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN ADLEN AN LTEAN LRDAN LEGAVLSHAN LSGAN LSRAN LTGAN LKSAN LQEAN LTDADLRGAN LHYADLSGADLNQAN LQNADLEGAN LRQAN LSGAN LSEAN LHGADLAQASLDRAN LEGA DLSAANLTEAMLSHARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLENANLTEAN LRDAN LEGAVLSHAN LSGAN LSRAN LTGAN LKSAN LQEAN LTDADLRGAN LHYADLSGADLNQAN LQNADLEGAN LRQAN LSGAN LSEAN LHGADLAQASLDRAN LEGADLSAANLTEAMLSHARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN ADLEN AN LTEAN LRDAN LEGAVLSHAN LSGAN LSRAN LTGAN LKSAN LQEAN LTDADLRGAN LHYADLSGADLNQAN LQNADLEGAN LRQAN LSGAN LSEAN LHGADLAQASLDRAN LEGA DLSAANLTEAMLSHARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNADLENANLTEAN LRDAN LEGAVLSHAN LSGAN LSRAN LTGAN LKSAN LQEAN LTDADLRGAN LHYADLSGADLNQAN LQNADLEGAN LRQAN LSGAN LSEAN LHGADLAQASLDRAN LEGADLSAANLTEAMLSHARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0667] SynRFR24.nct.3.x4 full capped sequence with linker - B48 [SEQ ID NO: 182] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNASLTGADLSYANLHHAN LSRAN LRSADLRNANLSHAN LSGAN LEEANLEAAN LRGADLHEANLSGADLQEANLTQANLKDANLSDANLEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEA MLTRANLEQADLSHANVQGAN LSEAN LEGAKVDLSFFTQAALEGAKFSEEQKKLLERAKGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHAN LSRAN LRSADLRNANLSHAN LSGAN LEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDANL EQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSHAN VQGAN LSEAN LEGAKVDLSFF TQAALEGAKFSEEQKKLLERAKGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRR G RRN FQHI N LQEI E LTN AS LTG AD LSYAN LH H AN LS RAN LRSAD LRN AN LS HAN LSGAN LE EAN LEAAN LR GADLHEAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM L TRAN LEQADLSHAN VQGAN LSEAN LEGAKVDLSFFTQAALEGAKFSEEQKKLLERAKGGGQGGQGGSGG SAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLS RAN LRSADLRN AN LSHAN LSGAN LEEAN LEAAN LRG ADLH EAN LSGADLQEAN LTQAN LKDAN LSDAN LE QADLAGADLQGAVLDGAN LHGAN LN NAN LSEAM LTRAN LEQADLSHANVQGAN LSEAN LEGAKVDLSFFT QAALEGAKFSEEQKKLLERAKGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0668] SynRFR24.nnt.2.x4 full capped sequence with linker - B59 [SEQ ID NO: 183] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQSLTAEEILARKA AGEKDFSGADLSHVNLSNASLTGADLSYANLH HAN LSRAN LRSADLRNANLSHAN LSGAN LEEAN LEAANL RGADLHEAN LSGADLQEAN LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRANLEQADLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQSLTAEEILARKAAGEKDFSGADLSHVNLSNASLTGADLSYANLHHANL SRANLRSADLRNANLSHAN LSGAN LEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDANL EQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRANLEQADLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQSLTAEEILARKA AGEKDFSGADLSHVNLSNASLTGADLSYANLH HAN LSRANLRSADLRNANLSHAN LSGAN LEEANLEAANL RGADLHEANLSGADLQEANLTQANLKDANLSDANLEQADLAGADLQGAVLDGAN LHGAN LN NAN LS EAM LTRANLEQADLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQSLTAEEILARKAAGEKDFSGADLSHVNLSNASLTGADLSYANLHHANL SRANLRSADLRNANLSHANLSGANLEEANLEAANLRGADLHEANLSGADLQEANLTQANLKDANLSDANL EQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRANLEQADLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0669] SynRFR24.new_caps.p3ElH.l.x4 full capped sequence with linker - B21 [SEQ ID NO: 184] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNANLAQANLHEANLSSAN LRGAN LS EAN LRGADLSHADLSGADLRQANLTAAN LHGAMLHGAVLTGADLNYANLQRANLTGANLEDADLSQANLSEANLHNANLQDADLSGASLSHANLDEAN LERADLKGANLENARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSG GSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLAQANLHEANLSSANL RGANLSEANLRGADLSHADLSGADLRQANLTAANLHGAMLHGAVLTGADLNYANLQRANLTGANLEDADL SQAN LSEAN LH NAN LQDAD LSG AS LSH AN LD EAN LE RAD LKG AN LE N ARTTG ARLD DAD LRG ATVD PVLW RTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRR GRRNFQHINLQEIELTNANLAQANLHEANLSSANLRGAN LSEAN LRGADLSHADLSGADLRQANLTAANLH GAMLHGAVLTGADLNYANLQRANLTGANLEDADLSQAN LSEAN LHNANLQDADLSGASLSHANLDEANLE RADLKGANLENARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGG SAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLAQANLHEANLSSANLR GAN LSEAN LRGADLSHADLSGADLRQANLTAANLHGAMLHGAVLTGADLNYANLQRANLTGANLEDADLS QANLSEANLHNANLQDADLSGASLSHANLDEANLERADLKGANLENARTTGARLDDADLRGATVDPVLWR TASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0670] SynRFR24.new_caps.p3ElR.l.x4 full capped sequence with linker - Bl [SEQ ID NO: 185] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AN LSEAN LRGAN LEDADLEGAVLQQAN LHGAN LRGADLRYAN LH RAN LSEAD LRHAN LSGADLEQADLSSADLTEAN LSNAN LSRADLHGAN LKGAN LTEAM LSDASLDAAN LTHAN LSGAN LQNANLNGANLAQARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNAN LSEAN LRGAN LEDAD LEGAVLQQAN LHGAN LRGADLRYAN LHRANLSEADLRHAN LSGADLEQADLSSADLTEAN LSNAN LS RAD LHGAN LKGAN LTEAM LSDASLDAAN LTHAN LSGAN LQN AN LNGANLAQARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRG RRN FQHIN LQEIELTN AN LSEAN LRGAN LEDADLEGAVLQQAN LHGAN LRGADLRYAN LH RAN LSEAD LRHAN LSGADLEQADLSSADLTEAN LSNAN LSRADLHGAN LKGAN LTEAM LSDASLDAAN LTHAN LSGAN LQNANLNGANLAQARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNANLSEANLRGANLEDAD LEGAVLQQANLHGANLRGADLRYANLHRANLSEADLRHANLSGADLEQADLSSADLTEANLSNANLSRAD LHG AN LKG AN LTEAM LSDAS LDAAN LTH AN LSG AN LQN AN LN G AN LAQARTTG ARLD DAD LRG ATVD PVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQKSDDG
[0671] SynRFR24.nc.x4.l6 full capped sequence with linker - L6 [SEQ ID NO: 186] MGSSHHHHHHHHHHSSGLVPRGSGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANLSHAN LSGAN LEEAN LEAAN LRGADLHEANLSGADLQEANLTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGANLHGAN LN NAN LSEA MLTRANLEQADLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHAN LS RAN LRSAD LRN AN LS HAN LSG AN LE EAN LEAAN LRG AD LH EAN LSG AD LQEAN LTQAN LKDAN LSDAN L EQADLAGADLQGAVLDGANLHGANLNNANLSEAMLTRANLEQADLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEY RRGRRNFQHINLQEIELTNASLTGADLSYANLHHANLSRANLRSADLRNANLSHANLSGANLEEAN LEAAN LRGADLHEANLSGADLQEANLTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGANLHGAN LN NAN LSEA MLTRANLEQADLSGARTTGARLDDADLRGATVDPVLWRTASLRGAKMEEEQRREYERARGGGQGGQGGS GGSAAAAAAAAGGSGGSGGQGGQRMRRDEILEEYRRGRRNFQHINLQEIELTNASLTGADLSYANLHHAN LS RAN LRSAD LRN AN LS HAN LSG AN LE EAN LEAAN LRG AD LH EAN LSG AD LQEAN LTQAN LKDAN LSDAN L EQADLAGADLQGAVLDGANLHGANLNNANLSEAMLTRANLEQADLSGARTTGARLDDADLRGATVDPVL WRTASLRGAKMEEEQRREYERARGGGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQQSDDG
[0672] N Cap [SEQ ID NO: 187]
[0673] SLTAAEVLALKAAGERDFSGADLSGIDLSG
[0674] N Cap[SEQ ID NO: 188]
[0675] SLTAEEILARKAAGEKDFSGADLSHVNLSN
[0676] C cap[SEQ ID NO: 189]
[0677] AKTTGADLSGANLEGATVDLSFYTEAKLTGATFSADQKKALARAKG
[0678] C cap [SEQ ID NO: 190]
[0679] ANVQGANLSEANLEGAKVDLSFFTQAALEGAKFSEEQKKLLERAKG
[0680] Solenoid - B9 [SEQ ID NO: 191] ADLEAANLKYANLHEADLSRANLTGANLTNANLHQANLTGANLSHANLSHAVLTNANLSGADLSEANLEGA NLAGADLRGANLQDANLQEANLDQASLRGANLRQANLHSAMLSEADLNRADLEGADLSDANLSG
[0681] Solenoid - B38 [SEQ ID NO: 192]
[0682] ADLSHADLSRADLKGAN LSGADLDHAVLREAN LAQAN LSGAN LESAN LHEADLNQAM LSGAN LTGASLRR ADLSEAN LQGAN LRGAN LEAAN LSNAN LQNADLSYAN LEEAN LTDAN LEDAN LHQAN LHGAN LTGSolenoid - B7 [SEQ ID NO: 193] ANLTQANLRSANLSGANLTRANLHNADLEGANLQGANLEDADLSHANLTDADLKNANLEGAVLSGANLEE AN LSQAN LQYAD LS HAN LS RAM LHQAS LAGAN LSG AD LH EAN LREAD LN AAN LE EAN LSG AD LDG
[0683] Solenoid – B11 [SEQ ID NO: 194] ADLSQANLTQADLSGANLQYAVLRRADLTNADLENANLEDANLHGADLSSANLDHAMLSGASLNDANLRQ AN LSEAN LSGAN LKGAN LSGADLHGAN LEH AN LQRAN LEAADLSEAN LTGAN LH EAN LAHAN LRG
[0684] Solenoid - B2 [SEQ ID NO: 195]
[0685] AVLQSANLEQAN LSGAN LSGAN LRQANLSGANLTGASLHEANLEGADLSNADLTAANLKNADLS RAN LSY AN LN DADLSEADLSGAN LRGAN LRDAN LDGADLHGAN LA RAM LEHADLTQAN LHHAN LQEAN LSE
[0686] Solenoid - B5 [SEQ ID NO: 196]
[0687] AN LQN AN LEEAN LSGADLSYAN LKEADLSSAN LRQASLHG AN LHGAN LAEAN LRRADLRQAN LSHAN LEG ADLSEAVLEGAN LN NAN LSDAN LEGAN LSQADLTGADLQGAN LHRAN LTDAN LSGADLSHAMLDA
[0688] Solenoid - B14 [SEQ ID NO: 197]
[0689] AN LQDAN LSEAN LKGADLSGAN LHRAN LSHAVLTQAN LEGAN LHGAN LRHADLHDADLAGADLRRAN LQE AN LSQAN LEYAMLSQAN LEEAN LSGAN LENADLSEADLDAANLESASLTGANLRGADLNGANLSN
[0690] Solenoid - B17 - [SEQ ID NO: 198]
[0691] ADLEN AN LTEAN LRDAN LEGAVLSHAN LSGAN LSRAN LTGAN LKSAN LQEAN LTDADLRG AN LHYADLSGA DLNQAN LQN ADLEGANLRQAN LSGAN LS EAN LHGADLAQASLDRANLEGADLSAANLTEAMLSH
[0692] Solenoid - B48 [SEQ ID NO: 199]
[0693] ASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAANLRGADLHEANLSGADLQEA NLTQANLKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRANLEQADLSH
[0694] Solenoid - B59 [SEQ ID NO: 200]
[0695] ASLTGADLSYAN LHHAN LSRAN LRSADLRNAN LSHAN LSGAN LEEAN LEAANLRGADLHEANLSGADLQEA N LTQAN LKDAN LSDAN LEQADLAGADLQGAVLDGAN LHGAN LN NAN LSEAMLTRAN LEQADLSG
[0696] Solenoid - B21 [SEQ ID NO: 201]
[0697] AN LAQANLHEANLSSAN LRGAN LS EAN LRGADLSHADLSGADLRQANLTAANLHGAMLHGAVLTGADLNY AN LQRAN LTGAN LEDADLSQANLS EAN LH NAN LQDADLSGAS LSHAN LDEANLERADLKGANLEN
[0698] Solenoid - Bl [SEQ ID NO: 202]
[0699] AN LSEAN LRGAN LEDADLEGAVLQQAN LHGAN LRGADLRYAN LHRAN LSEADLRHANLSGADLEQADLSS ADLTEANLSNANLSRADLHGANLKGANLTEAMLSDASLDAANLTHANLSGANLQNANLNGANLAQ
[0700] Linker [SEQ ID NO: 203]
[0701] GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQFIGURE LEGENDS
[0702] Figure 1: a) Droplets generated by pipetting 350 pLof 10 mg / mL protein solution with 75 pL of Captex 300 oil b) 30 mg / mL protein solution and Captex 300 oil pipetted at a 1:1 ratio. The protein solution was dyed with fluorescein, still in the self quenching regime, turning it orange, while the clear liquid is the Captex 300 c) 30 mg / mL protein solution and Captex 300 oil pipetted at a 5:4 ratio. The protein solution was dyed with fluorescein, still in the self quenching regime, turning it orange, while the clear liquid is the Captex 300.
[0703] Figure 2: Figure 2: a) 9:1 10 mg / mL protein solution to Captex 300 oil sample, sonicated with a 2 second on 2 second off pulse at 30% amplitude using a Sonics VibraCell VCX500 sonicator for 7.5 minutes total time b) lOOx microscope image of lOx diluted sample of a) c) Sample from solution seen in a), centrifuged at 21300 ref for 5 minutes, resulting in some apparent phase separation d) microscope image of mixture of top and middle phase of solution seen in c)
[0704] Figure 3: 10 mg / mL protein or distilled water, was mixed with the labelled ratio of Captex 300, and sonicated with a 2 second on 2 second off pulse at 25% amplitude using a Sonics VibraCell VCX500 sonicator for 40 seconds total time. Samples of the resulting emulsions were taken and diluted with distilled water by a factor of 5, and an OD measurement at 600 nm was taken with a Thermo Scientific NanoDrop One.
[0705] Figure 4: a) 20 mg / mL 20% EtOH v / v flowable hydrogel after being incubated overnight at 50°C, no difference was found between incubating at 37°C and 50°C b) Copper (II) hydrogel with 50 mM copper sulphate and 15 mg / mL
[0706] protein concentration c) Calcium (II) hydrogel with 25 mM calcium chloride and 15 mg / mL protein concentration, incubated overnight at 37°C
[0707] Figure 5: a) Image of plate containing various concentrations of protein and ethanol after being incubated at 37°C for 48 hours, b) Plot of measured turbidity at 550 nm of plate seen in a) over time with each subplot corresponding to each well. The mg / mL value is the concentration of protein, the % value refers to the v / v concentration of ethanol.
[0708] Figure 6: a) 20 mg / mL protein solution with 70% v / v EtOH hydrogel, immediately after mixing of the solutions b) hydrogel from a) extracted onto a plastic petri dishFigure 7: a) gloves with InstantBlue Coomasie stain on top of drier cream. Right to left, it is 4:1 Nursem caring hand cream:20 mg / mL 30% v / v EtOH hydrogel, Nursem caring hand cream and Nursem caring hand cream mixed with equivalent amount of protein powder as in the glove on the right, b) Protein Film made using 275 mg / mL protein solution spread over a powder coated lab stand base and left to dry over multiple days c) Silinized glass slides covered in (left to right) Nursem caring hand cream, 4:1 Nursem caring hand cream:20 mg / mL 30% v / v EtOH hydrogel and Nursem caring hand cream mixed with equivalent amount of protein powder
[0709] Figure 8: 8:17 Captex 300:protein solution with 23.6 mg / mL protein and 26.5% EtOH v / v end concentration in the aqueous phase end concentration, after overnight incubation in a 37°C shaking incubator at 875 RPM.
[0710] Figure 9: a) Taken from Hu et al, (ref 17) a method of coating droplets by passing through interface of two carrier liquids.
[0711] Figure 10: A) Filament picture examples; B) Filament / fibre birefringence of filaments produced using various concatemers of the invention. Shown are filaments produced by polypeptides of SEQ ID NO: 174, 176, 177, 178, 179, 180.
[0712] Figure 11: Tensile strength of filaments / fibres produced using various concatemers of the invention. Show are results produced by fibres produced from polypeptides of SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183.
[0713] Figure 12: Toughness of filaments / fibres produced using various concatemers of the invention. Shown are results for filaments / fibres produced from polypeptides of SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183.
[0714] EXAMPLES
[0715] Example 1: Droplet generation
[0716] The polypeptide that comprises or consists of a concatemer of at least two beta solenoids used in the Examples is the polypeptide set out in SEQ ID NO: 186 - other polypeptides are considered to behave similarly.The approaches to droplet generation taken were as follows: a) mechanical stirring using a magnetic stirrer bar in Thermo Scientific Chromcol 2 mL GC tubes; b) pipetting of the sample using a 1 mL pipette; and c) sonication.
[0717] Droplet generation via pipetting was done by pipetting the solution with a 1 mL pipette continuously for approximately 1 minute, setting a volume appropriate to take up most of the solution each time, but not so high as to cause the solution to be aspirated into the pipette. This would generate droplets on the scale of approximately 10 - 100 pm (see fig la) that would float at the top of the solution. It also allowed working with smaller sample volumes, as low as 180 pL, compared to a 400 pL minimum using the GC tubes. If too much oil was added (1:1) water in oil droplets would form, rather than oil in water, as seen in fig lb and lc, demonstrating the protein's amphiphilic nature Note that if no further processing steps were performed, the used protein solution could be separated from the droplets, and could be reused to generate more droplets.
[0718] Sonication is the third technique of droplet generation. It resulted in a stable emulsion of Captex 300 oil in the protein solution, as seen in 2a, that showed no signs of demixing for over 2 months. Sonication generated much smaller droplets of oil, on the scale of 1 pm, as can be seen in 2b. It could be destabilized by centrifugation at 21300 ref for 5 minutes, creating 3 separate phases. Further centrifugation, for an additional 20 minutes, did not noticeably increase the separation. The top layer proved quite hard, and could not be sampled without mixing with the middle layer. See Fig 2b. Note that sonication was able to emulsify 1:1 protein to oil loading ratios without issue, unlike pipetting. The 1:1 loaded emulsions behaved similarly to the 9:1 protein solution: oil emulsions, suggesting that it is indeed an oil in water emulsion.
[0719] A stability analysis was undertaken to assess the impact of protein on emulsion stability in comparison to water-only solutions. Optical density measurements at 600 nm were conducted on 5x dilutions of various emulsions to quantify this effect. Samples of the emulsions used for the optical density (OD) measurements were diluted by a factor of 5 as to bring the OD into a measurable range. Although there was a large variation in the OD measured for the 9:1 10 mg / mL protein solution to Captex 300 emulsion, it is clear that the protein significantly increased the emulsion stability, as seen in figure 3.
[0720] Example 2: Film Formation / Casting
[0721] Protein film formation was possible using protein suspended in buffer at a concentration between 67 - 275 mg / mL. Without adding plasticizer, the protein solution was spreadthinly over a given surface and left to dry at room temperature over the course of one to multiple days. Films cast at lower concentrations, 67 mg / mL, were not able to be pealed from the casting surface. Films cast at 125 mg / mL and above could be peeled off.
[0722] The films that could be separated from the casting surface were flexible, not tacky to the touch, and water soluble (see figure 7b). Depending on the thickness of the casting, they were flexible enough to be folded over themselves and had elongation lengths between 2 - 12 %. If a film could be peeled off the casting surface was dictated concentration and by the casting surface; films would stick to plastic and to silanized glass and could not be peeled off the surfaces. However, good separation could be achieved by casting the film onto powder-coated surfaces, e.g. lab stand bases.
[0723] Example 3: Hydrogel Generation
[0724] In order to encase the created droplets in hydrogel via a type of coacervation, conditions had to be used in which a hydrogel could form. Rather than investigating this directly with the droplets, initially, tests were run trying to create hydrogels without oil in the solution. In short, a flowable hydrogel was created at 20 mg / mL of protein and 20 - 30% v / v ethanol / water (all given as end concentrations) incubated overnight at 37°C (Figure 4a). These were the most promising conditions for hydrogel generation, both in terms of the end product, as well as the ease of production and price effectiveness and non toxicity of the components required.
[0725] Other methods of producing hydrogels were investigated. Copper Sulphate (anhydrous) was added to create 25 mM and 50 mM solutions with 15 mg / mL protein solution (end concentration) and created a flowable hydrogel that was blue in colour (Figure 4b). Similarly, calcium chloride at 25 mM would generate a flowable hydrogel but only when incubated overnight at 37°C (Figure 4c).
[0726] Neither exposing 10 mg / mL protein solutions to up to 95 °C as well as lowering the pH to pH 2 produced a gelled solution.
[0727] To investigate hydrogel formation more quantitatively the turbidity of the solution was measured over time in a plate reader. It is hypothesized that the turbidity is caused by increased beta sheet formation.As seen in figure 5, there is a clear difference between the hydrogels created at or below 30% v / v EtOH and at or above 40% v / v EtOH. This difference was observed continuously throughout all experiments, not only with ethanol, but also with copper, and was assumed to occur with calcium hydrogels as well. When the concentration of the hydrogel trigger was high, the hydrogel would form as a non flowable hydrogel, in which the network structure encompassed the entire structure. This resulted in a viscoelastic solid, that could not easily be separated into smaller sub units. This behaved very differently to the lower ethanol concentration hydrogels (Figure 6). They did not require any incubation or heating for the creation of the end product, however, it was deemed that the end product had fewer applications.
[0728] The flowable hydrogels were mixed at a 1:4 ratio by weight with a Nursem caring hand cream. Mixing was successful, with no noticeable lumps or major changes to the texture. The same was true of mixing the equivalent mass of protein powder directly into the cream, without the hydrogel formation step.
[0729] The resulting creams were spread onto a nitrile glove and let to dry to form a film. The films were stained blue with InstantBlue Coomasie. (Figure 7a & 7c). The motivation for incorporating the protein into the moisturizer was the film that the protein can form on its own. The protein should be able to form a microfilm on the skin when applied with the moisturizer, once the moisturizer is absorbed into the skin.
[0730] Example 4: Droplet Encapsulation
[0731] The most effective approach to encapsulating the droplets in protein that was found was to add 50% v / v EtOH directly to the oil droplet protein solution until a final ethanol concentration of 30% was reached, and then incubate these droplets in a shaking incubator at 37°C overnight. The shaking incubator purpose is to agitate the solution as to not minimize the clumping of the droplets that will occur. Agents can then be added to further stabilize the shell around the droplets. No method capable of accurately characterizing the shell was available, so it is unclear if the shell has the properties of a hydrogel, or is rather a skin of coagulated protein.
[0732] Droplets produced could be dried and rehydrated, with only some losses of droplets.. This was true for trials with 100% Captex 300 as the oil phase, that produced droplets that survived the entire procedure. Trials using 50% Captex 30050% phenetyl alcohol as the oil phase proved unstable after the drying step. A control trial was performedwithout protein, and even though droplets could be initially produced, they were not stable and would collapse to a continuous oil phase after centrifugation.
[0733] The motivation for choosing Captex 300 as the oil was to use an oil that did not originate from the petrochemical industry, that was relatively cost effective and that was safe to use for cosmetic, nutritional and healthcare applications. The trials mixing it with phenetyl alcohol were an attempt to load the droplets with a fragrance. Phenetyl alcohol is not miscible with water and was available, which is why it was used, however, it is unrealistic to assume a loading factor of 50% for fragrances.
[0734] As mentioned in Example 1, sonication created a total emulsion of the protein solution and the oil added. These behaved similarly to the pipetted droplets, in the sense that after they were created, by sonicating protein solution 1: 1 with Captex 300, they could be coagulated, further stabilized, dried and rehydrated. The droplets were smaller in diameter,, and it appeared that the process is more efficient than pipetting i.e. more droplets were obtained using the volume of protein, however, as no
[0735] methodology was available that could accurately measure the encapsulation efficiency, neither process was optimized.
[0736] Example 5 - Concatemers of the invention form fibres
[0737] Polypeptides of the invention that comprise or consist of a concatemer of beta solenoids as set out herein, are able to produce fibres and in some cases have particular advantageous properties. Features of the fibres are set out in Figures 10-12. For example fibres produced from the concatemer having a sequence of SEQ ID NO: 178 (SynRFR24.new_caps.p3ElS.l.x4) shows a high degree of toughness.
[0738] References
[0739] [1] S. Mitura, A. Sionkowska and A. Jaiswal, Journal of Materials Science: Materials in Medicine, 2020,
[0740] 31, 50.
[0741] [2] K. Bruyninckx and M. Dusselier, ACS Sustainable Chemistry Engineering, 2019, 7, 8041-8054.
[0742] [3] L. R' omer, J. Klein and R. Mehrwald, US20200270316A1, 2020.
[0743] [4] J. C. Soper, K. D. Young and T. T. Margaret, US6045835, 2000.
[0744] [5] B. K. Green and L. Schleicher, US2800457, 1957.[6] P. M. P. Lopes, D. Moldovan, M. Moldovan, R. Carpa, C. Saro, si, P. P”a, scut, “a, A. M. Moldovan, R. Fechete
[0745] and V. Popescu, Materials, 2022, 15, 2611.
[0746] [7] S. Seslija, D. Veljovic, M. K. Krusic, J. Stevanovic, S. Velickovic and I. Popovic, New Journal of
[0747] Chemistry, 2015, 40, 1618-1625.
[0748] [8] H. Xu, L. Shen, L. Xu and Y. Yang, Industrial Crops and Products, 2015, 74, 234-240.
[0749] [9] A. M. Jonker, D. W. P. M. L"owik and J. C. M. v. Hest, Chemistry of Materials, 2012, 24, 759-773.
[0750]
[0010] C. Ma, H. Pang, H. Liu, Q. Yan, J. Li and S. Zhang, Journal of Materials Chemistry B, 2021, 9,
[0751] 4230-4240.
[0752]
[0011] B. Balakrishnan and A. Jayakrishnan, Biomaterials, 2005, 26, 3941-3951.
[0753]
[0012] K. Schacht and T. Scheibel, Biomacromolecules, 2011, 12, 2488-2495.
[0754]
[0013] Z. A. Haider, M. Arai and K. Hirabayashi, Bioscience, Biotechnology, and Biochemistry, 1993, 57,
[0755] 1910-1912.
[0756]
[0014] S. Kapoor and S. C. Kundu, Acta Biomaterialia, 2016, 31, 17-32.
[0757]
[0015] U.-J. Kim, J. Park, C. Li, H.-J. Jin, R. Valluzzi and D. L. Kaplan, Biomacromolecules, 2004, 5, 786-792.
[0758]
[0016] A. Matsumoto, J. Chen, A. L. Collette, U.-J. Kim, G. H. Altman, P. Cebe and D. L. Kaplan, The
[0759] Journal of Physical Chemistry B, 2006, 110, 21630-21638.
[0760]
[0017] P. C. Hu, S. Li and N. Malmstadt, ACS Applied Materials & Interfaces, 2011, 3, 1434-1440.
[0761] 10
[0762] The invention is set out in the following numbered embodiment paragraphs.
[0763] Film
[0764] 1. A film comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0765] 2. The film according to paragraph 1 wherein the film is
[0766] (a) water insoluble; or
[0767] (b) water soluble3. The film according to paragraph 1 or 2 wherein the polypeptide prior to film formation is water soluble.
[0768] 4. The film according to any of the preceding embodiments wherein the film is flexible.
[0769] 5. The film according to any of the preceding paragraphs wherein the film does not comprise any plasticiser and is flexible, or is formed from a composition that did not comprise any plasticiser.
[0770] 6. The film according to any of the preceding paragraphs wherein the film does not comprise a plasticiser, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose.
[0771] 7. The film according to any of the preceding paragraphs wherein the film does not comprise:
[0772] a) a polyol, optionally does not comprise glycerol, sorbitol, ethylene glycol, propylene glycol, and / or polyethylene glycol (e.g. PEG 400 or PEG 600 but wider ranges of MWs possible);
[0773] b) urea;
[0774] c) one or more sugars, optionally does not comprise glucose, sucrose and / or fructose;
[0775] d) one or more lipids, optionally does not comprise oleic acid, linoleic acid and / or lecithin;
[0776] e) one or more amino acids, optionally does not comprise proline, arginine and / or lysine.
[0777] 8. The film according to any of the preceding paragraphs wherein the film forms on one or more surfaces, optionally wherein the one or more surfaces is an external component of a subject, optionally of a human subject.
[0778] 9. The film according to any of the preceding paragraphs wherein the film forms on a first surface and can then be transferred to one or more external components of a subject, optionally a human subject.
[0779] 10. The film according to paragraph 8 or 9 wherein the one or more external components of a subject is selected from the group comprising or consisting of: skin,hair, nails, and mucosa, optionally human skin, human hair, human nails and human mucosa.
[0780] 11. The film according to any of the preceding paragraphs wherein the film is flexible, and flexes with the skin, hair, nails and / or mucosa.
[0781] 12. The film according to any of the preceding paragraphs wherein the film is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.
[0782] 13. The film of any of the preceding paragraphs further comprising at least a second agent.
[0783] 14. The film of paragraph 13 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0784] 15. The film of paragraph 13 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0785] 16. The film according to any of paragraphs 1-14 wherein the film is a therapeutic film.
[0786] 17. The film according to paragraph 16 wherein the therapeutic film:
[0787] a) is a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0788] b) is a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0789] c) acts as a wound dressing;
[0790] d) acts as an antimicrobial
[0791] e) delivers one or more therapeutic agents to the skin of a subject; and / or f) is occlusive.
[0792] 18. The film of paragraph 14, 16 or 17 wherein the therapeutic agent is selected from the group comprising or consisting of
[0793] i) A therapeutic agent for local delivery; and / orii) A therapeutic agent for systemic delivery.
[0794] 19. The film according to any of the preceding paragraphs wherein the film is applied over a transdermal delivery system.
[0795] 20. The film according to any of paragraphs 1-13, 15, 18 and 19 wherein the film is a cosmetic film.
[0796] 21. The film according to paragraph 20 wherein the cosmetic film:
[0797] a) is a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0798] b) is a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0799] c) delivers one or more cosmetic agents to the skin, nails or mucosa of a subject; and / or
[0800] d) is occlusive.
[0801] 22. The film according to paragraph 20 or 21 wherein the cosmetic agent is selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, and antioxidants.
[0802] i) A cosmetic agent for local delivery; and / or
[0803] ii) A cosmetic agent for systemic delivery.
[0804] 23. The film according to any of the preceding paragraphs wherein the film is suitable for use in packaging, optionally is a water-soluble film for use in packaging.
[0805] 24. The film of paragraph 23 wherein the film is suitable for packaging food.
[0806] 25. A multilayer film comprising at least two layers, wherein at least one layer comprises or consists of a film according to any of the preceding paragraphs.
[0807] 26. A transdermal delivery system comprising the film of any one or more of the preceding paragraphs, optionally a therapeutic transdermal delivery system or a cosmetic transdermal delivery system.27. cosmetic composition comprising the film of any one or more of the preceding paragraphs.
[0808] 28. A therapeutic composition comprising the film of any one or more of the preceding paragraphs.
[0809] 29. A wound dressing comprising the film of any one or more of the preceding paragraphs.
[0810] 30. A flexible package comprising the film of any one or more of the preceding paragraphs.
[0811] 31. A container comprising a film seal wherein the film seal comprises the film of any one or more of the preceding paragraphs.
[0812] Method of making the film
[0813] 32. A method of producing a protein-based film, wherein the method comprises:
[0814] a) applying a protein solution that comprises at least a polypeptide to a surface; and
[0815] b) allowing the solution to dry
[0816] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0817] 33. The method of paragraph 32 wherein the surface is a solid surface.
[0818] 34. The method of paragraph 32 wherein the surface is a liquid surface wherein the protein solution and the liquid are immiscible.
[0819] For example the surface may be the surface of a hydrophobic liquid upon which the aqueous protein solution forms a layer.
[0820] 35. The method of any of paragraph 32-35 wherein the protein solution is an aqueous protein solution.36. The method of any of paragraphs 32-36 wherein the protein solution comprises a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSOCAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer,
[0821] optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride,
[0822] 37. The method of any of paragraphs 32-35 wherein the polypeptide is present in the protein solution at a concentration of at least 5 mg / mL, at least 7 mg / mL, at least 10 mg / mL, at least 12 mg / mL, at least 15 mg / mL, at least 17 mg / mL, optionally at least 18.7 mg / ml, at least 20 mg / mL, optionally at least 25 mg / ml, at least 30 mg / ml, optionally at least 35 mg / ml, optionally at least 37.5 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml, optionally at least 70 mg / ml, optionally at least 75 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml.
[0823] 38. The method of any of paragraphs 32-37 wherein the protein solution further comprises at least a second agent.
[0824] 39. The method of paragraph 38 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream, optionally
[0825] 40. The method of paragraph 38 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0826] 41. The method of any of paragraphs 32-40 wherein the solid surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon.42. The method of any of paragraphs 32-41 wherein said applying is selected from the group comprising or consisting of pouring, spreading, spraying, dip coating, spin coating, doctor blading, tape casting, interfacial casting, electrospraying, roll-to-roll coating, inkjet printing, brush application, microcasting, wire-bar coating, draw-down coating, slot-die coating, and / or immersion precipitation.
[0827] 43. The method of any of paragraphs 32-42 wherein the film is a film according to any of paragraphs 1-25.
[0828] Hydrogel
[0829] 44. A hydrogel comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0830] 45. The hydrogel according to paragraph 44 wherein the hydrogel is water insoluble.
[0831] 46. The hydrogel according to paragraph 44 or 45 wherein the polypeptide prior to hydrogel formation is water soluble.
[0832] 47. The hydrogel according to any of paragraphs 44-46 wherein the hydrogel is flexible.
[0833] 48. The hydrogel according to any of paragraphs 44-47 wherein the hydrogel is a flowable hydrogel.
[0834] 49. The hydrogel according to any of paragraphs 44-48 wherein the hydrogel is flexible even when the hydrogel does not comprise any plasticiser, or is formed from a composition that did not comprise any plasticiser.
[0835] 50. The hydrogel according to any of paragraphs 44-49 wherein the hydrogel does not comprise a plasticiser, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose.
[0836] 51. The hydrogel according to any of paragraphs 44-50 wherein the hydrogel forms on one or more surfaces or external components of a subject, optionally of a human subject.52. The hydrogel according to any of paragraphs 44-51 wherein the hydrogel forms on a first surface and can then be transferred to one or more external components of a subject, optionally a human subject.
[0837] 53. The hydrogel according to any of paragraphs 44-52 wherein the one or more external components of a subject is selected from the group comprising or consisting of: skin, hair, nails and / or mucosa, optionally human skin, human hair, human nails and human mucosa.
[0838] 54. The hydrogel according to any of paragraphs 44-53 wherein the hydrogel is flexible, and optionally flexes with the skin, hair, nails and / or mucosa.
[0839] 55. The hydrogel according to any of paragraphs 44-54 wherein the hydrogel is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.
[0840] 56. The hydrogel of any of the preceding paragraphs further comprising at least a second agent.
[0841] 57. The hydrogel of paragraph 56 wherein the hydrogel and second agent are present in a ratio of hydrogel:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or at least 1:10.
[0842] 58. The hydrogel of paragraph 56 or 57 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0843] 59. The hydrogel of paragraph 56 or 57 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum.
[0844] 60. The hydrogel according to any of paragraphs 44-58 wherein the hydrogel is a therapeutic hydrogel.
[0845] 61. The hydrogel according to paragraph 60 wherein the therapeutic hydrogel:a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0846] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0847] c) acts as a wound dressing;
[0848] d) acts as an antimicrobial
[0849] e) delivers one or more therapeutic agents to the skin, nails and / or mucosa of a subject.
[0850] 62. The hydrogel of any of paragraphs 58-61 wherein the therapeutic agent is selected from the group comprising or consisting of
[0851] A therapeutic agent for local delivery;
[0852] A therapeutic agent for systemic delivery
[0853] 63. The hydrogel of any of paragraphs 44-62 wherein the hydrogel is applied over a transdermal delivery system.
[0854] 64. The hydrogel according to any of paragraphs 44-57 or 63 wherein the hydrogel is a cosmetic hydrogel.
[0855] 65. The hydrogel according to paragraph 64 wherein the cosmetic hydrogel:
[0856] a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0857] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0858] c) delivers one or more cosmetic agents to the skin, nails and / or mucosa of a subject.
[0859] 66. The hydrogel according to paragraph 64 or 65 wherein the cosmetic agent is selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, and antioxidants.
[0860] 67. A multilayer hydrogel comprising at least two layers, wherein at least one layer comprises or consists of a hydrogel according to any of the preceding paragraphs.68. A transdermal delivery system comprising the hydrogel of any one or more of the preceding paragraphs, optionally a therapeutic transdermal delivery system or a cosmetic transdermal delivery system.
[0861] 69. A cosmetic composition comprising the hydrogel of any one or more of the preceding paragraphs.
[0862] 70. A therapeutic composition comprising the hydrogel of any one or more of the preceding paragraphs.
[0863] 71. A wound dressing comprising the hydrogel of any one or more of the preceding paragraphs.
[0864] 71a. A coacervate comprising a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0865] Method of making the hydrogel
[0866] 72. A method of producing a protein-based hydrogel, wherein the method comprises:
[0867] a) providing a protein solution that comprises at least a polypeptide;
[0868] b) providing a gelling agent;
[0869] c) mixing the protein solution with the gelling agent
[0870] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0871] 73. The method of paragraph 72 further comprising incubating the mixture of the protein solution and gelling agent for a period of time so as to allow the hydrogel to form, optionally incubating for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more;
[0872] and optionally incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C.74. The method of paragraph 72 or 73 wherein the protein solution is an aqueous protein solution.
[0873] 75. The method of any of paragraphs 72-74 wherein the protein solution comprises a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSOCAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer,
[0874] optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride,
[0875] 76. The method of any of paragraphs 72-75 wherein the polypeptide is present in the mixture of the protein solution and the gelling agent at a concentration of at least 5 mg / mL, at least 7 mg / mL, at least 7.5 mg / ml, at least 10 mg / mL, at least 12 mg / mL, at least 15 mg / mL, at least 17 mg / mL, optionally at least 18.7 mg / ml, at least 20 mg / mL, optionally at least 25 mg / ml, at least 30 mg / ml, optionally at least 35 mg / ml, optionally at least 37.5 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml, optionally at least 70 mg / ml, optionally at least 75 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml.
[0876] 77. The method of any of paragraphs 72-76 paragraph wherein the gelling agent is selected from the group comprising or consisting of:
[0877] i) ethanol; and / or
[0878] ii) metal 2+ ions, optionally Cu2+ or Ca2+, optionally copper sulphate or calcium chloride.
[0879] 78. The method of paragraph 77 wherein the concentration of ethanol in the mixture of the protein solution and the gelling agent is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or more.79. The method of any of paragraphs 72-78 wherein the gelling agent is ethanol, and:
[0880] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 20% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0881] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml.
[0882] 80. The method of any of paragraphs 72-78 paragraph wherein the gelling agent is ethanol, and:
[0883] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0884] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0885] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[0886] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0887] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0888] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0889] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0890] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[0891] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0892] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[0893] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;
[0894] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[0895] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[0896] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[0897] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml.
[0898] 81. The method of any of paragraphs 72-78 wherein the gelling agent is ethanol and the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of between 20-30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of 20 mg / ml.
[0899] 82. The method of any of paragraphs 72-78 wherein the hydrogel is a non-flowable hydrogel, and the gelling agent is ethanol and is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30%, optionally at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or at least 75%.
[0900] 83. The method of any of paragraphs 72-78 wherein the hydrogel is a flowable hydrogel, and the gelling agent is ethanol and is present in the mixture of the protein solution and the gelling agent at a concentration of at 30% or less, optionally less than 25%, 20%, 15%, or less than 10%.
[0901] 84. The method of paragraph72-77 wherein:
[0902] i) the gelling agent is copper sulphate, and is present in them mixture of the protein solution and the gelling agent at a concentration of at least 15 mM, or at least 20 mM, 25mM, 30 mM, 35 mM, 40 mM, 45 mM, 50mM, 55 mM, 60mM, 65 mM or 70 mM or more; or
[0903] ii) the gelling agent is calcium chloride, and is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mM, or at least 20 mM, 25mM, 30 mM, 35 mM, 40 mM, 45 mM, 50mM, 55 mM, 60mM, 65 mM or 70 mM or more.
[0904] 85. The method of any of paragraphs 72-84 wherein the gelling agent is not, or does not comprise or consist of any one or more of:
[0905] i) heat of 95C;ii) pH of 2 or lower;
[0906] iii) sodium tetraborate; and / or
[0907] iv) sodium tetraborate and hydrogen peroxide.
[0908] 86. The method of any of paragraphs 72-85 wherein the method further comprises mixing the hydrogel with a second agent.
[0909] 87. The method of paragraph 86 wherein the second agent is a liquid, a cream, or a powder.
[0910] 88. The method of paragraph 86 or 87 wherein the hydrogel and second agent are present in a ratio of hydrogel:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or at least 1:10.
[0911] 89. The method of any of paragraphs 86-88 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[0912] 90. The method of any of paragraphs 86-88 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0913] 91. The method of any of paragraphs 86-90 wherein the method further comprises applying the hydrogel to a surface, optionally wherein said applying is selected from the group comprising or consisting of pouring, spreading and spraying.
[0914] 92. The method of paragraph 91 wherein the surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon.
[0915] 93. A protein-based flowable hydrogel produced according to the following method:
[0916] a) providing a protein solution that comprises at least a polypeptide;
[0917] b) mixing the protein solution with the ethanol to produce a mixture of protein solution and ethanol; andc) incubating the mixture of protein solution and ethanol for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more, optionally incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C.
[0918] 94. A protein-based viscoelastic non-flowable hydrogel produced according to the following method:
[0919] a) providing a protein solution that comprises at least a polypeptide;
[0920] b) mixing the protein solution with the ethanol to produce a mixture of protein solution and ethanol
[0921] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids, and
[0922] wherein the concentration of ethanol in the mixture of protein solution and ethanol is at least 30%, optionally at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or at least 75%.
[0923] Hydrogel shell microcapsule
[0924] 95. A hydrogel shell microcapsule comprising or consisting of:
[0925] a) a core made of a material that is not miscible or is not fully miscible with water;
[0926] b) a hydrogel shell surrounding and containing the core;
[0927] wherein the hydrogel shell comprises or consists of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0928] 96. The hydrogel shell microcapsule of paragraph 95 wherein the core is of a material selected from the group comprising or consisting of: a non-polar liquid, optionally oil; or an organic solvent such as an alcohol (such as ethanol, propylene glycol), glycerine, or, deep eutectic solvents; or a non-water miscible gas that is a gas at a temperature of at least between 4C and 40C.97. The hydrogel shell microcapsule of any of paragraphs 95 or 96 wherein the core further comprises one or more therapeutic or cosmetic agents.
[0929] 98. The hydrogel shell microcapsule of paragraph 97 wherein the one or more therapeutic or cosmetic agent is selected from the group comprising or consisting of: a small molecule, a protein such as an antibody, hormone such as insulin, enzyme, food ingredient, flavour or fragrance.
[0930] 99. The hydrogel shell microcapsule of any of paragraphs 95-98 wherein the hydrogel shell microcapsule is at least 1 µm, at least 5 µm, at least 10 µm, at least 20 µm, at least 50 µm, at least 100 µm, at least 200 µm, preferably 10 - 100 µm in length.
[0931] 100. The hydrogel shell microcapsule of any of paragraphs 95-99 wherein the hydrogel shell microcapsule is at least 150 µL, at least 180 µL, at least 200 µL, at least 300 µL, at least 400 µL or at least 500 µL in volume.
[0932] 101. The hydrogel shell microcapsule of any of paragraphs 95-100 wherein the stability of the hydrogel shell microcapsule is greater than the stability of microcapsules formed without the polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0933] Method of making the hydrogel shell microcapsule
[0934] 102. A method of producing the hydrogel shell microcapsule of any of paragraphs 95-101, wherein the method comprises producing droplets of a material that is not miscible or is not fully miscible with water in an aqueous protein solution, wherein the protein solution comprises a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[0935] 103. The method of paragraph 102 wherein producing said droplets is achieved by:
[0936] i) sonicating a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution.
[0937] ii) stirring a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0938] iii) pipetting a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution; oriv) a microfluidic droplet generation method, optionally cross-flowing droplet generation, flow-focusing droplet formation, or co-flowing droplet formation.
[0939] 104. The method of paragraph 102 or 103 wherein said material that is not miscible or is not fully miscible with water is selected from the group comprising or consisting of: a non-polar liquid, optionally oil; or an organic solvent such as an alcohol (such as ethanol, propylene glycol), glycerine, or, deep eutectic solvents; or a non-water miscible gas that is a gas at a temperature of at least between 4C and 40C, Optionally wherein the material that is not miscible or is not fully miscible with water is oil, optionally Captex 300.
[0940] 105. The method of any of paragraphs 102-104 wherein the droplets are at least 1 µm, at least 5 µm, at least 10 µm, at least 20 µm, at least 50 µm, at least 100 µm, at least 200 µm, preferably 10 - 100 µm in length.
[0941] 106. The method according to any one of paragraphs 102-105, wherein the droplets are at least 150 µL, at least 180 µL, at least 200 µL, at least 300 µL, at least 400 µL or at least 500 µL in volume.
[0942] 107. The method according to any of paragraphs 102-106, wherein the ratio of the material that is not miscible or is not fully miscible with water and the aqueous protein solution is less than 1:1.
[0943] 108. The method according of any of paragraphs 102-106, wherein the ratio of the material that is not miscible or is not fully miscible with water and the aqueous protein solution is more than 1:1.
[0944] 109. The method according to any of paragraphs 102-108 wherein the method further comprises isolating the hydrogel shell microcapsules from the aqueous protein solution and optionally producing more hydrogel shell microcapsules from the aqueous protein solution.
[0945] Hydrogel with microcapsules
[0946] 110. A hydrogel comprising a plurality of hydrogel shell microcapsules wherein:
[0947] i) the hydrogel shell microcapsules comprise or consist of:a) a core made of a material that is not miscible or is not fully miscible with water;
[0948] b) a hydrogel shell surrounding and containing the core;
[0949] wherein the hydrogel shell comprises or consists of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids;
[0950] and
[0951] ii) the hydrogel that comprises the plurality of hydrogel shell microcapsules comprises or consists of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[0952] 111. The hydrogel comprising a plurality of hydrogel shell microcapsules of paragraph 110 wherein the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel shell is the same polypeptide as the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel that comprises the plurality of hydrogel shell microcapsules.
[0953] 112. The hydrogel comprising a plurality of hydrogel shell microcapsules of paragraph 110 wherein the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel shell is a different polypeptide to the polypeptide that comprises or consists of a concatemer of at least two beta solenoids of the hydrogel that comprises the plurality of hydrogel shell microcapsules.
[0954] 113. The hydrogel comprising a plurality of hydrogel shell microcapsules of any of paragraphs 110-112 wherein the hydrogel is water insoluble.
[0955] 114. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-113 wherein the hydrogel is flexible, and optionally flexes with the skin, hair, nails and / or mucosa.
[0956] 115. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-114 wherein the hydrogel is a flowable hydrogel.
[0957] 116. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-115 wherein the hydrogel is flexible even when the hydrogel does not comprise any plasticiser, or is formed from a composition that did not comprise any plasticiser.117. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-116 wherein the hydrogel does not comprise a plasticiser, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose.
[0958] 118. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-117 wherein the hydrogel forms on one or more surfaces or external components of a subject, optionally of a human subject.
[0959] 119. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-118 wherein the hydrogel forms on a first surface and can then be transferred to one or more external components of a subject, optionally a human subject.
[0960] 120. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-119 wherein the one or more external components of a subject is selected from the group comprising or consisting of: skin, hair, nails and / or mucosa, optionally human skin, human hair, human nails and human mucosa.
[0961] 121. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-120 wherein the hydrogel is capable of transdermal delivery of one or more agents when applied to the skin, nails or mucosa of a subject.
[0962] 122. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-121 further comprising at least a second agent.
[0963] 123. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-122 wherein the hydrogel and second agent are present in a ratio of hydrogel:second agent by weight of at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or at least 1:10.
[0964] 124. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-123 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.125. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-123 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum.
[0965] 126. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-124 wherein the hydrogel is a therapeutic hydrogel.
[0966] 127. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-124 and 126 wherein the therapeutic hydrogel:
[0967] a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0968] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0969] c) acts as a wound dressing;
[0970] d) acts as an antimicrobial;
[0971] e) delivers one or more therapeutic agents to the skin, nails and / or mucosa of a subject.
[0972] 128. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-123 wherein the hydrogel is a cosmetic hydrogel.
[0973] 129. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-123 and 128 wherein the cosmetic hydrogel:
[0974] a) is a protective hydrogel on the skin, hair, nails and / or mucosa and optionally traps moisture;
[0975] b) is a protective hydrogel on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[0976] c) delivers one or more cosmetic agents to the skin, nails and / or mucosa of a subject.
[0977] 130. The hydrogel comprising a plurality of hydrogel shell microcapsules according to any of paragraphs 110-123, 128 and 129 wherein the cosmetic agent is selected from the group comprising or consisting of: actives, functionals, pigments, dyes, fragrances, pigments, enzymes, coenzyme, vitamins, hyaluronic acid, peptides, amino acids, ceramides, probiotics, UV protective agents, and antioxidants.131. A multilayer hydrogel comprising a plurality of hydrogel shell microcapsules comprising at least two layers, wherein at least one layer comprises or consists of a hydrogel according to any of paragraphs 110-130.
[0978] Method of making hydrogel with capsules
[0979] 132. A method of making a hydrogel comprising a plurality of hydrogel shell microcapsules wherein said method comprises:
[0980] a) producing a plurality of droplets of a material that is not miscible or is not fully miscible with water in an aqueous protein solution, wherein the protein solution comprises a polypeptide that comprises or consists of a concatemer of at least two beta solenoids;
[0981] b) mixing the plurality of droplets with ethanol, optionally ethanol at a final concentration of 30%; and
[0982] optionally
[0983] c) incubating the mixture obtained in (b), optionally
[0984] i) incubating for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours or at least 48 hours or more;
[0985] ii) incubating at a temperature of at least 20 °C, at least 25 °C, at least 30 °C, at least 32 °C, at least 34 °C, at least 36 °C, at least 37 °C, preferably at a temperature of 35 °C - 40 °C; and / or
[0986] iii) incubating with agitation, optionally in a shaking incubator.
[0987] 133. The method of paragraph 132 wherein production of said droplets is achieved by:
[0988] i) sonicating a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0989] ii) stirring a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution;
[0990] iii) pipetting a mixture of the material that is not miscible or is not fully miscible with water and the aqueous protein solution; or
[0991] iv) a microfluidic droplet generation method, optionally cross-flowing droplet generation, flow-focusing droplet formation, or co-flowing droplet formation.134. The method of paragraph 132 or 133 further comprising the step of exposing the droplets to a stabilising agent.
[0992] Compositions and uses
[0993] 136. A composition comprising a plurality of hydrogel shell microcapsules according to any of the preceding paragraphs.
[0994] 137. A therapeutic composition comprising a plurality of hydrogel shell microcapsules according to any of the preceding paragraphs.
[0995] 138. A cosmetic composition comprising a plurality of hydrogel shell microcapsules according to any of the preceding paragraphs.
[0996] 139. A therapeutic film comprising a film according to any of the preceding paragraphs.
[0997] 140. A cosmetic film comprising a film according to any of the preceding paragraphs.
[0998] 141. A composition comprising a hydrogel according to any of the preceding paragraphs.
[0999] 142. A therapeutic composition comprising a hydrogel according to any of the preceding paragraphs.
[1000] 143. A cosmetic composition comprising a hydrogel according to any of the preceding paragraphs.
[1001] 144. A therapeutic composition comprising a polypeptide that comprises or consists of a concatemer of at least two beta solenoids
[1002] 145. A cosmetic composition comprising a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
[1003] An aqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids.146. Use of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids in a method of making a film, a hydrogel, a hydrogel shell microcapsule or a hydrogel comprising a plurality of hydrogel shell microcapsules of any of the preceding paragraphs.
[1004] 147. A method of treating a subject in need thereof, said method comprising administering any one more of the film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel according to any of the preceding paragraphs.
[1005] 148. A film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel according to any of the preceding paragraphs for use in a method of treating a subject in need thereof.
[1006] 149. Use of any one more of the film, therapeutic film, hydrogel, therapeutic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, wound dressing, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel according to any of the preceding paragraphs for the manufacture of a medicament for the treatment of a subject in need thereof.
[1007] 150. A method of cosmetic treatment said method comprising administering one or more of any one more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel according to any of the preceding paragraphs.
[1008] 151. Use of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, proteinbased flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs in the manufacture of a cosmetic or therapeutic agent.152. A method of providing a semi-permeable boundary layer between the skin and the environment, said method comprising applying any one or more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs the skin.
[1009] 153. A cosmetic method of maintaining hydration of the skin said method comprising applying any one or more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs to the skin.
[1010] 154. A cosmetic composition comprising a moisturising lotion and any one or more of the film, cosmetic film, hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs.
[1011] CONCATEMER
[1012] 155. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises an amino acid sequence that comprises at least 4 units of a consensus motif.
[1013] 156. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermaldelivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are rod-shaped,
[1014] optionally wherein one of the at least two beta solenoid has a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1;
[1015] optionally wherein both of the at least two beta solenoid have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1;
[1016] optionally wherein all of the beta solenoid have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1.
[1017] 157. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids has an aspect ratio of 10: 1 or less, optionally wherein all of the beta solenoid have an aspect ratio of 10:1 or less.
[1018] 158. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises between 4 and 3000 units of theconsensus motif, optionally between 5 and 2800, optionally between 6 and 2600, optionally between 7 and 2400, optionally between 8 and 2200, optionally between 9 and 2000, optionally between 10 and 1800, optionally between 11 and 1600, optionally between 12 and 1400, optionally between 13 and 1200, optionally between 14 and 1000, optionally between 15 and 800, optionally between 16 and 600, optionally between 17 and 500, optionally between 18 and 400, optionally between 19 and 300, optionally between 21 and 200, optionally between 22 and 150, optionally between 23 and 100, optionally between 24 and 90, optionally between 25 and 85, optionally between 26 and 80, optionally between 27 and 75, optionally between 28 and 70, optionally between 29 and 65, optionally between 30 and 60, optionally between 35 and 55, optionally between 40 and 50, optionally 45 units of the consensus motif.
[1019] 159. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises at least 5 units of the consensus motif, optionally at least 6 units, optionally at least 7 units, optionally at least 8 units, optionally at least 9 units, optionally at least 10 units, optionally at least 11 units optionally at least 12 units, optionally at least 13 units, optionally at least 14 units optionally at least 15 units, optionally at least 16 units, optionally at least 17 units optionally at least 18 units, optionally at least 19 units, optionally at least 20 units optionally at least 21 units, optionally at least 24 units, optionally at least 25 units optionally at least 26 units, optionally at least 27 units, optionally at least 28 units optionally at least 29 units, optionally at least 30 units, optionally at least 40 units optionally at least 50 units, optionally at least 60 units, optionally at least 70 units, optionally at least 80 units, optionally at least 90 units, optionally at least 100 units, optionally at least 200 units of the consensus motif.
[1020] 160. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or allof the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises the same number of units of the consensus motif.
[1021] 161. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids have a cross-section selected from the group consisting of a tesselatable cross-section, optionally a square, a rectangle, a parallelogram, a hexagon, or a triangle cross-section; or a circle or an oval crosssection.
[1022] 162. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are capable of forming a lyotropic liquid crystal mesophase when expressed as monomers.
[1023] 163. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein concatemer of at least two beta solenoids is capable of forming a lyotropic liquid crystal mesophase.
[1024] 164. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition,multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises units of a consensus motif selected from the group consisting of:
[1025] i) A X1L / F X2X3[SEQ ID NO: 147]
[1026] wherein X1is any residue
[1027] X2is any residue
[1028] X3is any residue;
[1029] optionally
[1030] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[1031] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[1032] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 148]
[1033] ii) A X1L X2X3[SEQ ID NO: 149]
[1034] wherein X1is any residue
[1035] X2is any residue
[1036] X3 is any residue;
[1037] optionally
[1038] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[1039] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[1040] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 150]
[1041] iii) A (N / D) L * X [SEQ ID NO: 151]
[1042] where * is a polar residue (C, R, H, K, D, E, S, T, N, Q) and X is any residue;
[1043] iv) (S / G / T / A)X(A / V / G)X(G / A)XX [SEQ ID NO: 152]
[1044] where X is any residue;
[1045] v) (S / G / T / A)X(A / V / G)X(G / A)XX(S / G / T / A)*(A / V / G)*(G / A)XX [SEQ ID NO: 153]where * is a hydrophobic residue and where X is any residue;
[1046] vi) SXAXGXXS*A*GXX [SEQ ID NO: 154]
[1047] where * is a hydrophobic residue and where X is any residue;
[1048] vii) NXAXGXXST(I / V)(G / A)GGXX [SEQ ID NO: 155]
[1049] where X is any residue;
[1050] viii) NXAXGXXSTIGGGXX [SEQ ID NO: 156]
[1051] where X is any residue;
[1052] ix) GXQX(V / I / L)XXGGXAXXTX(V / I / L)XXG [SEQ ID NO: 157]
[1053] where X is any residue;
[1054] optionally wherein (i), (ii) and (iii) generate a beta solenoid with a square crosssection; (iv), (v), (vi), (vii) and (viii) generate an oval shaped cross-section; and (ix) forms a triangular cross-section.
[1055] 165. The e film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,
[1056] optionally wherein at least two of the beta solenoid comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,
[1057] optionally wherein all of the beta solenoid comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,
[1058] optionally wherein the at least one, the at least two or all of the beta solenoid have a) at least 75% homology to any one of the sequences of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202, optionally at least 80% homology, optionally at least 85% homology, optionally at least 90% homology, optionally at least 95% homology,optionally at least 96% homology, optionally at least 97% homology, optionally at least 98% homology, optionally at least 99% homology, optionally 100% homology' or b) at least 75% sequence identity to any one of the sequences of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202, optionally at least 80% sequence identity, optionally at least 85% sequence identity, optionally at least 90% sequence identity, optionally at least 95% sequence identity, optionally at least 96% sequence identity, optionally at least 97% sequence identity, optionally at least 98% sequence identity, optionally at least 99% sequence identity, optionally 100% sequence identity.
[1059] 166. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises a capping sequence at a first end or a second end, or both the first end and the second end of the beta solenoid, optionally wherein the capping sequence prevents the beta solenoid from joining end-to-end and aggregating,
[1060] optionally wherein the capping sequence is an alpha helix.
[1061] 167. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the capping sequence comprises:
[1062] a) a sequence that conforms to the consensus sequence of SEQ ID NO: 82 and / or SEQ ID NO: 83, optionally wherein the first cap conforms to SEQ ID NO: 82 and the second cap conforms to SEQ ID NO: 83; and / or
[1063] b) any one or more of SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190.optionally wherein at least one of or both of or all of the capping sequence comprises a sequence with a) at least 80% homology, optionally at least 85% homology, optionally at least 90% homology, optionally at least 95% homology, optionally at least 96% homology, optionally at least 97% homology, optionally at least 98% homology, optionally at least 99% homology, optionally 100% homology to SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190; or b) at least 80% sequence identity, optionally at least 85% sequence identity, optionally at least 90% sequence identity, optionally at least 95% sequence identity, optionally at least 96% sequence identity, optionally at least 97% sequence identity, optionally at least 98% sequence identity, optionally at least 99% sequence identity, optionally 100% sequence identity to SEQ ID NO: 2, 3, 84-104, 187, 188 and 105-125, 189 or 190.
[1064] In a preferred embodiment each solenoid in the concatemer comprises an N-terminal cap and a C-terminal cap. Preferably the N-terminal cap is selected from any one of SEQ ID NO: 2, 84-104, 187, 188 or a sequence with at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2, 84-104, 187, 188; and the C-terminal cap is selected from any one SEQ ID NO: 3, 105-125, 189 or 190 or a sequence with at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 3, 105-125, 189 or 190.
[1065] 167a. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids does not consist of any of the sequences of SEQ ID NO: 1, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62; and / or SEQ ID NO: 66-80.
[1066] 168. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or allof the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are linked by a linker, optionally
[1067] i) wherein the linker is a flexible linker;
[1068] ii) wherein the linker or the flexible linker is formed from amino acid residues; and / or iii) wherein the beta solenoid and linker are transcribed and translated as a single unit.
[1069] 169. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the linker sequence is selected from the group consisting of a poly glycine linker, a poly alanine linker, a glycine rich linker, an alanine rich linker, a glycine and alanine rich linker, a glycine / alanine / serine rich linker, SEQ ID NO: 34 (GGGS), or SEQ ID NO: 168 (GGGSAAAAAAGGGS), or SEQ ID NO: 203 (GGQGGQGGSGGSAAAAAAAAGGSGGSGGSGGQGGQ).
[1070] In some preferred embodiments the linker is GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQ SEQ ID NO: 203.
[1071] 170. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the concatemer of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids has a molecular weight of at least 30 kDa, optionally at least 40 kDa, optionally at least 50 kDa, optionally at least 60 kDa, optionally at least 70 kDa, optionally at least 80 kDa, optionally at least 90 kDa, optionally at least 100 kDa, optionally at least 120 kDa, optionally at least 150 kDa, optionally at least 200 kDa, optionally at least 250 kDa, optionally at least 300 kDa, optionally at least 350 kDa, optionally at least 400 kDa, optionally at least 450 kDa, optionally at least 500 kDa, optionally at least 600 kDa, optionally at least 650 kDa, optionally at least 700 kDa, optionally at least 800 kDa, optionally at least 900 kDa, optionally at least 1000 kDa.;optionally between 30 kDa and 1000 kDa.
[1072] 171. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the concatemer of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids is soluble at high concentrations, optionally soluble at a concentration of at least 20 mg / ml, optionally at least 30 mg / ml, optionally at least 40 mg / ml, optionally at least 50 mg / ml, optionally at least 60 mg / ml, optionally at least 70 mg / ml, optionally at least 80 mg / ml, optionally at least 90 mg / ml, optionally at least 100 mg / ml, optionally at least 120 mg / ml, optionally at least 130 mg / ml, optionally at least 150 mg / ml, optionally at least 170 mg / ml, optionally at least 190 mg / ml, optionally at least 200 mg / ml, optionally at least 250 mg / ml, optionally at least 300 mg / ml, optionally at least 350 mg / ml, optionally at least 400 mg / ml,
[1073] optionally soluble in a solvent selected from the group consisting of:
[1074] a) a buffer selected from the group consisting of any one or more of: MES, Bis-tris methane, ADA, ACES, Bis-tris propane, PIPES, MOPSO, Cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, Acetamidoglycine, TAPSO, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, Tris, Glycinamide, Glycylglycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSOCAPSO, CAPS, CABS, Bicine, sodium citrate buffer, sodium bicarbonate buffer, phosphate buffer, borate buffer,
[1075] optionally wherein the buffer comprises one or more salts, optionally sodium chloride and / or potassium chloride,
[1076] optionally wherein the buffer is at a pH range of 3 to 10, optionally pH 7;
[1077] b) an organic solvent, optionally HFIP.
[1078] 172. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or allof the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids has:
[1079] a) a high net charge, optionally has a net charge of at least +3 charge units, optionally at least +5 charge units, optionally at least +7 charge units, optionally at least +10 charge units, optionally at least +15 charge units, optionally at least +20 charge units, optionally at least +25 charge units, optionally at least +30 charge units, optionally at least +35 charge units, optionally at least +40 charge units, optionally at least +45 charge units, optionally at least +50 charge units, optionally at least +55 charge units, optionally at least +60 charge units, optionally at least +65 charge units, optionally at least +70 charge units, optionally at least +75 charge units, optionally at least +80 charge units, optionally at least +85 charge units, optionally at least +90 charge units, optionally at least +95 charge units, optionally at least +100 charge units, optionally at a pH range of 3 to 10, optionally pH 7;
[1080] b) a high negative net charge, optionally has a net charge of less than -3 charge units, optionally at less than -5 charge units, optionally less than -7 charge units, optionally less than -10 charge units, optionally less than -15 charge units, optionally less than -20 charge units, optionally less than -25 charge units, optionally less than -30 charge units, optionally less than -35 charge units, optionally less than -40 charge units, optionally less than -45 charge units, optionally less than -50 charge units, optionally less than -55 charge units, optionally less than -60 charge units, optionally less than -65 charge units, optionally less than -70 charge units, optionally less than -75 charge units, optionally less than -80 charge units, optionally less than -85 charge units, optionally less than -90 charge units, optionally less than -95 charge units, optionally less than -100 charge units, optionally at a pH range of 3 to 10, optionally pH 7
[1081] c) a net charge of at least +3 charge units, optionally at least +5 charge units, optionally at least +7 charge units, optionally at least +10 charge units, optionally at least +15 charge units, optionally at least +20 charge units, optionally at least +25 charge units, optionally at least +30 charge units, optionally at least +35 charge units, optionally at least +40 charge units, optionally at least +45 charge units, optionally at least +50 charge units, optionally at least +55 charge units, optionally at least +60 charge units, optionally at least +65 charge units, optionally at least +70 charge units, optionally at least +75 charge units, optionally at least +80 charge units, optionally at least +85 charge units, optionally at least +90 charge units, optionally at least +95charge units, optionally at least +100 charge units, optionally at least +200 charge units, optionally at least +300 charge units, optionally at least +400 charge units, optionally at least +500 charge units, optionally at least +600 charge units, optionally at least +700 charge units, optionally at least +800 charge units, optionally at least +900 charge units, optionally at least +1000 charge units, optionally at least +2000 charge units, optionally at least +3000 charge units, optionally at least +4000 charge units, optionally at least +5000 charge units, optionally at least +6000 charge units, optionally at least +7000 charge units, optionally at least +8000 charge units, optionally at least +9000 charge units, optionally at least +10000 charge units;
[1082] and / or
[1083] d) a high negative net charge, optionally has a net charge of less than -3 charge units, optionally at less than -5 charge units, optionally less than -7 charge units, optionally less than -10 charge units, optionally less than -15 charge units, optionally less than -20 charge units, optionally less than -25 charge units, optionally less than -30 charge units, optionally less than -35 charge units, optionally less than -40 charge units, optionally less than -45 charge units, optionally less than -50 charge units, optionally less than -55 charge units, optionally less than -60 charge units, optionally less than -65 charge units, optionally less than -70 charge units, optionally less than -75 charge units, optionally less than -80 charge units, optionally less than -85 charge units, optionally less than -90 charge units, optionally less than -95 charge units, optionally less than -100 charge units, optionally less than -200 charge units, optionally less than -300 charge units, optionally less than -400 charge units, optionally less than -500 charge units, optionally less than -600 charge units, optionally less than -700 charge units, optionally less than -800 charge units, optionally less than -900 charge units, optionally less than -1000 charge units, optionally less than -2000 charge units, optionally less than -3000 charge units, optionally less than -4000 charge units, optionally less than -5000 charge units, optionally less than -6000 charge units, optionally less than -7000 charge units, optionally less than -8000 charge units, optionally less than -9000 charge units, optionally less than -10000 charge units.
[1084] 173. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelasticnon-flowable hydrogel of any of the preceding paragraphs wherein the concatemer of at least two beta solenoids comprises at least three beta solenoids, optionally at least four beta solenoids, optionally at least 5 beta solenoids, optionally at least 6 beta solenoids, optionally at least 7 beta solenoids, optionally at least 8 beta solenoids, optionally at least 9 beta solenoids, optionally at least 10 beta solenoids, optionally at least 11 beta solenoids, optionally at least 12 beta solenoids, optionally at least 13 beta solenoids, optionally at least 14 beta solenoids, optionally at least 15 beta solenoids, optionally at least 16 beta solenoids, optionally at least 17 beta solenoids, optionally at least 18 beta solenoids, optionally at least 19 beta solenoids, optionally at least 20 beta solenoids, optionally at least 21 beta solenoids, optionally at least 22 beta solenoids, optionally at least 23 beta solenoids, optionally at least 24 beta solenoids, optionally at least 25 beta solenoids, optionally at least 26 beta solenoids, optionally at least 27 beta solenoids, optionally at least 28 beta solenoids, optionally at least 29 beta solenoids, optionally at least 30 beta solenoids, optionally at least 35 beta solenoids, optionally at least 40 beta solenoids, optionally at least 45 beta solenoids, optionally at least 50 beta solenoids, optionally at least 55 beta solenoids, optionally at least 60 beta solenoids, optionally at least 65 beta solenoids, optionally at least 70 beta solenoids, optionally at least 75 beta solenoids, optionally at least 80 beta solenoids, optionally at least 85 beta solenoids, optionally at least 90 beta solenoids, optionally at least 95 beta solenoids, optionally at least 100 beta solenoids.
[1085] 174. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein the concatemer of at least two beta solenoids comprises or consists of one or more of the sequences according to SEQ ID NO: 29-32, 158-162, and 174-186
[1086] Preferably the concatemer of at least two beta solenoids comprises or consists of one or more of the sequences according to SEQ ID NO: 178 or 186, preferably 178.
[1087] 175. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelasticnon-flowable hydrogel of any of the preceding paragraphs wherein the concatemer of at least two beta solenoids is capable of being expressed by a cell or a cell-free transcription and translation system, optionally
[1088] a) wherein the cell is a prokaryotic cell, optionally a bacterial cell, optionally an E. coli cell, a Bacillus subtilis cell, a Bacillus megaterium cell, a Vibrio natriegens cell, or a Pseudomonas fluorescens cell; or
[1089] b) wherein the cell is a eukaryotic cell, optionally a yeast cell, optionally Pichia pastoris or Saccharomyces cerevisiae; an insect cell, optionally a baculovirus infected insect cell; or a mammalian cell, optionally a baculovirus infected mammalian cell, a HEK293 cell, a HeLa cell, or CHO cells.
[1090] 176. A concatemer of at least two beta solenoids comprising or consisting of any of the following sequences: SEQ ID NO: 178, SEQ ID NO: 186, or SEQ ID NO: 174-177 or 179-185.
[1091] 177. The concatemer of paragraph 176 wherein the concatemer comprises or consists of SEQ ID NO: 178 or 186, optionally 178.
[1092] 178. A fibre comprising the concatemer according to any of paragraphs 176 or 177.
[1093] 179. The fibre according to paragraph 178 wherein the fibre has been produced via a wet-spinning method.
[1094] 180. A fibre according to any of paragraphs 178 or 179 wherein the fibre comprises more than one different concatemer according to any of paragraphs 176 or 177.
[1095] 181. A fibre according to any of paragraphs 178 or 179 wherein the fibre comprises at least two different concatemers, wherein at least one concatemer is a concatemer according to any of paragraphs 176 or 177 and at least a second concatemer is a concatemer as defined in any of the preceding paragraphs.
[1096] 182. A yarn comprising a fibre according to any of paragraphs 178-181.
[1097] 183. A yarn comprising at least two different fibres according to any of paragraphs 178-181.
[1098] 184. A textile comprising the concatemer according to any of paragraphs 176 orl77, or the fibre according to any of paragraphs 178-181.185. Use of a concatemer according to any of paragraphs 176 or 177, a fibre according to any of paragraphs 178-181 or a textile according to paragraph 184 in the production of any one or more of:
[1099] sportswear (e.g. for protective uses such as rash guards); Protective wear for motorcyclists and / or other motorsports; Personal protective equipment (e.g. body armour, protective underwear for soldiers); Blast containment; Blade containment (e.g. for aircraft engines); Textiles for parachutes; Ropes; Textiles for clothing; Textiles for shoes; general medical textiles; Wound dressings; Resorbable and non-resorbable surgical sutures; Resorbable and non-resorbable stents; Guide-wires for surgery (including non-metallic guide wires suitable for MRI); Biocompatible coatings for implanted medical devices; Surgical meshes; Scaffolds for 3D tissue engineering.
[1100] 186. Sportswear (e.g. for protective uses such as rash guards); Protective wear for motorcyclists and / or other motorsports; Personal protective equipment (e.g. body armour, protective underwear for soldiers); Blast containment; Blade containment (e.g. for aircraft engines); Textiles for parachutes; Ropes; Textiles for clothing; Textiles for shoes; general medical textiles; Wound dressings; Resorbable and non-resorbable surgical sutures; Resorbable and non-resorbable stents; Guide-wires for surgery (including non-metallic guide wires suitable for MRI); Biocompatible coatings for implanted medical devices; Surgical meshes; or Scaffolds for 3D tissue engineering comprising a concatemer according to any of paragraphs 176 or 177, a fibre according to any of paragraphs 178-181 or a textile according to paragraph 184.
[1101] 187. An aqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids.
[1102] 188. An aqueous cosmetic composition comprising a cosmetic agent and a concatemer of at least two beta solenoids, optionally wherein the cosmetic composition is an aqueous cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum.189. A method of making an aqueous therapeutic composition comprising a therapeutic agent and a concatemer of at least two beta solenoids, said method comprising mixing an aqueous therapeutic agent with a concatemer of at least two beta solenoids wherein the concatemer of at least two beta solenoids is in a powdered or lyophilised form.
[1103] 190. A method of making an aqueous cosmetic composition comprising a cosmetic agent and a concatemer of at least two beta solenoids, said method comprising mixing an aqueous cosmetic agent with a concatemer of at least two beta solenoids wherein the concatemer of at least two beta solenoids is in a powdered or lyophilised form, optionally wherein the cosmetic agent is an aqueous cosmetic lotion, cream, ointment, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, flavouring, pigment or serum.
[1104] 191. The film, therapeutic film, cosmetic film, hydrogel, therapeutic hydrogel, cosmetic hydrogel, hydrogel shell microcapsules, therapeutic hydrogel shell microcapsules, cosmetic hydrogel shell microcapsules, multilayer film, transdermal delivery system, composition, therapeutic composition, cosmetic composition, multilayer hydrogel, protein-based flowable hydrogel or protein-based viscoelastic non-flowable hydrogel of any of the preceding paragraphs wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 195.
[1105] The invention is set out in the following numbered embodiment paragraphs.
[1106] 1. A polypeptide that is a concatemer of at least two beta solenoids comprising or consisting of any of the following amino acid sequences: SEQ ID NO: 178, SEQ ID NO: 186, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184 or SEQ ID NO: 185.
[1107] 2. The polypeptide of paragraph 1 wherein the concatemer comprises or consists of SEQ ID NO: 178.
[1108] 3. A fibre comprising the polypeptide according to any of paragraphs 1 or 2.4. A film comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[1109] 5. The film of paragraph 4 wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises an amino acid sequence that comprises at least 4 units of a consensus motif.
[1110] 6. The film of any one of paragraphs 4 or 5 wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are linked by a linker, optionally
[1111] i) wherein the linker is a flexible linker;
[1112] ii) wherein the linker or the flexible linker is formed from amino acid residues; and / or
[1113] iii) wherein the beta solenoid and linker are transcribed and translated as a single unit.
[1114] 7. The film of any one of paragraphs 4-6 wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids each comprise an N-terminal cap and a C-terminal cap, and a linker, wherein the linker links the C-terminal cap of one solenoid to the N-terminal cap of the second solenoid.
[1115] 8. The film of any one of paragraph 6 or 7 wherein the linker is formed from amino acid residues and has a sequence selected from the group consisting of a poly glycine linker, a poly alanine linker, a glycine rich linker, an alanine rich linker, a glycine and alanine rich linker, a glycine / alanine / serine rich linker, SEQ ID NO: 34 (GGGS), or SEQ ID NO: 168 (GGGSAAAAAAGGGS), and / or SEQ ID NO: 203 (GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQ).
[1116] 9. The film according to any of paragraphs 4-8 wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises units of a consensus motif selected from the group consisting of:
[1117] i) A X1L / F X2X3[SEQ ID NO: 147]
[1118] wherein X1is any residueX2is any residue
[1119] X3 is any residue;
[1120] optionally
[1121] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[1122] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[1123] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 148]
[1124] ii) A X1L X2X3[SEQ ID NO: 149]
[1125] wherein X1is any residue
[1126] X2is any residue
[1127] X3 is any residue;
[1128] optionally
[1129] wherein Xi is A, C, D, E, I, K, L, M, N, R, S, T or V
[1130] X2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or Y
[1131] X3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 150]
[1132] iii) A (N / D) L * X [SEQ ID NO: 151]
[1133] where * is a polar residue (C, R, H, K, D, E, S, T, N, Q) and X is any residue;
[1134] iv) (S / G / T / A)X(A / V / G)X(G / A)XX [SEQ ID NO: 152]
[1135] where X is any residue;
[1136] v) (S / G / T / A)X(A / V / G)X(G / A)XX(S / G / T / A)*(A / V / G)*(G / A)XX [SEQ ID NO: 153] where * is a hydrophobic residue and where X is any residue;
[1137] vi) SXAXGXXS*A*GXX [SEQ ID NO: 154]
[1138] where * is a hydrophobic residue and where X is any residue;
[1139] vii) NXAXGXXST(I / V)(G / A)GGXX [SEQ ID NO: 155]
[1140] where X is any residue;
[1141] viii) NXAXGXXSTIGGGXX [SEQ ID NO: 156]where X is any residue;
[1142] ix) GXQX(V / I / L)XXGGXAXXTX(V / I / L)XXG [SEQ ID NO: 157]
[1143] where X is any residue;
[1144] optionally wherein (i), (ii) and (iii) generate a beta solenoid with a square crosssection; (iv), (v), (vi), (vii) and (viii) generate an oval shaped cross-section; and (ix) forms a triangular cross-section.
[1145] 10. The film according to any of paragraphs 4-9 wherein one or both or all of the beta solenoid domains of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,
[1146] optionally wherein at least two of the beta solenoid comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,
[1147] optionally wherein all of the beta solenoid comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202.
[1148] 11. The film according to any of paragraphs 4-10 wherein the polypeptide that comprises or consists of a concatemer is a polypeptide according to any of paragraphs 1-3.
[1149] 12. The film according to any of paragraphs 4-11 wherein the film is water soluble.
[1150] 13. The film according to any of paragraphs 4-12 wherein the film is flexible.
[1151] 14. The film according to any of paragraphs 4-13 wherein the film does not comprise:
[1152] a) any plasticiser and is flexible, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose;
[1153] b) a polyol, optionally does not comprise glycerol, sorbitol, ethylene glycol, propylene glycol, and / or polyethylene glycol (e.g. PEG 400 or PEG 600 but wider ranges of MWs possible);
[1154] c) urea;d) one or more sugars, optionally does not comprise glucose, sucrose and / or fructose;
[1155] e) one or more lipids, optionally does not comprise oleic acid, linoleic acid and / or lecithin; and / or
[1156] f) one or more amino acids, optionally does not comprise proline, arginine and / or lysine.
[1157] 15. The film according to any of paragraphs 4-14 wherein the film comprises a second agent.
[1158] 16. The film of paragraph 15 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
[1159] 17. The film of paragraph 15 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum, active, functional, pigment, dye, fragrance, pigment, enzyme, coenzyme, vitamin, hyaluronic acid, peptide, amino acid, ceramide, probiotic, UV protective agent, and / or antioxidant.
[1160] 18. The film according to paragraph 17 wherein the film:
[1161] a) is a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;
[1162] b) is a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;
[1163] c) acts as a wound dressing;
[1164] d) acts as an antimicrobial
[1165] e) delivers one or more therapeutic agents to the skin of a subject; and / or f) is occlusive.
[1166] 19. The film according to any of paragraphs 4-18 wherein the film is suitable for use in packaging, optionally is:
[1167] a) a water-soluble film for use in packaging; and / or
[1168] b) suitable for packaging food.20. A multilayer film comprising at least two layers, wherein at least one layer comprises or consists of a film according to any of the preceding claims.
[1169] 21. A method of producing the film according to any of paragraphs 4-19 wherein the method comprises:
[1170] a) applying a protein solution that comprises at least a polypeptide to a surface; and
[1171] b) allowing the solution to dry
[1172] wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids, optionally wherein the polypeptide is a polypeptide of any of claims 1-3.
[1173] 22. The method of paragraph 21 wherein the protein solution further comprises at least a second agent, optionally wherein the second agent:
[1174] a) is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream; or
[1175] b) is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment, serum, active, functional, pigment, dye, fragrance, pigment, enzyme, coenzyme, vitamin, hyaluronic acid, peptide, amino acid, ceramide, probiotic, UV protective agent, and / or antioxidant.
[1176] 23. The method of any of paragraphs 21 or 22 wherein the solid surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionally human hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon.
[1177] 24. A hydrogel comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[1178] 25. A method of producing the hydrogel of paragraph 24 wherein the method comprises:
[1179] a) providing a protein solution that comprises at least a polypeptide;
[1180] b) providing a gelling agent;
[1181] c) mixing the protein solution with the gelling agentwherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
[1182] 26. The method of paragraph 25 wherein
[1183] the gelling agent is selected from the group comprising or consisting of:
[1184] i) ethanol; and / or
[1185] ii) metal 2+ ions, optionally Cu2+ or Ca2+, optionally copper sulphate or calcium chloride.
[1186] 27. The method of paragraph 25 or 26 wherein the gelling agent is ethanol, and:
[1187] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[1188] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[1189] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[1190] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[1191] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[1192] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[1193] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[1194] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;
[1195] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[1196] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;
[1197] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;
[1198] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;
[1199] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;
[1200] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;
[1201] the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at le...
Claims
CLAIMS1. A film comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
2. The film of claim 1 wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids comprises an amino acid sequence that comprises at least 4 units of a consensus motif.
3. The film of any one of claims 1 or 2 wherein one or both or all of the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids are linked by a linker, optionallyi) wherein the linker is a flexible linker;ii) wherein the linker or the flexible linker is formed from amino acid residues; and / oriii) wherein the beta solenoid and linker are transcribed and translated as a single unit.
4. The film of any one of claims 1-3 wherein the at least two beta solenoids of the polypeptide that comprises or consists of a concatemer of at least two beta solenoids each comprise an N-terminal cap and a C-terminal cap, and a linker, wherein the linker links the C-terminal cap of one solenoid to the N-terminal cap of the second solenoid.
5. The film of any one of claim 3 or 4 wherein the linker is formed from amino acid residues and has a sequence selected from the group consisting of: SEQ ID NO: 203 (GGQGGQGGSGGSAAAAAAAAGGSGGSGGQGGQ), SEQ ID NO: 168 (GGGSAAAAAAGGGS), a poly glycine linker, a poly alanine linker, a glycine rich linker, an alanine rich linker, a glycine and alanine rich linker, a glycine / alanine / serine rich linker, and / or SEQ ID NO: 34 (GGGS).
6. The film according to any of claims 1-5 wherein one or both or all of the at least two beta solenoids of the polypeptide that are present in the concatemer of at least two beta solenoids comprises units of a consensus motif selected from the group consisting of:i) A X1L / F X2X3[SEQ ID NO: 147]wherein X1is any residueX2is any residueX3is any residue;optionallywherein X1is A, C, D, E, I, K, L, M, N, R, S, T or VX2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or YX3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 148]ii) A X1L X2X3[SEQ ID NO: 149]wherein X1is any residueX2is any residueX3is any residue;optionallywherein X1is A, C, D, E, I, K, L, M, N, R, S, T or VX2is A, C, D, E, F, G, H, I, K, N, Q, R, S, T, V, W, or YX3is A, C, D, E, G, H, I, K, N, Q, R, S, Y; [SEQ ID NO: 150]iii) A (N / D) L * X [SEQ ID NO: 151]where * is a polar residue (C, R, H, K, D, E, S, T, N, Q) and X is any residue;iv) (S / G / T / A)X(A / V / G)X(G / A)XX [SEQ ID NO: 152]where X is any residue;v) (S / G / T / A)X(A / V / G)X(G / A)XX(S / G / T / A)*(A / V / G)*(G / A)XX [SEQ ID NO: 153] where * is a hydrophobic residue and where X is any residue;vi) SXAXGXXS*A*GXX [SEQ ID NO: 154]where * is a hydrophobic residue and where X is any residue;vii) NXAXGXXST(I / V)(G / A)GGXX [SEQ ID NO: 155]where X is any residue;viii) NXAXGXXSTIGGGXX [SEQ ID NO: 156]where X is any residue;ix) GXQX(V / I / L)XXGGXAXXTX(V / I / L)XXG [SEQ ID NO: 157]where X is any residue;optionally wherein (i), (ii) and (iii) generate a beta solenoid with a square crosssection; (iv), (v), (vi), (vii) and (viii) generate an oval shaped cross-section; and (ix) forms a triangular cross-section.
7. The film according to any of claims 1-6 wherein one or both or all of the beta solenoid domains of the polypeptide that are present in the concatemer of at least two beta solenoids comprises or consists of the sequence of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,optionally wherein at least two of the beta solenoids comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202,optionally wherein all of the beta solenoids comprise or consist of the sequence of any one of SEQ ID NO: 1, 8-28, 169, or SEQ ID NO: 191-202.
8. The film according to any of claims 1-7 wherein the polypeptide that comprises or consists of a concatemer of at least two beta solenoids has a sequence that comprises or consists of any of the following amino acid sequences: SEQ ID NO: 178, SEQ ID NO: 186, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184 or SEQ ID NO: 185.
9. The film according to any of claims 1-8 wherein the film is water soluble.
10. The film according to any of claims 1-9 wherein the film is flexible.
11. The film according to any of claims 1-10 wherein the film does not comprise:a) any plasticiser and is flexible, optionally wherein the plasticiser is a triol, optionally wherein the triol is glycerine or sorbitol, or wherein the plasticiser is sucrose;b) a polyol, optionally does not comprise glycerol, sorbitol, ethylene glycol, propylene glycol, and / or polyethylene glycol (e.g. PEG 400 or PEG 600 but wider ranges of MWs possible);c) urea;d) one or more sugars, optionally does not comprise glucose, sucrose and / or fructose;e) one or more lipids, optionally does not comprise oleic acid, linoleic acid and / or lecithin; and / orf) one or more amino acids, optionally does not comprise proline, arginine and / or lysine.
12. The film according to any of claims 1-11 wherein the film comprises a second agent.
13. The film of claim 12 wherein the second agent is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream.
14. The film of claim 12 wherein the second agent is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment or serum, active, functional, pigment, dye, fragrance, pigment, enzyme, coenzyme, vitamin, hyaluronic acid, peptide, amino acid, ceramide, probiotic, UV protective agent, and / or antioxidant.
15. The film according to claim 14 wherein the film:a) is a protective film on the skin, hair, nails and / or mucosa and optionally traps moisture;b) is a protective film on the skin, hair, nails and / or mucosa and protects against moisture, friction and / or other irritants;c) acts as a wound dressing;d) acts as an antimicrobiale) delivers one or more therapeutic agents to the skin of a subject; and / or f) is occlusive.
16. The film according to any of claims 1-15 wherein the film is suitable for use in packaging, optionally is:a) a water-soluble film for use in packaging; and / orb) suitable for packaging food.
17. The film according to any of claims 3-16 where the linker has a sequence of SEQ ID NO: 203.
18. The film according to any of claims 3-16 where the linker has a sequence of SEQ ID NO: 168.
19. A multilayer film comprising at least two layers, wherein at least one layer comprises or consists of a film according to any of the preceding claims.
20. A method of producing the film according to any of claims 1-18 wherein the method comprises:a) applying a protein solution that comprises at least a polypeptide to a surface; andb) allowing the solution to drywherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids, optionally wherein the polypeptide is a polypeptide that is a concatemer of at least two beta solenoids, wherein the concatemer has a sequence that comprises or consists of any of the following amino acid sequences: SEQ ID NO: 178, SEQ ID NO: 186, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184 or SEQ ID NO: 18521. The method of claim 20 wherein the protein solution further comprises at least a second agent, optionally wherein the second agent:a) is a therapeutic agent, optionally a therapeutic active ingredient, a therapeutic lotion, cream, emollient or topical cream; orb) is a cosmetic agent, optionally a cosmetic lotion, cream, emollient, moisturiser, shampoo, conditioner, sunscreen, make up such as foundation or lipstick, fragrance, pigment, serum, active, functional, pigment, dye, fragrance, pigment, enzyme, coenzyme, vitamin, hyaluronic acid, peptide, amino acid, ceramide, probiotic, UV protective agent, and / or antioxidant.
22. The method of any of claims 20 or 21 wherein the solid surface is selected from the group comprising or consisting of skin, optionally human skin, hair optionallyhuman hair, nail optionally human nail, mucosa optionally human mucosa, glass, plastic, and silicon.
23. A polypeptide that is a concatemer of at least two beta solenoids, wherein the concatemer comprises or consists of any of the following amino acid sequences: SEQ ID NO: 178, SEQ ID NO: 186, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184 or SEQ ID NO: 185.
24. The polypeptide of claim 23 wherein the concatemer comprises or consists of SEQ ID NO: 178.
25. A fibre comprising the polypeptide according to any of claims 23 or 24.
26. A hydrogel comprising or consisting of a polypeptide wherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
27. A method of producing the hydrogel of claim 26 wherein the method comprises:a) providing a protein solution that comprises at least a polypeptide;b) providing a gelling agent;c) mixing the protein solution with the gelling agentwherein the polypeptide comprises or consists of a concatemer of at least two beta solenoids.
28. The method of claim 27 whereinthe gelling agent is selected from the group comprising or consisting of:i) ethanol; and / orii) metal 2+ ions, optionally Cu2+ or Ca2+, optionally copper sulphate or calcium chloride.
29. The method of claim 27 or 28 wherein the gelling agent is ethanol, and:the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 30% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 40% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 7.5 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 10 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 15 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 20 mg / ml;the ethanol is present in the mixture of the protein solution and the gelling agent at a concentration of at least 50% and the protein is present in the mixture of the protein solution and gelling agent at a concentration of at least 30 mg / ml.
30. A hydrogel shell microcapsule comprising or consisting of:a) a core made of a material that is not miscible or is not fully miscible with water;b) a hydrogel shell surrounding and containing the core;wherein the hydrogel shell comprises or consists of a polypeptide that comprises or consists of a concatemer of at least two beta solenoids.
